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Abstract 
This thesis is focused on the development and application of methods for the intramolecular 
nucleophilic addition of tethered nucleophiles to cyclopropenes. Addition of carbon-, nitrogen, and 
oxygen-nucleophiles was demonstrated to provide access to γ-aminobutyric acid (GABA) 
derivatives and biologically relevant cyclopropane-fused heterocyclic rings (heteroazepanones, 
heteroazocanones, and pyrrolidinones). The thesis is divided into five chapters, which discuss not 
only the development and elaboration of our chemistry, but also biological importance and 
alternative methods for synthesis of target heterocycles presented in literature. 
Chapter one is a review of biological activity, occurrence in nature, and synthetic approaches 
for the preparation of heteroazepanones and heteroazocanones. The chapter will describe methods 
based on cyclization and ring expansion reactions, as well as multicomponent and tandem 
methods. 
Chapter two focuses on the one-pot synthesis of various γ-aminobutyric acid (GABA) amides 
through unassisted nucleophilic addition of primary and secondary amines across the double bond 
of cyclopropene-3-carboxamides. Initial nucleophilic attack is followed by a ring opening of the 
resulting donor-acceptor cyclopropanes. Subsequent in situ reduction of enamine or imine 
intermediates allows to access substituted GABA derivatives. 
Chapter three describes a formal intramolecular nucleophilic substitution reaction of 
bromocyclopropanes with nitrogen ylides generated in situ from N-benzyl carboxamides. This 
reaction represents the 5-exo-trig cyclization through intermolecular base-assisted nucleophilic 
addition of tethered benzylic anion to cyclopropenes generated in situ by dehydrohalogenation of 
bromocyclopropanes. 
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Abstract (Continued) 
Chapter four describes modular assembly of enantiopure cyclopropane-fused oxazepanones 
through a strain-release-driven, cation-templated intramolecular nucleophilic addition of tethered 
alkoxides to prochiral cyclopropenes. The mechanism of enantiomeric induction is detailed. The 
biological profile exhibited by some of obtained 2-oxa-5-azabicyclo[5.1.0]octan-6-ones is 
characterized by promising activity against Mycobacterium abscessus coupled with apparent low 
general toxicity against cultured human cells. 
The final chapter covers ring-retentive 7- and 8-exo-trig nucleophilic attack of tethered 
nitrogen-based nucleophiles at cyclopropene double bond. The described potassium-templated 
cyclization proceeds in highly regio- and diastereoselective fashion and provides expedited access 
to previously unknown drug-like scaffolds including several structures with promising anti-cancer 
properties. 
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Abbrevations 
 
[H] or [red] reduction 
°C degrees Celsius 
µL microliter 
2D two-dimensional 
A acceptor group 
Å angstrom 
Ac acetyl 
ACC aminocyclopropanecarboxylic acid 
AcOH acetic acid 
ACS American Chemical Society 
Ad adamantyl 
AIBN azobisisobutyronitrile 
AIDS acquired immunodeficiency syndrome 
Alk alkyl 
aq. aqueous 
Ar aryl 
Bn benzyl 
Boc tert-butyloxycarbonyl  
br. broad 
Bu butyl 
C carbon 
cat. catalyst 
Cbz carboxybenzyl group 
cm centimeter 
cod 1,5-cyclooctadiene 
COSY correlation spectroscopy 
Cy cyclohexyl 
D donor group 
d doublet 
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DAC donor–acceptor cyclopropanes 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
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DIPEA N,N-diisopropylethylamine 
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DIPP 2,6-diisopropylphenyl 
DMAP 4-(dimethylamino)pyridine 
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Et ethyl 
et al. and others 
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EtOAc ethyl acetate 
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EWG electron withdrawing group 
FID flame ionization detector 
Fmoc fluorenylmethyloxycarbonyl 
FT IR Fourier-transform infrared spectroscopy 
g gram 
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h or hr hour 
Hal halogen 
Het heteryl 
HIV human immunodeficiency virus 
HOBt 1-hydroxybenzotriazole 
HRMS high-resolution mass spectrometry 
Hz hertz 
IC50 inhibitory concentration at 50% 
i-Pr isopropyl 
IR infrared spectroscopy 
J coupling constant 
kcal Calorie (kilocalorie) 
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Ki inhibitor constant 
L liter or ligand 
LA Lewis acid 
LDA lithium diisopropylamide 
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liq. liquid 
m multiplet or meter 
M molarity or molecular ion 
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Me methyl 
MeOH methanol 
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mm millimeter 
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MTT measuring cell metabolic activity 
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NOESY nuclear Overhauser effect spectroscopy 
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PAO phenyl arsine oxide 
Pd/C palladium on carbon 
Ph phenyl 
ppm parts per million 
Pr propyl 
PTC phase-transfer catalyst 
Rf  retention factors 
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RT or rt room temperature 
s singlet 
sat. saturated 
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t triplet 
t- tert- 
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Chapter 1. Synthesis and biological importance of heteroazepanones 
and heteroazocanones  
1.1 Introduction 
 
Numerous synthetic routes towards medium-sized heterocycles have been developed due to 
their wide natural occurrence and great potential for drug applications. Nevertheless, the 
preparation of medium-sized rings still represents a synthetic challenge. Cyclization of seven- or 
eight-membered heterocycles is problematic 5  because of a combination of issues related to 
enthalpy and entropy. The increase in ring strain and unfavorable interactions are needed to be 
overcome when the open-chain starting material approaches the ring-shaped transition state. In 
addition to that, the event of the two chain terminals coming close enough to interact represents 
the entropy issue. The presence of a carboxylic amide bond in the starting material further 
complicates cyclization by imposing the restrictions on rotational freedom in non-cyclic  precursor 
and thus preventing the ends of the linear starting material from coming to each other’s proximity. 
 
1.2 Nomenclature 
 
The nomenclature of the described heterocyclic compounds is highly inconsistent in literature. 
For convinience, the term “oxazepanones” (Figure 1) is used in this work to refer to both 
substituted 1,4-oxazepan-5-ones and their various unsaturated analogs, usually referred to as 
oxazepinones. Similarly, term “diazepanones” is used for both 1,4-diazepan-5-ones and their 
unsaturated counterparts, diazepinones, with different unsaturation degrees. 
Likewise, the term “oxazocanones” (Figure 2) is used for both 1,5-oxazocan-4-ones and 
oxazocinones, whereas the term “diazocanones” refers to substituted 1,5-diazocan-2-one and 
diazocinones. 
19 
 
 
Figure 1. Heteroazepanones 
 
 
Figure 2. Heteroazocanones 
 
In cases when some statement is applied to both oxazepanones and diazepanones the term 
“heteroazepanones” is used. Also, the term “heteroazocanones” refers to both oxazocanones and 
diazocanones. 
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1.3 Occurrence in Nature and Biological activity 
 
1.3.1 Occurrence in nature 
 
The heteroazepanone moiety is found in a large number of natural products, which possess a 
broad spectrum of biological activities.6 
Several natural products have been isolated containing a oxazepanone ring (Figure 3). One 
example is inducamide C, isolated from a chemically induced mutant strain of streptomyces sp. 
and exhibiting modest cytotoxicity (IC50 10 μM against the NSCLC cell line).
7a Compound 1, with 
a similar lactone core, was isolated from the methanolysis mixture of the marine 
immunosuppressant lipopeptide microcolin A and shows relatively potent immunosuppressive 
activity (IC50 8.1 nM of human splenocyte proliferation).
7b Additionally, a bacterial metabolite 
was isolated from the Gram-negative bacterium serratia marcescens and was identified as serratin, 
but its biological activities have not been evaluated yet.8 
 
 
Figure 3. Oxazepanone-containing natural products 
 
The pyrrolo[2,1-c][1,4]benzodiazepines (Figure 4) are an established class of heterocyclic 
antibiotics.9,10 Since the isolation from cultures of streptomyces some members of this class such 
as tomaymycin (IC50 3 mcg/mL against escherichia coli and IC50 0.2 mcg/mL against bacillus 
subtilis), neothramycin A, and anthramycin (MIC of 1.56 µg/ml against bacillus subtilis and 0.78 
21 
 
µg/ml against streptococcus pyogenes) were shown to be antibiotics with potent antitumor activity. 
It was shown that neothramycin A also possess capabilities as an antiprotozoal drug, and even 
possible uses in DNA fluorescence based assays. Sibiromycin11 is an aminoglycoside antibiotic 
(MIC of 0.25–2 μg/ml against staphylococcus aureus, similar level of activity against bacillus 
subtilis and escherichia coli) produced by streptosporangium sibiricum that also exhibits 
antitumour properties. 
 
 
Figure 4. Pyrrolo[2,1-c][1,4]benzodiazepines antibiotics 
 
Numerous natural products with the benzodiazepinone core structure (Figure 5) have been 
isolated and purified. Among them circumdatin alkaloid family isolated from a culture of the 
fungus aspergillus ochraceus displayed a large array of biological activities. 12 , 13  Moreover, 
asperlicin is a mycotoxin, derived from the fungus aspergillus alliaceus. It acts as a selective 
antagonist for the cholecystokinin receptor CCKA (ED50 of 27.7 µmole/kg in preventing CCK-8 
inhibition of charcoal meal gastric emptying in mice), and has been used as a lead compound for 
the development of a number of novel CCKA antagonists with potential clinical applications. 
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Additional representatives of this class include benzomalvins A–C (benzomalvins A have shown 
inhibitory activity against neuropeptide substance P witk Ki value at the human neurokinin NK1 
receptors) from penicillium sp,14  circumdatins A–G (circumdatins F exhibited an antifouling 
activity against bugula neritina larval settlement with ED50 of 8.8 µg/mL) from aspergillus 
ochraceus,15 and sclerotigenin from penicillium sclerotigenum16 a good number of which are 
biologically active. 
 
 
Figure 5. Benzodiazepinone-containing natural products 
 
Examples of naturally-occurring heteroazocanones are scarce. The naturally-occurring 
homalium alkaloids17 (Figure 6) were isolated from the homalium pronyense guillaum contain 
diazocanone core are believed to be biogenically-derived from spermine. Even thogh very little is 
known about the biological role of these unique structures, they have been the targets of many 
synthetic efforts. 
 
Figure 6. Homalium alkaloids 
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1.3.2 Medicinal applications and pharmacological activity 
 
Molecules containing heteroazepanone moiety have found both clinical and commercial 
success. A number of clinically important pharmaceuticals contain seven-membered rings with 
two heteroatoms. The most common of these compounds incorporate two nitrogen atoms in a 1,4-
relationship with an associated aromatic ring.  
Pharmacologically active dibenzoheteroazepanes and their structural analogues (Figure 7) 
containing a heteroaryl-fused heteroazepane ring6 account for a significant portion of widely 
prescribed azepine-based drugs. For example, Nitroxazepine (brand name Sintamil) is a tricyclic 
antidepressant which was reported to be used as an antidepressant agent. It is also indicated for the 
treatment of nocturnal enuresis. Nevirapine, marketed under the trade name Viramune, is the HIV-
1 reverse transcriptase inhibitor used to treat and prevent HIV/AIDS, specifically HIV-1. 18 
Pirenzepine (Gastrozepin), an M1 selective antagonist, is used in the treatment of peptic ulcers, as 
it reduces gastric acid secretion and reduces muscle spasm. Dibenzepin, sold under the brand name 
Noveril, is a tricyclic antidepressant used for the treatment of depression. Dibenzepin is used 
mainly in the treatment of major depressive disorder. 
 
 
Figure 7. Pharmacologically active dibenzoheteroazepanes and their structural analogues 
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Other examples of pharmaceutically important benzodiazepanones (Figure 8) include 
Clobenzepam, an antihistamine and anticholinergic drug, and Diazepinomicin, 19 an antimicrobial 
alkaloid from a marine micromonospora sp., which is a potent inhibitor of the RAS/RAF/MAPK 
signaling pathway with potential to treat multiple solid tumors. 
 
 
Figure 8. Pharmaceutically important benzodiazepanones 
 
Benzodiazepines (Figure 9) are a class of psychoactive drugs whose core chemical structure is 
the fusion of a benzene ring and a diazepine ring known to enhance the effect of the 
neurotransmitter gamma-aminobutyric acid (GABA) at the GABAA receptor, resulting in sedative, 
sleep-inducing, anti-anxiety, anticonvulsant, and muscle relaxant properties.20 
For instance, Bretazenil21 is an imidazopyrrolobenzodiazepine anxiolytic drug which is derived 
from the benzodiazepine family. Its high-potency results from high affinity binding to 
benzodiazepine binding sites where it acts as a partial agonist. Flumazenil22 sold under the trade 
name Anexate is a selective GABAA antagonist. It has antagonistic and antidote properties to 
therapeutically used benzodiazepines, through competitive inhibition. It is primarily used to treat 
benzodiazepine overdoses and to help reverse anesthesia. Arfendazam 23  has sedative and 
anxiolytic effects similar to those produced by other benzodiazepine derivatives, but is a partial 
agonist at GABAA receptors, so the sedative effects are relatively mild and it produces muscle 
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relaxant effects only at very high doses. Lofendazam23 is an active metabolite of arfendazam which 
is also used as a human pharmaceutical with sedative and anxiolytic effects. Telenzepine24 is a 
thienobenzodiazepane acting as selective M1 antimuscarinic agent. It is used in the treatment of 
peptic ulcers. 
 
 
Figure 9. Pharmaceutically important benzoheteroazepanones 
 
Additionally, several benzoxazepanone derivatives25 (Figure 9) have been found to have highly 
potent affinity for 5-HT1A serotonin receptor along with good selectivity over dopamine adrenergic 
receptors. Piclozotan displayed a nanomolar level of activity as a selective 5-HT1A receptor agonist 
and is currently being developed for treatment of the acute phase of cerebral infarction at phase II 
in clinical trial. 
The unwanted side-effects of the above mentioned naturally occurring antibiotics, 
pyrrolo[2,1-c][1,4]benzodiazepines, led to fruitful research on the synthesis of their analogues 
(Figure 10). One promising outcome of this research was the work of Wang and co-workers26 who 
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designed and synthesized the indole-containing pyrrolobenzodiazepine IN6CPBD and found that 
this compound exhibited high cytotoxicity against human melanoma and displayed enhanced DNA 
sequence selectivity. A significant breakthrough was the discovery of pyrrolobenzodiazepine 
dimers, capable of creating cross-links in the DNA by forming covalent bonds to guanine bases at 
each end of the molecule, for example SJG-136, which is reported to be in Phase II clinical trials.  
 
 
Figure 10. Synthetic pyrrolo[2,1-c][1,4]benzodiazepine antibiotics 
 
Figure 11. Pharmaceutically significant heteroazocanones 
 
Pharmaceutical applications of heteroazocanones (Figure 11) are more scarce compared to their 
seven-membered analogs. Nevertheless, some potent Neurokinin receptor NK1 antagonists 
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possess oxazocanones moiety (2 and 3). The eight-membered ring system is known to be an 
effective core region 27 , 28  and it fits well with the NK1 receptor. The diazocanone 
BDRM50171126 29  was shown to be active as a selective caspase-1 inhibitor, a class of 
pharmaceutical agents which have shown promising anti-inflammatory and analgesic activity and 
are effective in the treatment of rheumatoid arthritis. Another diazocanone-containing drug 
candidate SM-337 exhibited high potency as a cell growth inhibitor and in induced apoptosis in 
the MDA-MB-231 cancer cell line. 
 
1.4 Synthetic approaches 
 
Existing routes to heteroazepanones and their analogs containing an eight-membered ring 
(Scheme 1) largely rely on the preparation of lactams, such as intermolecular acylation of N-
nucleophiles by carboxylic acid derivatives (Chapter 1.5.2), intermolecular alkylation of primary 
or secondary amides (Chapter 1.5.4), and ring expansion reactions, including Beckmann and 
Schmidt rearrangements (Chapter 1.7). 
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Scheme 1 
 
Another group of methods involves ring closure through the formation of ether or amine moiety 
by means of nucleophilic substitution (Chapter 1.5.1) or reductive amination reactions (Chapter 
1.5.3). 
Due to the inherent difficulties of seven- and especially eight-membered ring formation, other 
more exotic cyclization methods often relying on strain release driven ring opening of small rings 
were developed (Chapter 1.5.5). 
Numerous reported multicomponent methods for assembly of heteroazepanone and 
heteroazocanone are known. Such methods often utilize carbonylation reactions (Chapter 1.6.1), 
double aminations (Chapter 1.6.2), or other cyclization methods applied in tandem sequence 
(Chapter 1.6.3). 
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1.5 Cyclizations 
1.5.1 Intermolecular Nucleophilic Substitution 
 
The earliest examples of using intermolecular aromatic substitution (Scheme 2) in the synthesis 
of benzo- and heteroaryl-fused heteroazepanones and heteroazocanones date to the 1960s. The 
preparation of oxazepanones30 ,31,32 (7, n = 0) and oxazocanones33 (7, n = 1) can be achieved 
through nucleophilic intramolecular cyclization of corresponding aryl halides (6) with a base (such 
as sodium ethoxide or potassium carbonate) in DMF at high temperature (160 – 170 °C). Starting 
materials (6) for such cyclization are commonly prepared by condensation of carboxylic acid 
derivatives (4) and amines (5) (See chapter 1.5.2).  
 
Scheme 2 
 
 
A similar strategy can be employed in the synthesis of diazepanones 834,35 and diazocanones 
9 36  (Scheme 3). For instance, base-mediated CuI/L-proline-catalyzed intramolecular aryl 
amination reaction as the key step was used by Majumdar35 in the preparation of 1,4-
benzodiazepinones 9 (Scheme 3a). Also, Fu36 has developed an efficient method for the 
preparation of medium- and large-sized nitrogen heterocycles via copper-catalyzed intramolecular 
N-arylation of phosphoramidates (9, X = DIPP) and carbamates (9, X = Boc) (Scheme 3b). 
Introduction of the phosphoryl group or tert-butoxycarbonyl at amine nitrogen in 9 was shown to 
improve intramolecular cyclization under copper catalysis, and this protecting groups can be easily 
removed under the mild conditions. 
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Scheme 3 
 
 
It was further shown that this methodology can be used for preparation of chiral substrates 
(Scheme 4). 37,38,39,40  For example, Schultz and co-workers38 have performed intermolecular 
cyclization of ortho-halogen substituted benzamides 11 (derived from chiral 1,2- and 1,3-amino 
alcohols), by a nucleophilic aromatic substitution process (Scheme 4a).Utilization of tertiary 
amides resulted in intramolecular cyclization to give benzoxazepanones 12 in good to excellent 
yields. Similarly, chiral oxazocanones 14 can be prepared via a “one-pot” deprotection/cyclization 
sequence (Scheme 4b).39,41 Upon treatment with various sources of basic fluoride (e.g., TBAF, 
CsF) in DMF at 85 °C, substrates 13 cyclized smoothly to afford the desired eight-membered rings 
14 in nearly quantitative yields. 
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Scheme 4 
 
 
A common variation of the described protocol utilizes intramolecular nucleophilic 
displacement of a nitro group in aromatic nitro compounds for preparation of seven- and eight-
membered heterocycles (Scheme 5). Samet and co-workers42 demonstrated that intramolecular 
nucleophilic displacement of a nitro group in ortho-nitrobenzoic acid amides 15 and 17 is a general 
method of preparing benzannulated seven- and eight-membered heterocycles 16 and 18. 
 
Scheme 5 
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1.5.2 Acylation of Nitrogen Nucleophiles by Carboxylic Acid Derivatives 
 
Historically, methods for synthesis of heteroazepanones and heteroazocanones largely rely on 
the lactam preparation protocols. Acylation of nitrogen nucleophiles by carboxylic acid derivatives 
can be considered the most straightforward cyclization method for such heterocycles. The effective 
synthesis of seven- and in some cases eight-membered rings via direct cyclization has been 
accomplished. The success of these reactions depends greatly on a ring size mainly due to the 
unfavorable enthalpic and entropic factors.43,44 
The earliest examples of employing this methodology for synthesis of diazepanones45,46 (20, X 
= NH) and oxazepanones47 (20, X = O) date back to the 1960’s and 1970’s respectively (Scheme 
6). It was shown that seven-membered cycles 20 can be produced by direct intermolecular 
acylation of amino group in 19 with carboxylic acids, esters or acyl chlorides.  
 
Scheme 6 
 
 
Commonly employed amide coupling reagents such as 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) 48 , 49  dicyclohexyl carbodiimide (DCC), 50  and 1-
hydroxybenzotriazole (HOBt) 51  can be used to facilitate the desired cyclization under mild 
conditions thus broadening the substrate scope of the reaction. For instance, optically active 
benzoxazepanes 22 can be prepared from chiral aminocarboxylic acid derivatives 21 by cyclization 
using DCC and HOBt (Scheme 7).52,53 
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Scheme 7 
 
 
Application of intramolecular amide coupling in synthesis of heteroazocanones (Scheme 8) is 
more scarce due to the unfavorable entropic factors of eight-membered ring closure5. Examples of 
this approach can be can be seen in the work by Korakas and Varvounis54  on synthesis of 
pyrrolobenzodiazepanes 23 (Scheme 8a) or in the report by Liebigs and co-workers55 showing 
preparation of dibenzoazocanes 24 (Scheme 8b). Preferential formation of seven-membered rings 
over eight-membered rings can also be shown using the example of work by Cale et al. (Scheme 
8c).56 Intermolecular acylation of tertiary amides 25 was followed by rearrangement yielding 
seven-membered lactams 26 exclusively, whereas eight-membered lactams 27 were not observed. 
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Scheme 8 
 
 
Bunce and Schammerhorn57 have developed a common variation of such acylative cyclization 
protocol (Scheme 9a). Various dibenzo-fused oxazepanones (29, X = O) and diazepanones (29, X 
= NH) were successfully obtained via a tandem reduction–lactamization reaction under dissolving 
metal conditions using iron and acetic acid. Tandem reactions involving reduction of an aromatic 
nitro group of 28 and trapping the aniline nitrogen with a suitably positioned carbonyl-containing 
functionality using iron powder in acetic acid at 115 °C affords the target heterocycles in >90% 
yield. It was also demonstrated that catalytic hydrogenation would not furnish the desired lactam 
(29) formation from these substrates (28) (Scheme 9b). Isolated products of simple reduction of 
the nitro group (amino compounds 30) can be heated in xylene at 140 °C to effect lactam formation. 
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Scheme 9 
 
 
1.5.3 Schiff base condensation 
 
A widely applicable method for the synthesis of diazepanones and diazocanones by 
intermolecular reaction between amines and carbonyl compounds is shown in Scheme 10. A three-
step procedure has been employed by Kassiou58 starting from the ortho-aminobenzophenone 31 
with the aniline nitrogen first acylated with a haloacetyl halide to give corresponding amides and 
subsequent aminolysis affording α-aminoamides 32. Following intramolecular Schiff base 
condensation afforded the benzazepanes 33 in 30–70% yields over three steps. It was further 
demonstrated that a single-step method can be employed using the same o-aminobenzophenones 
31 with a glycine ester hydrochloride to afford the target benzodiazepinone-type structures 33 in 
similar yields. 
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Scheme 10 
 
 
A similar strategy was employed by Butin et al. for making pyrrolobenzodiazepanes 36 
(Scheme 11).59 Their method is based on a one pot reduction of the nitro group in 34 to amino 
group and subsequent cyclization with concomitant formation of the diazepine and pyrrole rings. 
Reduction of corresponding ortho-nitrobenzamides 34 in glacial acetic acid with iron powder 
produced non-isolable amines that cyclized spontaneously to afford intermediate benzodiazepines 
35 which underwent another cyclocondensation to afford target pyrrolobenzodiazepanes 36. 
 
Scheme 11 
It was also demonstrated that Schiff base condensation methodology can be applied to form the 
eight-membered ring of diazocanones (Scheme 12). For instance, Wang et al.60  performed a 
tandem palladium-catalyzed hydrogenative conditions sequence that included reductive Cbz-
deprotection of 37 followed by condensation of the exposed amino group with the nearby aldehyde 
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group. The corresponding imine was readily reduced under reaction conditions to provide the 
desired product 38. 
 
Scheme 12 
 
 
1.5.4 Amide alkylation 
 
Ring closure through intermolecular alkylation of primary and secondary amides can be viewed 
as one of the alternative methods of heteroazepanone and heteroazocanone synthesis. An example 
of a strategically straightforward way of using this method was realized by Al-Tel et al. (Scheme 
13a).61 Modular CuI-L-proline catalyzed strategy for the synthesis of starting materials for eight- 
and nine-membered heteroatom ring systems (39) followed by base-mediated ring closure 
furnished various oxazocanones (40, X = O) and diazocanones(40, X = NH). Similarly, 
oxazepanones 43 can be made from N-substituted-o-chlorobenzamides 41 and o-halogenated 
phenols 42 (Scheme 13b).62 
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Scheme 13 
 
Some alternative methods of amide alkylation include using tethered ketones, double or triple 
bonds (Scheme 14). A facile and versatile synthesis of oxazepanones (45, X = O) and diazepanones 
(45, X = NH) from ketoamides 44 via Al(OTf)3-mediated cascade cyclization and ionic 
hydrogenation using the Et3SiH has been developed by Yin (Scheme 14a).
63 In the work by 
Schmid and co-workers 64  ortho-(2-propynyl)oxybenzamides 46 were cyclized under base 
catalysis to furnish seven-membered rings 47 (Scheme 14b) and lithium 
cyclohexylisopropylamide (Li-CHIP) in N-methylpyrrolidone was shown to be most efficient. It 
was also demonstrated by Ueda that appropriate ortho-allylaminobenzamide derivatives 48 can be 
used in an intermolecular cyclization using benzeneselenenyl chloride (Scheme 14c). 
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Scheme 14 
 
An interesting method for construction of the dibenzoxazepanone skeleton from the readily 
available substituted ortho-(aryloxy)benzamides 49 through an intramolecular cyclization 
involving a direct oxidative C–N bond formation in the final step was shown by Du. 65  As 
illustrated in Scheme 15, the N-methoxy oxazepanones 50 could be readily converted to N-
unsubstituted oxazepanone 51, through a palladium catalyzed hydrogenation reaction, which 
allows for the further derivatization of the free NH moiety. 
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Scheme 15 
 
 
1.5.5 Other ring closure methods 
 
Due to the unfavorable enthalpic and entropic factors43,44 the effective synthesis of seven- and 
especially eight-membered rings often rely on more exotic cyclization methods. Among them 
using strain release energy of small rings is one of the most dominant. Cyclizations described in 
Chapters 4 and 5 naturally fall into this category. 
An efficient two-step preparation of chiral oxazepanones 55 and oxazocanones starting from 
aminoalcoholes 52 and oxiranecarboxylic acid derivatives 53 (Scheme 16a) was initially 
discovered by Liebscher66 and further developed by Ohnmach and co-workers.67 Cyclization of 
substituted oxiranecarboxamides 54 in the presence of ZnCl2 furnished the desired seven-
membered cycles 55 in excellent yields. In all cases these cyclizations occurred with inversion of 
configuration. The effect of ZnCl2, in the product formation is believed to be the coordination of 
the zinc ion at NH and the oxirane oxygen atom activating the oxirane ring and directing the attack 
of the phenolic OH to the ß-position. It was further demonstrated that the same methodology can 
be applied to the broad range of chiral ethanolamines 5767 (Scheme 16c) and ortho-
phenylenediamines 5668 (Scheme 16b). The most efficient catalyst identified for the ring closure 
of the intermediate epoxyamides was found to be the Sc(OTf)3. 
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Scheme 16 
 
As demonstrated by Broggini,69a ortho-aminobenzamides 58 containing propynyl substituent 
on the amide nitrogen can serve as readily accessible precursors for the oxazocanone core (Scheme 
17). For example, diazotization of aniline nitrogen of 58 and in situ azide (59) formation by 
addition of sodium azide, followed by heating the resulting mixture under reflux in toluene, 
afforded the tricyclic product 60 in moderate yield. Thomas69b has shown that same sequence 
involving diazotization, azide addition followed by 1,3-dipolar cycloaddition reaction can be 
performed using polymer supported carbodiimide. 
 
Scheme 17 
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An intramolecular aza-Wittig reaction of the appropriately substituted phosphanimine 61 was 
utilized by Molina70 as a key step in synthesis of a pyrrolobenzodiazepane ring system (Scheme 
18). This approach allows cyclization of the diazepane ring (63) to occur under neutral and 
extremely mild reaction conditions and involves a simple work-up procedure. Staudinger reaction 
of azides 61 with tertiary phosphines directly led to the pyrrolo[2,1-c][1,4]benzodiazepanes 63 in 
yields of 90% and above at 0 °C and the conversion was completed in 1 hour. Moreover, when the 
highly reactive tributylphosphine was used as a cyclization agent, formation of intermediate 62 
was performed at lower temperature (–10 °C) and completion of the cyclization reaction required 
a shorter period of time (30 minutes). 
 
Scheme 18 
 
 
1.6 Multicomponent and tandem methods 
 
1.6.1 Carbonylation reaction  
 
Several strategies of constructing medium ring heterocycles involving carbonylation reaction 
with phosgene or transition metal-catalyzed transformations with different CO sources are 
described in literature.  
In 1982, Nagai71 reported an intermolecular acylation of ortho-isocyanatophenoxybenzenes 65, 
affording dibenzoxazepanones 66 in good yield (Scheme 19). Treatment of substituted ortho-
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aminophenoxybenzene starting materials 64 with phosgene, followed by cyclization with 
aluminum trichloride, afforded the desired oxazepanones 66. Likewise, both stages of this 
sequence can be performed in one pot if o-dichlorobenzene is used as a solvent, as demonstrated 
by Wagh.72 
 
Scheme 19 
 
 
An intramolecular carbonylation reaction has been performed by Lu and Alper6c, using 
appropriately substituted ortho-iodophenols 68 and nitrobenzenes 67 as starting materials and 
palladium-complexed dendrimers supported on silica (Scheme 20). The results showed that 
dendritic catalysts display high activity, affording oxygen (Scheme 20a) or nitrogen-containing 
(Scheme 20b) seven- or eight-membered ring fused heterocycles 69 an 70 in excellent yields. The 
transition-metal-catalyzed carbonylation reaction is a powerful tool in organic chemistry, however 
the difficulties associated with the separation of products from the reaction mixture and the 
recovery of the expensive, and sometimes toxic, catalysts are major drawbacks in these 
transformations. However, it was demonstrated that proposed silica-supported catalysts can be 
easily recovered by simple filtration in air and reused for up to eight cycles with only a slight loss 
of activity. The wide functional group compatibility of this carbonylation method was further 
demonstrated: reaction was shown to tolerate fluoro, chloro, methoxy, acetyl, and 
methoxycarbonyl groups. 
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Scheme 20 
 
 
Morimoto and co-workers 73  designed conceptually similar CO gas-free carbonylative 
cyclization of organic halides 71, with tethered nucleophiles using aldehydes as a substitute for 
carbon monoxide (Scheme 21). It was shown that described rhodium-catalyzed transformation can 
be used to access substituted oxazepanones 72. Elimination of the need for the direct use of carbon 
monoxide, achieved by utilizing various organic and inorganic carbonyls as a substitute for carbon 
monoxide makes carbonylation more experimentally simple and easy to use. 
 
Scheme 21 
 
 
45 
 
A base-mediated one-pot protocol for the modular synthesis of diversely-substituted 
benzoxazepanones 73 has been developed by Shen and Wu (Scheme 22a). 74  The desired 
transformation is achieved through an aromatic nucleophilic substitution (SNAr, O-arylation) 
followed by aminocarbonylation and spontaneous cyclization. Another one-pot synthesis of a 
broad range of oxazepanone substrates that relies on transition metal-catalyzed carbonylation was 
described by Chouhan and Alper (Scheme 22b). 75  This domino process includes ring-
opening/carboxamidation reactions of various N-tosylaziridines 74 with a range of ortho-
halophenols 75 under phase-transfer catalysis. The method was shown to be compatible with a 
range of cyclic or acyclic N-tosylaziridines 74 and ortho-halophenols or pyridinols 75 providing 
facile access to a variety of benzo- and pyrido-oxazepanones 76. 
 
Scheme 22 
 
 
In the work by Ryu and co-workers76 oxazepanone ring (79) formation is achieved through a new 
carbonylative annulation method for five- to seven-membered ring lactam synthesis (Scheme 23). 
Intermolecular substitution at nitrogen by α,β-unsaturated acyl radicals 78 (generated in situ from 
a variety of substituted N-phenethylalkynylamines 77) took place accompanied by elimination of 
an phenethyl radical.  
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Scheme 23 
 
 
1.6.2 Double amination 
 
Intermolecular copper-catalyzed double amination of aryl bromides 80 can proceed to afford 
substituted diazepanones 82 as demonstrated by Ma et al. (Scheme 24).77 N-Aryl aminocarbonyl 
groups was shown to greatly promote the copper-catalyzed coupling of aryl halides with amines. 
Therefore, double coupling reactions of dibromides with primary amines 81 offers an alternative 
direct pathway for preparing medium-sized rings under mild conditions.  
 
Scheme 24 
 
 
A general and highly efficient protocol for the synthesis of dibenzo-fused oxazepanones, 
diazepanones, and their structural analogues was reported by Tsvelikhovsky and Buchwald 
(Scheme 25).78 In the presence of catalytic quantities of palladium, readily accessible anilines (83, 
X = NH) or phenols (83, X = O) containing ester functionality in ortho position and 1,2-
dihaloarenes 84 were cross-coupled in the presence of ammonia to provide intermediate 86 and 
then spontaneous intramolecular condensation occurred to furnish the corresponding seven-
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membered ring of 87 in one step. This synthetic strategy is based on the assumption that at the 
reaction condition, initially formed precursor 85 would generate intermediate 86 via cross-
coupling with ammonia and then further spontaneously undergo an intramolecular condensation 
to form the corresponding dibenzodiazepanones (87, X = NH) and dibenzoxazepanones (X = O). 
 
Scheme 25 
 
 
A conceptually similar approach can be realized using primary amine substrates. For example, 
a large diversity can be quickly achieved in the three-component synthesis based on the Ugi 
reaction using bifunctional starting materials 88 containing aldehyde and carboxylic acid as 
reported by Zhang (Scheme 26).79 
 
Scheme 26 
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1.6.3 Other multicomponent methods 
 
Numerous reported multicomponent methods of heteroazepanone and heteroazocanone 
synthesis rely on utilizing cyclization methods previously described in Chapter 1.5 in tandem 
sequence. For instance, dibenzodiazepinones 91 can be prepared in one pot from ethyl ortho-
iodobenzoates 89 and ortho-phenylenediamines 90 (Scheme 27a). Initial nucleophilic substitution 
and subsequent intramolecular acylation can be achieved using combination of CuI and K3PO4.
80 
It was also demonstrated by Wu81 that ortho-halogenated benzaldehydes 92 can be used as reaction 
partners for ortho-aminophenoles 93 under oxidative conditions to allow the formation of dibenzo-
fused oxazepanones 94 (Scheme 27b). In a conceptually similar transformation reported by Vega82 
a nucleophilic attack on aziridine 95 followed by an intermolecular acylation provides expedited 
access to diazepanones 96 (Scheme 27c).  
 
Scheme 27 
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Another group of bicomponent methods also relying on nucleophilic substitution as a first step, 
uses amide alkylation in order to cyclize initially formed intermediates. For example, Ma 83 
reported an effective regioselective synthesis of fused oxazepanone skeleton (99, X = O) from 
commercially available N-substituted salicylamides (97, X = O) and 1,2-difluorobenzenes 98 
(Scheme 28). It was further shown84 that the same method is similarly efficient for the synthesis 
of benzodiazepines (99, X = NH) from ortho-aminobenzamides (97, X = NH). 
 
Scheme 28 
 
 
An inherently elegant reaction between acrylic acid derivatives (101, 104) and aminoalcohols85 
103 (Scheme 29b) or diamines86 100 (Scheme 29a) can be utilized to make oxazepanones 105 or 
diazepanones 102 respectively. An interesting related transformation was reported by Lang and 
Wang. 87  Enantioselective NHC-catalyzed amination of α-bromoenals 106 with ortho-
benzodiamines 107 yielded corresponding products of formal [4+3] annulation 108 in high yields 
with excellent enantioselectivities (Scheme 29c).  
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Scheme 29 
 
 
Scheme 30 
 
 
A conceptually interesting way to access regio-isomeric dibenzoxazepanones 111 and 112 from 
aminoquinoline benzamides 109 and ortho-bromophenols 110 was reported by Zhu88 (Scheme 
30). Through the choice of conditions, the reaction can be directed to proceed towards 111 via a 
sequential C−H etherification and subsequent amide alkylation, both controlled by the 
aminoquinoline group (removable directing auxiliary) and Cu(I), or in direction of 112 through a 
C−H etherification followed by Smiles rearrangement promoted by Cu(II) and t-BuOK. 
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1.7 Ring expansion 
 
Historically, methods for lactam synthesis largely relied on ring expansion rearrangements of 
oximes (Beckmann rearrangement) and adizohydrin intermediates (Schmidt rearrangements) 
obtained from ketones. Unfortunately, in many cases this inherently elegant transformations 
require harsh reaction conditions which limit its usefulness to carefully chosen substrates and cause 
regioselectivity problems.89 
The first reported example of using Beckmann rearrangement in synthesis of oxazepanones was 
carried out by McEvoy and Allen in 1970 (Scheme 31a).90 The rearrangement of the oxime 113 
furnished a separable mixture of lactams 114 and 115, in which lactam 114, the product of aryl 
migration, prevailed. Similar results were obtained by Moormann91 for heteroazepanones (Scheme 
31b). Various ketones 116 were converted to oximes 117, and then Beckmann rearrangement 
produced a 7:3 mixture of isomeric lactams 118 and 119 that were separated using column 
chromatography. 
 
Scheme 31 
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In response to these problems, many groups have reported modifications of the reaction that 
allows the transformation to proceed under milder conditions. For instance, Augustine et al.Ошибка! 
Закладка не определена. reported an efficient catalytic method for the Beckmann rearrangement of 
ketoximes 120 to amides 121 mediated in excellent yields by a catalytic amount (15 mol %) of 
propylphosphonic anhydride (T3P) at room temperature (Scheme 32). The main advantages of this 
environmentally friendly protocol include procedural simplicity, particularly ease of isolation of 
the products, and remarkable functional group tolerance. Other reagents used to facilitate Beckman 
rearrangement towards heteroazepanones at mild conditions include Ca(NTf2)2,
92  cyanuric 
trichloride,93 and combination of InBr3 with AgOTf.
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Scheme 32 
 
 
Early examples of using Schmidt rearrangement in heteroazepanone synthesis include works 
by Wright95 and Lindwall96. Substituted chromanones 122 were subjected to sodium azide in 
presence of sulfuric acid and then in some cases treated with alkyl iodides to form corresponding 
oxazepanones 123 in 24 – 67% yield (Scheme 33a). Schmidt reaction with an unsymmetrical 
ketone can theoretically lead to two possible products. It is notable that even though in the reaction 
with 4-chromanone (122, R1 = H) while the yields did not rule out the formation of both possible 
isomers (123 and 124) an alternative benzoxazepanone 124 has not been detected in the reaction 
mixture. In a similar reaction performed by Skalitzky and co-workers 97  substituted 
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dihydroquinolinones 125 were converted to corresponding diazepanones 126 by means of Schmidt 
rearrangement (Scheme 33b). The desired transformation was achieved in yields around 85% using 
sodium azide and methanesulfonic acid. Although the described reaction is quite efficient, the 
regioselectivity of the rearrangement was reported to be problematic to control. In addition to the 
desired product 126, the regioisomeric amide 127 was also formed in ∼10% yield. 
 
Scheme 33 
 
 
Despite the development of a variety of new protocols of Schmidt rearrangement its utility in 
many cases is limited by to the severity of the reaction conditions required to effect the ring 
expansion. Strong protic or Lewis acids are often required, giving rise to the problematic side 
reactions observed in acid labile molecules. In order to overcome this scope limitations Evans et 
al. 98  have developed the protocol for a photoinduced Schmidt rearrangement of the 
azidotriisopropylsilyl ethers 129 (Scheme 34), which are prepared by the direct azidonation of the 
triisopropylsilyl enol ethers 128. The reaction was shown to be applicable to heterocyclic starting 
materials and afforded oxazepanones 130 in yields over 80% at 0 °C in one hour. 
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Scheme 34 
 
 
A synthetic route to the enantiopure oxazepanones reported by Aube99  represents another 
interesting application of Schmidt rearrangement (Scheme 35). The Lewis acid-mediated azido-
Schmidt reaction of chiral azido alcohol 132 with ketone 131 furnished a 9:1 diastereomeric 
mixture of ring-expanded lactams 133 and 134 in 75% overall yield. These lactams were separated 
using chromatography, and the major product 133 was subjected to reductive removal of the 
phenethyl group using metal ammonia to provide the enantiopure product 135. 
 
Scheme 35 
 
 
Stevens rearrangement is another example of ring expansion reaction which was used in 
oxazepanone synthesis.100 Fluoride ion-induced desilylation of trimethylsilylmethylpiperazinium 
ions 136 was shown to lead to corresponding methylides 137 which underwent rearrangement to 
form seven-membered rings 138 (Scheme 36). 
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Scheme 36 
 
 
Many reported strategies of heteroazepanone and heteroazocanone synthesis through ring 
expansion rely on ring opening of azeridines (Scheme 37). For example,101  treatment of the 
appropriately substituted dihydroquinazolinones 139 with potassium tert-butoxide allowed 
formation of aziridine intermediates 140 and yielded the benzodiazepanones 141 (Scheme 37a). It 
was shown that transformation is initiated by anion formation through N-deprotonation. The next 
step was ring closure to aziridine 140, which then isomerized to the benzodiazepane 141. In 
another study,102 a synthetic sequence consisting of cycloaddition of dichlorocarbene to the C=N 
double bond of benzoxazin 142 (Scheme 37b), leading to the formation of the gem-dihaloazirino-
fused heterocycle 143, and subsequent aziridine ring opening with N–C bond breaking with 
trifluoroacetic acid at room temperature was shown to furnish benzoxazepanone 144. Likewise, 
irradiation of the azides 145 (Scheme 37c) resulted in ring expansion to yield the desired seven-
membered ring 147 via the azirine intermediates 146 as reported by Sashida et al.103 
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Scheme 37 
 
 
Ring expansion of azetidines was also shown to be a viable strategy for diazepanone and 
diazocanone synthesis. In the study by Buchwald and co-workers,104 a simple method for the 
preparation of medium ring heterocycles 151 employing a Cu-catalyzed coupling of a β-lactams 
149 with an aryl bromide or iodide 148 followed by intramolecular attack of a pendant amino 
group in 150 has been developed (Scheme 38a). A ring-expansion step proceeded through an 
intramolecular transamidation reaction. Similarly, tethered halides 152 treated with liquid 
ammonia gave directly the corresponding seven-, eight-, and nine-membered ring-expanded 
azalactams 153 in good yield as shown by Crombie et al. (Scheme 38b).105 
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Scheme 38 
 
 
Yet another strategy for diazepanone and diazocanone synthesis relies on ring opening in fused 
heterocyclic systems. For example, in the work by Sherrill106 unsubstituted diazocanone 155 was 
obtained via cleavage of the N-N bond in tetrahydropyrazolopyrazole ring system 154 (Scheme 
39) which was accomplished in high yield by catalytic hydrogenation using Raney nickel. 
 
Scheme 39 
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1.8 Conclusion 
 
Heteroazepanones and heteroazocanones are a structural moieties found in a wide range of 
natural products, which possess a broad spectrum of biological activities, as well as important 
building blocks for drugs that have found both clinical and commercial success. 
The utility of this heterocyclic substrates along with their importance for medicinal chemistry 
stimulated the development of many methods for their preparation. Despite the synthetic 
challenges associated with the cyclization of medium-sized rings, numerous strategies have been 
developed, including methods based on cyclization and ring expansion reactions, along with 
multicomponent and tandem methods. 
However, there are much fewer approaches for preparing enantiomerically pure 
heteroazepanones and heteroazocanones. Helping to address this problem we designed methods 
for the diastereoselective addition of tethered chiral nucleophiles to prochiral cyclopropenes that 
allow the expedited access to stereodefined cyclopropane-fused oxazepanones and diazepanones 
(See Chapters 4 and 5). 
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Chapter 2. Nucleophilic addition of amines to cyclopropenes en route to 
GABA amides 
 
2.1 Introduction 
 
Cyclopropanes are characterized by enhanced strain energy.  This feature allows for the 
utilization of strain-release driven transformations such as a ring opening. The propensity of 
donor–acceptor cyclopropanes145 (DAC) (156) toward ring cleavage (Scheme 40a) is proportional 
to polarization of the C–C bond between electron-donating and electron-withdrawing groups. In 
our studies107 of DACs, we investigated the possibility to access substituted GABA derivatives 
158 via the ring opening of DAC 157 (Scheme 40b). 
 
Scheme 40 
 
 
γ-Aminobutyric acid (GABA) is the prominent inhibitory neurotransmitter in the mammalian 
central nervous system which plays a principal role in reducing neuronal excitability,108 and is a 
species of immense importance for modern bioorganic and medicinal chemistry. This motif is 
omnipresent in natural products, including Bistramide A (Figure 12).109 
GABA derivatives are also widely used in numerous over-the-counter and prescription 
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medicinal agents, such as Lyrica (Pregabalin), Noofen (Phenibut), Lioresal (Baclophen), or anti-
arthritic drug Trocade (Cipemastat) (Figure 12). 
 
 
Figure 12. Pharmacologically important GABA derivatives 
 
2.2 Prior attempts of Nucleophilic addition of amines to 3,3-disubstituted cyclopropenes 
 
In order to achieve the polarization required for cyclopropane ring cleavage, strong EWGs are 
commonly employed. A typical example would be two ester groups (159),110 additionally activated 
by a Lewis acid (“pull” strategy) (Scheme 41a), which leads to products 160 with an “extra” 
carboxylate moiety at the α-carbon. The possibility to employ an alternative “push” strategy 
(Scheme 41b) by taking advantage of our formal nucleophilic substitution methodology that allows 
for installation of various N-moieties in the cyclopropane ring (161) was previously proposed in a 
report from our group.107 Herein we demonstrate the proof of concept and employment of this 
strategy toward synthesis of GABA amide derivatives. 
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Scheme 41 
 
 
Formal nucleophilic substitution of halocyclopropanes 162107 provides convenient access to 
various cyclopropylamine derivatives 166, including carboxamides and sulphonamides of trans-β-
aminocyclopropanecarboxylic acid (β-ACC), N-cyclopropylhetaryls and N-cyclopropylanilines  
(Scheme 42).107,111 These reactions proceed via a base-driven nucleophilic addition across the 
double bond of conjugate cyclopropene 165.112,113 However, attempts to isolate hydroamination 
products resulting from the addition of electron-rich amine derivatives to the in situ generated, 
very electrophilic 1-substituted cyclopropenes 165 were unsuccessful. Small amount of water 
generated as by-product upon dehydrohalogenation of 162 in the presence of KOH resulted in a 
rapid, amine-mediated ring-opening hydration of intermediate cyclopropene 165 affording 
aldehyde 167 (Scheme 42).107 Furthermore, nitrogen nucleophiles do not easily add to less 
electrophilic, non-conjugate 3,3-disubstituted cyclopropenes 163 under conditions used for 
generation thereof.114 This reaction was completely suppressed by a much more facile addition of 
an alkoxide (employed as a base for dehydrohalogenation step), to afford cyclopropanol ether 164. 
Thus, employment of stable, isolated cyclopropenes 163 115  was envisaged as an alternative 
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approach to hydroamination that could be carried out under alcohol- and/ or water-free conditions. 
 
Scheme 42 
 
 
2.3 Accessing GABA derivatives via the ring opening of donor–acceptor cyclopropanes 
 
Herein, we have successfully employed a “push” strategy for ring opening of “push–pull” 
cyclopropanes 171 generated in situ via the unassisted nucleophilic addition of electron-rich 
amines across the double bond of cyclopropene-3-carboxamides 168 (Scheme 43). This concept 
was utilized in efficient one-pot synthesis of GABA derivatives 170. 
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Scheme 43 
 
Firstly, we exposed neat N,N-diethyl-1-methylcycloprop-2-ene-1-carboxamide (168a, R1 = R2 
= Et)115 to diethylamine (169a, R4 = R3 = Et, 3.0 equiv.) at various temperatures to monitor the 
ring opening (Scheme 43a). It was found that heating the mixture at 100 °C allowed for complete 
and clean ring cleavage. The GC analysis of crude reaction mixtures showed a single product peak, 
attributed to enamine 172aa. Next, the crude mixture was treated with borohydride (NaBH4 or 
NaBH(OAc)3) in dichloromethane to afford the target amide 170aa as a single product in good 
yield. 
It was anticipated that the addition of an electron-rich amino group would help trigger the 
desired bond cleavage in an intermediate 171 (Scheme 43b). The resulting zwitterionic 
intermediate 174, in the presence of a proton source, would be stabilized in a form of an imine 172 
(if derived from primary amine 169) or an enamine 173, respectively. Species 172 or 173 can 
subsequently be reduced in situ to give GABA amide 170, or be employed in various imine or 
enamine chemistry. 
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Scheme 44 
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Interestingly, under similar conditions, diisopropylamine (169b) did not react at all (170ad in 
Scheme 44), leaving cyclopropene 168a intact even after extended heating at 125 °C. Apparently, 
this bulky amine was insufficiently nucleophilic to enable the hydroamination step (170ab). In 
contrast, cyclic secondary amines, such as pyrrolidine (169c), morpholine (169d), and N-ethyl- 
(169e), N-benzylpiperazines (169f) afforded GABA amides 170ad–170af in good yields. N,N-
Diisopropyl-1-methylcycloprop-2-ene-1-carboxamide (168b) and (1-methylcycloprop-2-en-1-
yl)(pyrrolidin-1-yl)methanone (168c) proved to be similarly efficient as 168a with a number of 
secondary amines. Reaction with primary amines, such as phenethylamine (169g), benzylamine 
(169h), and n-butylamine (169j), also proceeded uneventfully, although somewhat more 
sluggishly. It was also necessary to raise the temperature to 140 °C to drive the reaction with 
aniline (168i) to complete conversion.  
Finally, a possibility to induce a diastereoselective ring cleavage upon  the addition of chiral 
amines was probed (Scheme 44) by reacting cyclopropene 168a with α-phenylethylamine (169k). 
Unfortunately, transfer of stereochemical information from a remote stereogenic center was not 
efficient, and the corresponding adduct 170ak was produced as a 1 : 1 mixture of two 
diastereomers. 
 
2.4 Conclusion 
An efficient one-pot synthesis of various GABA amides has been demonstrated. Unassisted 
nucleophilic addition of primary and secondary amines across the double bond of cyclopropene-
3-carboxamides is followed by a ring opening of the resulting donor-acceptor cyclopropanes. 
Subsequent in situ reduction of enamine or imine intermediates allows access to substituted GABA 
derivatives. 
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2.5 Experimental 
 
2.5.1 General information 
 
NMR spectra were recorded on a Bruker Avance DRX-500 with a dual carbon/proton 
cryoprobe (CPDUL). 13C NMR spectra were registered with broadband decoupling. The (+) and 
(-) designations represent positive and negative intensities of signals in 13C DEPT-135 
experiments. IR spectra were recorded on a Shimadzu FT-IR 8400S instrument. HRMS was 
carried out on LCT Premier (Micromass Technologies) instrument; ESI TOF detection techniques 
were used. GC analyses were performed on a Shimadzu GC-2010 gas chromatograph with FID 
detector and equipped with an AOC20i auto-injector and an AOC-20S auto-sampler tray (150 
vials); 30 m 0.25 mm 0.25 mm capillary column, SHR5XLB, polydimethylsiloxane; 5% Ph was 
employed. Helium (99.96%), additionally purified by passing consecutively through a CRS 
oxygen/moisture/hydrocarbon trap (#202839) and VICI oxygen/moisture trap (P100-1), was used 
as a carrier gas. Hydrogen gas was used as FID fuel; zero-grade air and zerograde nitrogen were 
used as an oxidant and make-up gas, respectively, for the FID. All these gases were purified by 
passing through CRS #202839 traps. The following GC parameters were used for all analyses: 
carrier gas flow rate 2.5 mL/min; oven temperature program: 50 °C (2 min) - 20 °C/min - 230 °C 
(6 min), injector temperature 275 °C. Column chromatography was carried out on silica gel 
(Sorbent Technologies, 40-63 µm). Pre-coated silica gel plates (Sorbent Technologies Silica XG 
200 µm) were used for TLC analyses. Anhydrous dichloromethane was obtained by passing 
degassed commercially available HPLC-grade inhibitor-free solvents consecutively through two 
columns filled with activated alumina and stored over molecular sieves under nitrogen. Water was 
purified by dual stage deionization followed by dual stage reverse osmosis. Synthesis of starting 
materials: N,N-diethyl-1-methylcycloprop-2-ene-1-carboxamide (168a), N,N-diisopropyl-1-
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methylcycloprop-2-ene-1-carboxamide (168b) and (1-methylcycloprop-2-en-1-yl)(pyrrolidin-1-
yl)methanone (168c) was detailed in previously published paper from our group.115 Commercially 
available amines: aniline (169i), diethylamine (169a), pyrrolidine (169c), morpholine (169d), n-
butylamine (169j) were dried with granulated potassium hydroxide and distilled immediately prior 
to use. All other reagents were purchased from commercial vendors and used as received. 
 
2.5.2 Synthesis of GABA-amide derivatives 
 
N,N-Diethyl-2-methyl-4-morpholinobutanamide (170ad): 
Typical procedure: Oven-dried 2 mL Weaton vial was charged 
with N,N-diethyl-1-methylcycloprop-2-ene-1-carboxamide (168a) 
(100 mg, 0.65 mmol, 1.0 equiv) and morpholine (169d) (86 µL, 85 mg, 0.96 mmol, 1.5 equiv).  
The mixture was stirred at 100 oC for 1 h, then NaBH4 (25 mg, 0.65 mmol, 1.0 equiv) in dry 
dichloromethane (2 mL) was added, and the resulting solution was stirred overnight at r.t.  The 
reaction mixture was partioned between 2M aqueous NaOH (2 mL) and ethyl acetate (2 mL).  The 
organic phase was separated, the aqueous layer was extracted with ethyl acetate (2 x 2 mL).  
Combined organic layers were concentrated in vacuum and diluted with 2M aqueous HCl (3 mL).  
The resulting solution was washed with ethyl acetate (3 x 5 mL), then basified with NaOH and 
extracted with ethyl acetate (3 x 5 mL).  Combined organic layers were washed with brine (5 mL), 
dried with MgSO4 and evaporated.  Preparative column chromatography of residue on silica gel 
doped with 0.5% of triethylamine in EtOAc afforded the titled compound as a yellow oil, Rf  0.25 
(EtOAc).  Yield 107 mg (0.44 mmol, 68%). 1H NMR (500 MHz, CDCl3) δ 3.67 (t, J = 4.7 Hz, 
4H), 3.45–3.27 (m, 4H), 2.76–2.72 (m, 1H), 2.42 (br. s, 2H), 2.36 (br. s, 2H), 2.30–2.24 (m, 2H), 
1.92–1.88 (m, 1H), 1.55–1.51 (m, 1H), 1.18 (t, J = 7.2 Hz, 3H), 1.11 (d, J = 6.8 Hz, 3H), 1.09 (d, 
J = 7.1 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 175.7, 67.2 (-, 2C), 56.8 (-), 53.8 (-, 2C), 42.0 (-), 
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40.4 (-), 33.4 (+), 31.0 (-), 18.6 (+), 15.0 (+), 13.2 (+); FT IR (NaCl, cm-1): 2930, 2854, 2806, 1659, 
1643, 1614, 1445, 1427, 1379, 1359, 1257, 1116, 1070, 995, 854, 793, 773; HRMS (TOF ES): 
found 265.1880, calculated for C13H26N2O2Na (M+Na) 265.1892 (4.5 ppm).  
 
4-(Diethylamino)-N,N-diethyl-2-methylbutanamide (170aa):  Was 
prepared according to Typical Procedure, N,N-diethyl-1-
methylcycloprop-2-ene-1-carboxamide (168a) (100 mg, 0.65 mmol, 
1.0 equiv) and diethylamine (169a) (202 µL, 143 mg, 1.95 mmol, 3.0 equiv).  The reaction was 
carried out at 100 oC for 1 hr.  Reduction with NaBH4, acid-base extraction followed by preparative 
column chromatography on silica gel afforded the title compound as a yellow oil, Rf 0.28 
(DCM/MeOH 10:1).  Yield 98 mg (0.43 mmol, 66%).  1H NMR (500 MHz, CDCl3) δ 3.44–3.36 
(m, 2H), 3.31–3.20 (m, 2H), 2.71–2.64 (m, 1H), 2.54–2.43 (m, 4H), 2.43–2.32 (m, 2H), 1.85–1.81 
(m, 1H), 1.50–1.46 (m, 1H), 1.15 (t, J = 7.1 Hz, 3H), 1.08 (d, J = 6.8 Hz, 3H), 1.06 (d, J = 7.1 Hz, 
3H), 0.97 (t, J = 7.1 Hz, 6H); 13C NMR (126 MHz, CDCl3) δ 175.7, 50.5 (-), 46.7 (-, 2C), 41.9 (-), 
40.4 (-), 33.5 (+), 31.3 (-), 18.4 (+), 15.0 (+), 13.2 (+), 11.7 (+, 2C); FT IR (NaCl, cm-1): 2968, 
2932, 2799,1637, 1448, 1429, 1379, 1261, 1126, 1070; HRMS (TOF ES): found 251.2095, 
calculated for C13H28N2ONa (M+Na) 251.2099 (1.6 ppm). 
 
N,N-Diethyl-2-methyl-4-(pyrrolidin-1-yl)butanamide (170ac):  
Was prepared according to Typical Procedure, N,N-diethyl-1-
methylcycloprop-2-ene-1-carboxamide (168a) (100 mg, 0.65 mmol, 
1.0 equiv) and pyrrolidine (169c) (160 µL, 139 mg, 1.95 mmol, 3.0 equiv).  The reaction was 
carried out at 100 oC for 1 hr.  Reduction with NaBH4, acid-base extraction followed by preparative 
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column chromatography on silica gel afforded the title compound as a yellow oil, Rf 0.30 
(DCM/MeOH 10:1).  Yield 104 mg (0.46 mmol, 71%).  1H NMR (500 MHz, CDCl3) δ 3.42–3.36 
(m, 2H), 3.34–3.23 (m, 3H), 2.76–2.71 (m, 1H), 2.50–2.44 (m, 4H), 2.37–2.34 (m, 1H), 1.92–1.88 
(m, 1H), 1.74 (br. s, 4H), 1.61–1.57 (m, 1H), 1.16 (t, J = 7.1 Hz, 3H), 1.11–1.07 (m, 6H); 13C NMR 
(126 MHz, CDCl3) δ 175.7, 54.1 (-), 54.1 (-, 2C), 41.9 (-), 40.4 (-), 33.8 (+), 33.3 (-), 23.6 (-, 2C), 
18.4 (+), 15.0 (+), 13.2 (+); FT IR (NaCl, cm-1): 2968, 1786, 1634, 1464, 1433, 1379, 1261, 1221, 
1128, 1097, 752, 733; HRMS (TOF ES): found 227.2117, calculated for C13H27NO2 (M+H) 
227.2123 (2.6 ppm). 
 
N,N-Diethyl-2-methyl-4-(phenylamino)butanamide (170ai):  
Was prepared according to Typical Procedure, N,N-diethyl-1-
methylcycloprop-2-ene-1-carboxamide (168a) (100 mg, 0.65 
mmol, 1.0 equiv) and aniline (169i) (118 µL, 121 mg, 1.30 mmol, 2.0 equiv).  The reaction was 
carried out at 140 oC for 5 hrs.  Reduction with NaBH4, acid-base extraction followed by 
preparative column chromatography on silica gel afforded the title compound as a yellow oil, Rf 
0.30 (DCM/MeOH 15:1).  Yield 110 mg (0.44 mmol, 68%).  1H NMR (400 MHz, CDCl3) δ 7.15 
(t, J = 7.5 Hz, 2H), 6.67 (t, J = 7.3 Hz, 1H), 6.57 (d, J = 7.9 Hz, 2H), 3.74 (br. s, 1H), 3.42–3.34 
(m, 2H), 3.32–3.24 (m, 2H), 3.15–3.04 (m, 2H), 2.83–2.74 (m, 1H), 2.17–2.04 (m, 1H), 1.71–1.63 
(m, 1H), 1.16 (d, J = 6.8 Hz, 3H), 1.14–1.09 (m, 6H); 13C NMR (101 MHz, CDCl3) δ 175.5, 148.4, 
129.2 (+, 2C), 117.2 (+), 112.7 (+, 2C), 42.4 (-), 41.9 (-), 40.5 (-), 33.9 (+), 33.9 (-), 18.6 (+), 14.9 
(+), 13.2 (+); FT IR (NaCl, cm-1): 3350, 2972, 1932, 1628, 1603, 1508, 1466, 1433, 1321, 1260, 
750, 733, 694; HRMS (TOF ES): found 271.1773, calculated for C15H24N2ONa (M+Na) 271.1786 
(4.8 ppm). 
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4-(Benzylamino)-N,N-diethyl-2-methylbutanamide (170ah):  
Was prepared according to Typical Procedure, N,N-diethyl-
1-methylcycloprop-2-ene-1-carboxamide (168a) (100 mg, 
0.65 mmol, 1.0 equiv) and benzylamine (169h) (142 µL, 139 mg, 1.30 mmol, 2.0 equiv).  The 
reaction was carried out at 115 oC for 2 hrs.  Reduction with NaBH4, acid-base extraction followed 
by preparative column chromatography on silica gel afforded the title compound as a yellow oil, 
Rf 0.33 (DCM/MeOH 10:1).  Yield 111 mg (0.42 mmol, 65%).  
1H NMR (400 MHz, CDCl3) δ 
7.29–7.17 (m, 5H), 3.76–3.69 (m, 2H), 3.36–3.24 (m, 4H), 2.80–2.71 (m, 1H), 2.64–2.52 (m, 2H), 
2.47 (br. s, 1H), 1.93–1.85 (m, 1H), 1.59–1.51 (m, 1H), 1.12 (t, J = 7.1 Hz, 3H), 1.06–1.01 (m, 
6H); 13C NMR (101 MHz, CDCl3) δ 175.9, 139.9, 128.5 (+, 2C), 128.4 (+, 2C), 127.1 (+), 54.0 (-), 
47.2 (-), 42.0 (-), 40.5 (-), 34.4 (-), 33.6 (+), 18.4 (+), 15.0 (+), 13.2 (+); FT IR (NaCl, cm-1): 3282, 
2972, 2931, 1634, 1454, 1433, 1379, 1263, 1219, 1125, 1097, 733, 698; HRMS (TOF ES): found 
285.1933, calculated for C16H26N2ONa (M+Na) 285.1943 (3.5 ppm). 
 
N,N-Diethyl-2-methyl-4-(phenethylamino)butanamide 
(170ag):  Was prepared according to Typical Procedure, 
N,N-diethyl-1-methylcycloprop-2-ene-1-carboxamide 
(168a) (100 mg, 0.65 mmol, 1.0 equiv) and phenethylamine (169g) (123 µL, 118 mg, 0.98 mmol, 
1.5 equiv).  The reaction was carried out at 100 oC for 2 hrs.  Reduction with NaBH4, acid-base 
extraction followed by preparative column chromatography on silica gel afforded the title 
compound as a yellow oil, Rf 0.32 (DCM/MeOH 15:1).  Yield 135 mg (0.49 mmol, 75%).  
1H 
NMR (400 MHz, CDCl3) δ 7.28 (t, J = 7.7 Hz, 2H), 7.20–7.18 (m, 3H), 3.41–3.20 (m, 4H), 2.88 
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(t, J = 6.1 Hz, 2H), 2.84–2.81 (m, 2H), 2.78 (br.s, 1H), 2.78–2.69 (m, 1H), 2.69–2.57 (m, 2H), 
1.92–1.83 (m, 1H), 1.64 - 1.55 (m, 1H), 1.14 (t, J = 7.1 Hz, 3H), 1.10 (d, J = 6.7 Hz, 3H), 1.08 (t, 
J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 175.8, 139.8, 128.8 (+, 2C), 128.6 (+, 2C), 126.3 
(+), 51.0 (-), 47.4 (-), 42.0 (-), 40.5 (-), 36.1 (-), 34.1 (-), 33.6 (+), 18.3 (+), 15.0 (+), 13.2 (+); FT 
IR (NaCl, cm-1): 3303, 2970, 2932, 1632, 1452, 1433, 1379, 1261, 924, 910, 738, 700; HRMS 
(TOF ES): found 277.2275, calculated for C17H29N2O (M+H) 277.2280 (1.8 ppm). 
 
N,N-Diethyl-4-(4-ethylpiperazin-1-yl)-2-methylbutanamide 
(170ae):  Was prepared according to Typical Procedure, N,N-
diethyl-1-methylcycloprop-2-ene-1-carboxamide (168a) 
(100 mg, 0.65 mmol, 1.0 equiv) and 1-ethylpiperazine (169e) (124 µL, 111 mg, 0.98 mmol, 1.5 
equiv).  The reaction was carried out at 100 oC for 1 hr.  Reduction with NaBH4, acid-base 
extraction followed by preparative column chromatography on silica gel afforded the title 
compound as a yellow oil, Rf 0.25 (DCM/MeOH 15:1).  Yield 126 mg (0.47 mmol, 72%).  
1H 
NMR (400 MHz, CDCl3) δ 3.48–3.35 (m, 2H), 3.33–3.19 (m, 2H), 2.71 (td, J = 13.7, 6.8 Hz, 1H), 
2.37 (br. s, 8H), 2.38 (q, J = 7.1 Hz, 2H), 2.29–2.16 (m, 2H), 1.87 (td, J = 13.6, 8.0 Hz, 1H), 1.52 
(td, J = 13.3, 7.3 Hz, 1H), 1.16 (t, J = 7.1 Hz, 3H), 1.10–1.04 (m, 9H); 13C NMR (101 MHz, CDCl3) 
δ 175.8, 56.3 (-, 2C), 53.2 (-), 53.0 (-), 52.4 (-, 2C), 42.0 (-), 40.5 (-), 33.6 (+), 31.6 (-), 18.6 (+), 
15.0 (+), 13.3 (+), 12.0 (+); FT IR (NaCl, cm-1): 2968, 2932, 2808, 1643, 1634, 1467, 1447, 1431, 
1259, 1164, 1132, 1026, 943, 781; HRMS (TOF ES): found 270.2535, calculated for C15H32N3O 
(M+H) 270.2545 (3.7 ppm). 
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4-(4-Benzylpiperazin-1-yl)-N,N-diethyl-2-
methylbutanamide (170af):  Was prepared according 
to Typical Procedure, N,N-diethyl-1-methylcycloprop-
2-ene-1-carboxamide (168a) (100 mg, 0.65 mmol, 1.0 equiv) and 1-benzylpiperazine (169f) (169 
µL, 172 mg, 0.98 mmol, 1.5 equiv).  The reaction was carried out at 100 oC for 1 hr.  Reduction 
with NaBH4, acid-base extraction followed by preparative column chromatography on silica gel 
afforded the title compound as a yellow oil, Rf 0.33 (DCM/MeOH 12:1).  Yield 159 mg (0.48 
mmol, 74%).  1H NMR (400 MHz, CDCl3) δ 7.27–7.19 (m, 5H), 3.46 (s, 2H), 3.52–3.36 (m, 2H), 
3.34–3.20 (m, 2H), 2.76–2.68 (m, 1H), 2.45 (br. s, 8H), 2.35–2.22 (m, 2H), 1.88 (td, J = 13.6, 7.9 
Hz, 1H), 1.53 (td, J = 13.4, 7.1 Hz, 1H), 1.17 (t, J = 7.1 Hz, 3H), 1.11–1.07 (m, 6H); 13C NMR 
(101 MHz, CDCl3) δ 175.7, 138.2, 129.3 (+, 2C), 128.3 (+, 2C), 127.2 (+), 63.2 (-), 56.3 (-, 2C), 
53.2 (-), 53.1 (-, 2C), 42.0 (-), 40.5 (-), 33.7 (+), 31.4 (-), 18.6 (+), 15.1 (+), 13.3 (+); FT IR (NaCl, 
cm-1): 2969, 2934, 2808, 1632, 1452, 1433, 1379, 1363, 1346, 1136, 1013, 924, 910, 733, 698; 
HRMS (TOF ES): found 332.2689, calculated for C20H34N3O (M+H) 332.2702 (3.9 ppm). 
 
N,N-Diethyl-2-methyl-4-((1-
phenylethyl)amino)butanamide (170ak):  Was prepared 
according to Typical Procedure, N,N-diethyl-1-
methylcycloprop-2-ene-1-carboxamide (168a) (100 mg, 0.65 mmol, 1.0 equiv) and 1-
phenylethylamine (169k) (126 µL, 118 mg, 0.98 mmol, 1.5 equiv).  The reaction was carried out 
at 100 oC for 3 hrs.  Reduction with NaBH4, acid-base extraction followed by preparative column 
chromatography on silica gel afforded the title compound as a yellow oil, Rf 0.27 (DCM/MeOH 
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15:1).  Yield 117 mg (0.42 mmol, 65%), dr 1:1.  1H NMR (400 MHz, CDCl3) δ 8.01 (br. s, 2H), 
7.53 (t, J = 6.3 Hz, 4H), 7.39–7.31 (m, 6H), 4.18–4.12 (m, 2H), 3.39–3.18 (m, 8H), 2.88–2.83 (m, 
1H), 2.82–2.72 (m, 3H), 2.66–2.58 (m, 2H), 2.08–1.91 (m, 4H), 1.76 (t, J = 7.2 Hz, 6H), 1.10 (t, J 
= 7.0 Hz, 6H), 1.03–0.98 (m, 3H), 1.00 (t, J = 5.8 Hz, 6H), 0.95 (d, J = 6.9 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ 175.4, 175.1, 137.4, 137.2, 129.2 (+, 2C), 129.2 (+, 2C), 129.1 (+), 129.0 (+), 
127.9 (+, 2C), 127.9 (+, 2C), 58.6 (+), 58.5 (+), 43.4 (-), 42.8 (-), 42.4 (-), 42.2 (-), 40.7 (-), 40.5 
(-), 34.0 (-), 33.7 (-), 29.9 (+), 29.7 (+), 21.1 (+), 20.7 (+), 17.8 (+), 17.4 (+), 14.9 (+, 2C), 13.0 (+, 
2C); FT IR (NaCl, cm-1): 3437, 2972, 2749, 1624, 1456, 1382, 1264, 1218, 1078, 768, 703; HRMS 
(TOF ES): found 277.2269, calculated for C17H29N2O (M+H) 277.280 (4.0 ppm). 
 
4-(Diethylamino)-2-methyl-1-(pyrrolidin-1-yl)butan-1-one 
(170ca):  Was prepared according to Typical Procedure, (1-
methylcycloprop-2-en-1-yl)(pyrrolidin-1-yl)methanone (168c) (100 
mg, 0.66 mmol, 1.0 equiv) and diethylamine (169a) (205 µL, 145 mg, 1.98 mmol, 3.0 equiv).  The 
reaction was carried out at 100 oC for 1 hr.  Reduction with NaBH4, acid-base extraction followed 
by preparative column chromatography on silica gel afforded the title compound as a yellow oil, 
Rf 0.27 (DCM/MeOH 10:1).  Yield 97 mg (0.43 mmol, 65%).  
1H NMR (400 MHz, CDCl3) δ 
3.55–3.49 (m, 1H), 3.45–3.39 (m, 3H), 3.06  (q, J = 7.1 Hz, 4H), 2.99–2.89 (m, 2H), 2.72–2.63 
(m, 1H), 2.18–2.09 (m, 1H), 2.02–1.92 (m, 2H), 1.89–1.83 (m, 3H), 1.38 (t, J = 7.2 Hz, 6H), 1.17 
(d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 173.1, 49.3 (-), 46.6 (-), 46.6 (-, br., 2C), 46.1 
(-), 36.1 (+), 26.9 (-), 26.2 (-), 24.3 (-), 17.8 (+), 8.9 (+, 2C); FT IR (NaCl, cm-1): 3422, 2971, 1620, 
1468, 1443, 1344, 1271, 1040, 733, 701; HRMS (TOF ES): found 249.1941, calculated for 
C13H26NO2Na (M+Na) 249.1943 (0.8 ppm). 
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2-Methyl-4-morpholino-1-(pyrrolidin-1-yl)butan-1-one (170cd):  
Was prepared according to Typical Procedure, (1-
methylcycloprop-2-en-1-yl)(pyrrolidin-1-yl)methanone (168c) (100 mg, 0.66 mmol, 1.0 equiv) 
and morpholine (169d) (86 µL, 86 mg, 0.99 mmol, 1.5 equiv).  The reaction was carried out at 100 
oC for 1 hr.  Reduction with NaBH4, acid-base extraction followed by preparative column 
chromatography on silica gel afforded the title compound as a yellow oil, Rf 0.26 (DCM/MeOH 
20:1).  Yield 108 mg (0.45 mmol, 68%).  1H NMR (400 MHz, CDCl3) δ 3.65 (t, J = 4.5 Hz, 4H), 
3.59–3.54 (m, 1H), 3.45–3.38 (m, 3H), 2.66–2.57 (m, 1H), 2.42–2.35 (m, 4H), 2.33–2.23 (m, 2H), 
1.94–1.88 (m, 3H), 1.86–1.79 (m, 2H), 1.55–1.47 (m, 1H), 1.10 (d, J = 6.8 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ 175.0, 67.2 (-, 2C), 57.0 (-), 53.8 (-, 2C), 46.6 (-), 45.8 (-), 36.1 (+), 30.8 (-), 
26.3 (-), 24.5 (-), 17.9 (+); FT IR (NaCl, cm-1): 2968, 2870, 1625, 1468, 1441, 1341, 1273, 1117, 
1071, 916, 867, 753, 703, 664; HRMS (TOF ES): found 257.2586, calculated for C13H25N2O2 
(M+H) 241.1916 (0.0 ppm). 
4-(Benzylamino)-2-methyl-1-(pyrrolidin-1-yl)butan-1-one 
(170ch):  Was prepared according to Typical Procedure, (1-
methylcycloprop-2-en-1-yl)(pyrrolidin-1-yl)methanone (168c) 
(100 mg, 0.66 mmol, 1.0 equiv) and benzylamine (169h) (94 µL, 92 mg, 0.86 mmol, 1.3 equiv).  
The reaction was carried out at 100 oC for 2 hrs.  Reduction with NaBH4, acid-base extraction 
followed by preparative column chromatography on silica gel afforded the title compound as a 
yellow oil, Rf 0.30 (DCM/MeOH 15:1).  Yield 112 mg (0.43 mmol, 65%).  
1H NMR (400 MHz, 
CDCl3) δ 7.28–7.22 (m, 4H), 7.20–7.16 (m, 1H), 3.76 (q, J = 13.2 Hz, 2H), 3.46–3.40 (m, 1H), 
3.36–3.30 (m, 3H), 3.21 (br. s, 1H), 2.65–2.61 (m, 3H), 1.90–1.82 (m, 3H), 1.78–1.71 (m, 2H), 
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1.67–1.58 (m, 1H), 1.01 (d, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 175.2, 138.2, 128.7 
(+, 2C), 128.7 (+, 2C), 127.6 (+), 53.4 (-), 46.7 (-), 46.5 (-), 46.0 (-), 36.1 (+), 33.0 (-), 26.3 (-), 
24.4 (-), 17.4 (+); FT IR (NaCl, cm-1): 3426, 2966, 2928, 2872, 1628, 1454, 1435, 1340, 743, 700; 
HRMS (TOF ES): found 261.1960, calculated for C16H25N2O (M+H) 261.1967 (2.7 ppm). 
 
2-Methyl-1,4-di(pyrrolidin-1-yl)butan-1-one (170cc):  Was 
prepared according to Typical Procedure, (1-methylcycloprop-2-en-
1-yl)(pyrrolidin-1-yl)methanone (168c) (100 mg, 0.66 mmol, 1.0 
equiv) and pyrrolidine (169c) (163 µL, 141 mg, 1.98 mmol, 3.0 equiv).  The reaction was carried 
out at 100 oC for 1 hr.  Reduction with NaBH4, acid-base extraction followed by preparative 
column chromatography on silica gel afforded the title compound as a yellow oil, Rf 0.33 
(DCM/MeOH 10:1).  Yield 108 mg (0.48 mmol, 73%).  1H NMR (400 MHz, CDCl3) δ 3.55–3.50 
(m, 1H), 3.44–3.36 (m, 3H), 2.63–3.58 (m, 1H), 2.45 (br. s, 4H), 2.41–2.33 (m, 2H), 1.92–1.87 (m, 
3H), 1.84–1.77 (m, 2H), 1.72 (br. s, 4H), 1.60–1.51 (m, 1H), 1.09 (d, J = 6.6 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ 175.1, 54.2 (-), 54.1 (-, 2C), 46.5 (-), 45.7 (-), 36.2 (+), 33.1 (-), 26.3 (-), 24.5 
(-), 23.6 (-, 2C), 17.6 (+); FT IR (NaCl, cm-1): 2968, 2874, 2791, 1626, 1618, 1460, 1431, 1340,  
2968, 2932, 2799,1637, 1448, 1429, 1379, 1261, 1126; HRMS (TOF ES): found 225.1962, 
calculated for C13H25N2O (M+H) 225.1967 (2.2 ppm). 
 
4-(Butylamino)-N,N-diisopropyl-2-methylbutanamide 
(170bj):  Was prepared according to Typical Procedure, N,N-
diisopropyl-1-methylcycloprop-2-ene-1-carboxamide (168b) 
(100 mg, 0.55 mmol, 1.0 equiv) and butylamine (169j) (164 µL, 121 mg, 1.65 mmol, 3.0 equiv).  
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The reaction was carried out at 100 oC for 1 hr.  Reduction with NaBH4, acid-base extraction 
followed by preparative column chromatography on silica gel afforded the title compound as a 
yellow oil, Rf 0.28 (DCM/MeOH 10:1).  Yield 108 mg (0.42 mmol, 76%).  
1H NMR (400 MHz, 
CDCl3) δ 4.01 (br. s, 1H), 3.46 (br. s, 1H), 2.71–2.63 (m, 1H), 2.57–2.46 (m, 4H), 2.02 (br. s, 1H), 
1.84 (td, J = 14.1, 7.5 Hz, 1H), 1.49 (dt, J = 13.3, 6.7 Hz, 1H), 1.40 (dt, J = 14.6, 7.2 Hz, 2H), 
1.31–1.22 (m, 8H), 1.17–1.14 (t, J = 5.4 Hz, 6H), 1.04 (d, J = 6.8 Hz, 3H), 0.84 (t, J = 7.3 Hz, 3H); 
13C NMR (101 MHz, CDCl3) δ 175.5, 49.7 (-), 47.9 (-), 47.9 (+, br.), 45.7 (+), 35.1 (+), 34.5 (-), 
32.2 (-), 21.4 (+, br., 2C), 20.8 (+), 20.7 (+), 20.5 (-), 18.2 (+), 14.0 (+); FT IR (NaCl, cm-1): 2962, 
2930, 1631, 1466, 1441, 1371, 1303, 1213, 1134, 1040, 754; HRMS (TOF ES): found 257.2581, 
calculated for C15H32N2O (M+H) 255.2593 (4.7 ppm). 
 
N,N-Diisopropyl-2-methyl-4-(pyrrolidin-1-yl)butanamide (170bc):  
Was prepared according to Typical Procedure, N,N-diisopropyl-1-
methylcycloprop-2-ene-1-carboxamide (168b) (100 mg, 0.55 mmol, 
1.0 equiv) and butylamine (169c) (136 µL, 118 mg, 1.65 mmol, 3.0 equiv).  The reaction was 
carried out at 100 oC for 1 hr.  Reduction with NaBH4, acid-base extraction followed by preparative 
column chromatography on silica gel afforded the title compound as a yellow oil, Rf 0.31 
(DCM/MeOH 15:1).  Yield 102 mg (0.40 mmol, 73%).  1H NMR (400 MHz, CDCl3) δ 4.01 (br. 
s, 1H), 3.44 (br. s, 1H), 2.67 (dt, J = 13.5, 6.7 Hz, 1H), 2.47–2.37 (m, 5H), 2.35–2.28 (m, 1H), 
1.85 (dt, J = 17.1, 6.7 Hz, 1H), 1.69 (s, 4H), 1.50 (td, J = 14.1, 6.3 Hz, 1H), 1.29 (d, J = 6.2 Hz, 
6H), 1.15–1.13 (m, 6H), 1.03 (d, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 175.4, 54.1 (-), 
54.1 (-, 2C), 47.9 (+, br.), 45.6 (+), 35.1 (+), 33.2 (-), 23.5 (-, 2C), 21.4 (+), 21.3 (+), 20.8 (+), 20.8 
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(+), 18.2 (+); FT IR (NaCl, cm-1): 2964, 2787, 1633, 1464, 1440, 1370, 1211, 1136, 1040, 752; 
HRMS (TOF ES): found 255.2435, calculated for C15H31N2O (M+H) 255.2436 (0.4 ppm). 
 
4-(Diethylamino)-N,N-diisopropyl-2-methylbutanamide (170ba):  
Was prepared according to Typical Procedure, N,N-diisopropyl-1-
methylcycloprop-2-ene-1-carboxamide (168b) (100 mg, 0.55 mmol, 
1.0 equiv) and diethylamine (169a) (171 µL, 121 mg, 1.65 mmol, 3.0 equiv).  The reaction was 
carried out at 100 oC for 1 hr.  Reduction with NaBH4, acid-base extraction followed by preparative 
column chromatography on silica gel afforded the title compound as a yellow oil, Rf 0.26 
(DCM/MeOH 10:1).  Yield 100 mg (0.39 mmol, 71%).  1H NMR (400 MHz, CDCl3) δ 4.06–3.98 
(br. m, 1H), 3.45 (br. s, 1H), 2.66 (dt, J = 13.5, 6.7 Hz, 1H), 2.57 (q, J = 7.0 Hz, 4H), 2.46 (t, J = 
7.4 Hz, 2H), 1.88 (td, J = 14.6, 7.5 Hz, 1H), 1.49 (td, J = 13.4, 7.1 Hz, 1H), 1.33 (d, J = 6.6 Hz, 
6H), 1.17 (t, J = 5.9 Hz, 6H), 1.07–1.02 (m, 9H); 13C NMR (101 MHz, CDCl3) δ 175.1, 50.3 (-), 
47.9 (+, br.), 46.8 (-, 2C), 45.7 (+), 35.0 (+), 30.4 (-), 21.4 (+, br., 2C), 20.8 (+), 20.8 (+), 18.2 (+), 
11.4 (+, 2C); FT IR (NaCl, cm-1): 2967, 2932, 1636, 1630, 1466, 1439, 1372, 1211, 1134, 1038, 
755; HRMS (TOF ES): found 257.2586, calculated for C15H33N2O (M+H) 257.2593 (2.7 ppm). 
 
N,N-Diisopropyl-2-methyl-4-
(phenethylamino)butanamide (170bg):  Was prepared 
according to Typical Procedure, N,N-diisopropyl-1-
methylcycloprop-2-ene-1-carboxamide (168b) (100 mg, 0.55 mmol, 1.0 equiv) and 
phenethylamine (169g) (104 µL, 100 mg, 0.83 mmol, 1.5 equiv).  The reaction was carried out at 
100 oC for 2 hrs.  Reduction with NaBH4, acid-base extraction followed by preparative column 
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chromatography on silica gel afforded the title compound as a yellow oil, Rf 0.35 (DCM/MeOH 
15:1).  Yield 100 mg (0.39 mmol, 76%).  1H NMR (400 MHz, CDCl3) δ 7.34 (t, J = 7.8 Hz, 2H), 
7.22–7.16 (m, 3H), 4.03 (br. s, 1H), 3.50 (br. s, 1H), 2.87–2.84 (m, 2H), 2.80–2.76 (m, 2H), 2.74–
2.65 (m, 1H), 2.63–2.53 (m, 2H), 1.86 (td, J = 13.9, 7.5 Hz, 1H), 1.62 (br. s, 1H), 1.52 (dt, J = 
13.5, 6.5 Hz, 1H), 1.36–1.33 (m, 6H), 1.21–1.16 (m, 6H), 1.08 (d, J = 6.8 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ 175.5, 140.2, 128.8 (+, 2C), 128.6 (+, 2C), 126.2 (+), 51.3 (-), 47.9 (+, br.), 47.8 
(-), 45.8 (+), 36.5 (-), 35.0 (+), 34.6 (-), 21.5 (+, br., 2C), 20.9 (+), 20.8 (+), 18.3 (+); FT IR (NaCl, 
cm-1): 2967, 1629, 1629, 1372, 1213, 1121, 1040, 755, 701; HRMS (TOF ES): found 305.2595, 
calculated for C19H33N2O (M+H) 305.2593 (0.7 ppm). 
 
N,N-Diisopropyl-2-methyl-4-morpholinobutanamide (170bd):  
Was prepared according to Typical Procedure, N,N-diisopropyl-1-
methylcycloprop-2-ene-1-carboxamide (168b) (100 mg, 0.55 
mmol, 1.0 equiv) and morpholine (169d) (71 µL, 72 mg, 0.83 mmol, 1.5 equiv).  The reaction was 
carried out at 100 oC for 1.5 hours.  Reduction with NaBH4, acid-base extraction followed by 
preparative column chromatography on silica gel afforded the title compound as a yellow oil, Rf 
0.28 (DCM/MeOH 20:1).  Yield 98 mg (0.36 mmol, 66%).  1H NMR (400 MHz, CDCl3) δ 4.05 
(br. s, 1H), 3.66 (t, J = 4.2 Hz, 4H), 3.48 (br. s, 1H), 2.74–2.66 (m, 1H), 2.44–2.41 (br. m, 2H), 
2.36–2.31 (br. m, 2H), 2.31–2.21 (m, 2H), 1.89 (td, J = 13.5, 7.6 Hz, 1H), 1.48 (td, J = 13.4, 6.8 
Hz, 1H), 1.33 (t, J = 4.3 Hz, 6H), 1.20–1.18 (m, 6H), 1.06 (d, J = 6.8 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ 175.3, 67.1 (-, 2C), 56.8 (-), 53.8 (-, 2C), 47.9 (+, br.), 45.7 (+), 34.8 (+), 30.9 (-), 
21.4 (+, br., 2C), 20.9 (+), 20.9 (+), 18.5 (+); FT IR (NaCl, cm-1): 2965, 2855, 2807, 1638, 1629, 
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1462, 1441, 1371, 1305, 1273, 1119, 1038, 916, 866, 752; HRMS (TOF ES): found 271.2391, 
calculated for C15H31N2O2 (M+H) 271.2386 (1.8 ppm). 
 
4-(Benzylamino)-N,N-diisopropyl-2-methylbutanamide 
(170bh):  Was prepared according to Typical Procedure, N,N-
diisopropyl-1-methylcycloprop-2-ene-1-carboxamide (168b) 
(100 mg, 0.55 mmol, 1.0 equiv) and benzylamine (169h) (78 µL, 77 mg, 0.72 mmol, 1.3 equiv).  
The reaction was carried out at 100 oC for 2 hrs.  Reduction with NaBH4, acid-base extraction 
followed by preparative column chromatography on silica gel afforded the title compound as a 
yellow oil, Rf 0.30 (DCM/MeOH 15:1).  Yield 109 mg (0.38 mmol, 68%).  
1H NMR (400 MHz, 
CDCl3) δ 7.27–7.26 (m, 4H), 7.24–7.17 (m, 1H), 4.03 (br. s, 1H), 3.73 (s, 2H), 3.46 (br. s, 1H), 
2.77–2.68 (m, 1H), 2.64–2.52 (m, 2H), 1.91 (dt, J = 14.2, 7.4 Hz, 1H), 1.84 (br.s, 1H), 1.52 (td, J 
= 13.3, 6.6 Hz, 1H), 1.33–1.28 (m, 6H), 1.18–1.14 (m, 6H), 1.05 (d, J = 6.8 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ 175.4, 140.3, 128.4 (+, 2C), 128.2 (+, 2C), 126.9 (+), 53.99 (-), 47.8 (+, br.), 
47.31 (-), 45.7 (+), 34.9 (+), 34.5 (-), 21.3 (+, br., 2C), 20.8 (+), 20.7 (+), 18.3 (+); FT IR (NaCl, 
cm-1): 2965, 2930, 2872, 1634, 1439, 1370, 1327, 1304, 1211, 1119, 1040, 737, 698; HRMS (TOF 
ES): found 291.2430, calculated for C18H31N2O (M+H) 291.2436 (2.1 ppm). 
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Chapter 3. Intramolecular nucleophilic addition of stabilized benzylic 
anions to cyclopropenes 
3.1 Introduction 
 
The base-assisted additions of heteroatom nucleophiles to cyclopropenes 176 generated in situ 
from stable halocyclopropanes 175 have emerged as a convenient route towards complex 
cyclopropyl scaffolds, 116  complementary to existing transition metal-catalyzed methodologies 
(Scheme 45a).117,118 
Oxygen-,111,114, 119  nitrogen-,107,114, 120  sulfur-, 121  or halogen-based 122  entities have been 
successfully added, in either an inter- or an intramolecular fashion.123 The employment of carbon-
based nucleophilic species in non-catalyzed transformations of these types has thus far been less 
abundant. The apparent challenges associated with a strong basicity of organometallic reagents on 
the one hand, and a lower reactivity of stabilized carbon nucleophiles, such as enolates, toward 
non-conjugate cyclopropenes on the other hand, have limited the application of this chemistry. 
The addition of strong carbon nucleophiles (organometallic reagents) to cyclopropenes (177) 
has been known since the 1970s (Scheme 45b). 124  An enantioselective variant of these 
transformation exploiting a copper-catalyzed carbozincation 3,3-disubstituted cyclopropenes 178 
was later shown by Marek (Scheme 45c).125 Recently, Gong demonstrated the Michael addition of 
enolates to highly activated conjugate cyclopropenyl ketone 179 generated in situ, which was 
accompanied by the cleavage of the three-membered ring (Scheme 45d).126 
In this work, we explore an intramolecular addition of nitrogen ylides, generated from N-
benzylcarboxamides 180 to non-conjugated cyclopropenes 181 (Scheme 45e). 
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Scheme 45 
 
 
3.2 Unexpected rearrangement of cyclopropene N-benzyl carboxamides 
 
Previously it was demonstrated that a very efficient 1,2-dehydrohalogenation of 
bromocyclopropanes 183 en route to cyclopropenes 184 could be achieved using mild alkoxide 
bases in THF in the presence of catalytic amounts of 18-crown-6 ether (Scheme 46).115a Compared 
to the classical protocol in dry DMSO this modification allowed for more convenient isolation and 
improved overall yields of cyclopropenes. This proved to be particularly beneficial for the 
synthesis of functionalized cyclopropenes, such as tertiary carboxamides 185 bearing an alkyl 
group and an electron rich aryl group (Scheme 46b).115a 
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Scheme 46 
 
 
In course of continuous efforts to expand the scope of available cyclopropenes 184 obtained 
through well-established dehydrohalogenation of bromocyclopropanes 183, we discovered an 
unusual reaction, involving a formal intramolecular nucleophilic substitution of 
bromocyclopropanes with nitrogen ylides 181 generated in situ from N-benzyl carboxamides 180 
(Scheme 47). 
In attempt to obtain N,N-benzyl substituted cyclopropeneamide 185a we subjected 
corresponding bromocyclopropane 180a to standard reaction conditions (Scheme 47). 
Surprisingly, instead of olefin 185a, a mixture of diastereomeric lactams 182a was produced in ca. 
60% yield.127  Employing excess of freshly sublimed tert-butoxide and carrying out the reaction 
under strictly anhydrous conditions allowed for the improvement of the yield up to 80%, but did 
not affect the diastereomeric composition of the product (Scheme 47). 
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Scheme 47 
 
 
This transformation represents an intramolecular, ring-retentive 5-exo-trig cyclization of non-
conjugated cyclopropenes 181 with nitrogen ylides, generated from N-benzylcarboxamides 181 in 
the presence of relatively mild alkoxide bases. This process allowed for the straightforward and 
highly expeditious assembly of biologically relevant 3-azabicyclo[3.1.0]hexan-2-one scaffolds, 
although in only moderate yields and selectivity. This was a pleasant surprise, since this scaffold 
occurs in nature 128  and has significant importance for medicinal chemistry 129  and synthetic 
methodology.130 
 
3.3 Intramolecular nucleophilic addition of carbanions generated from N-benzylamides to 
cyclopropenes 
 
This unexpected 5-exo-trig cyclization was apparently triggered by the base-assisted 
deprotonation at the benzylic position of cyclopropene intermediate 185a (Scheme 48a). The 
formation of anionic species in an α-position to nitrogen in carboxamides is well precedented.131 
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Stoichiometric deprotonation needed for intermolecular alkylation normally requires strong 
organometallic bases such as t-BuLi or n-BuLi (Scheme 48b).131 For intramolecular reactions, 
however, the use of LDA and even t-BuOK has also been reported to be particularly successful in 
the Hurtly arylation (Scheme 48c).132 
 
Scheme 48 
 
 
In order to provide support to this mechanism, we reasoned that lowering the C–H acidity of 
the benzylic group would prevent formation of benzylic anion thus shutting down the 5-exo-trig 
cyclization pathway and divert reaction to the initially desired dehydrohalogenation. Indeed, 
bromocyclopropanes 180b,c possessing electron-donating substituents in an aromatic ring 
produced the corresponding cyclopropenes 185b,c as sole isolable products in moderate yields 
(Scheme 49a). 
On the contrary, incorporation of strong electron-withdrawing substituents would lead to the 
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stabilization of the benzylic anion and thus result in reduced nucleophilicity, which would make 
the cyclization pathway inefficient. Hence, the reaction of 180d, bearing a CF3 group in the para-
position, afforded a very poor yield of bicyclic product 182d (Scheme 49b), while para-NO2 
analog 180e simply decomposed under the reaction conditions (Scheme 49c). 
 
Scheme 49 
 
 
To our delight, substrates possessing neutral or moderately electron-withdrawing substituents 
cyclized smoothly affording the corresponding 3-azabicyclo[3.1.0]hexan-2-ones in moderate to 
high yields (Scheme 50). Remarkably, this reaction demonstrated high tolerance to steric 
hindrance at the nitrogen atom, as we were able to efficiently cyclize the substrates bearing (a) 
primary, Me (180j– 180m) and n-Bu (180f); (b) secondary, i-Pr and Cy (180h,g, respectively); 
and (c) tertiary, t-Bu (180i) groups. Interestingly, steric hindrance on the nitrogen atom influences 
diastereoselectivity; however, this effect is quite weak. 
86 
 
Scheme 50 
 
 
Unfortunately, all of the bicyclic products 182 were obtained as mixtures of endo- and exo-
diastereomers. This was to be expected, considering the relatively high acidity of the tertiary 
benzylic C–H group at C-4 in final cyclic products, and the possibility of a facile base-assisted 
epimerization under the reaction conditions. The cyclization of ylide 181, generated by the 
deprotonation of cyclopropenyl amide 185, should provide cyclopropyl anion 186 (Scheme 51). 
Subsequent protonation affords a mixture of exo-182 and endo-182 products, and their initial ratio 
depends on stereo-electronic factors at the cyclization step. However, the final product ratio is 
determined by a thermodynamic equilibrium that occurs via stabilized cyclic ylide 187.  
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Scheme 51 
Scheme 52 
 
 
 
The exo-/endo-ratio change can be monitored in time by GC (shown for compound 182m, 
Scheme 52). Results of the GC-monitoring for cyclization reactions were used to choose the best 
reaction duration and the appropriate quenching time for each particular product. In some cases, 
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such as with ortho-chlorinated derivative 182l, deprotonation at C-4 cannot be achieved efficiently 
due to steric hindrance, so the final diastereomeric ratio matches that for the initialy observed 
distribution (Scheme 53).  
 
Scheme 53 
 
 
 
The low degrees of diastereoselectivity can be attributed to the too small difference in the 
thermodynamic stabilities of endo- and exo-diastereomers of the cyclized product in five-
membered scaffold 182. Our DFT modeling showed that exo-182j is more stable than endo-182j 
by only 1.50 kcal mol−1, which corresponds to the best typically achieved dr of around 70 : 30.2 
Also, this modeling helped to assign relative configurations of the diastereomeric bicyclic 
products. Indeed, calculation showed that dihedral angles between (C-4)–H and (C-5)–H bonds in 
endo- and exo-isomers are 36.8 ° and 94.4 °, respectively.2 This suggests that the value of the 
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corresponding vicinal spin–spin coupling constants for endo-isomers should be larger. Indeed, the 
benzylic proton signals in the 1H NMR spectra appeared as doublets for the isomers (endo) and as 
singlets for another one (exo).  
Also, the relative configuration of exo-182j was independently and unambiguously assigned by 
single-crystal X-ray diffraction (Figure 13).  
 
 
Figure 13. X-ray crystal structure of compound exo-182j (CCDC #1575277) 
 
3.4 Conclusion 
A cascade, base-assisted dehydrohalogenation/5-exo-trig nucleophilic cyclization of stabilized 
benzylic anions to cyclopropenes was discovered. This reaction represents the first example of the 
non-catalytic addition of carbon nucleophiles to unactivated cyclopropenes. The obtained results 
are valuable as a proof of concept and are being applied in design of the diastereoselective 
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cyclization of carbon-based nucleophiles to obtain six- and seven-membered ring systems. The 
latter models are expected to allow for better stereo-electronic control, due to a more substantial 
difference in the thermodynamic stabilities of the corresponding diastereomers.  
 
3.5 Experimental 
3.5.1 General information 
 
NMR spectra were recorded on a Bruker Avance DRX-500 spectrometer (500 MHz) equipped 
with a dual carbon/proton cryoprobe (CPDUL) or with a BBO probe or on a Bruker Avance DPX-
400 spectrometer (400 MHz) equipped with a quadrupleband gradient probe (H/C/P/F QNP). 13C 
NMR spectra were recorded with broadband decoupling. IR spectra were recorded on a 
ThermoFisher Nicolet™ iS™ 5 FT-IR spectrometer. HRMS was carried out on a LCT Premier 
(Micromass Technologies) instrument employing ESI TOF detection techniques. Glassware used 
in moisture-free syntheses was flame dried under vacuum prior to use. Column chromatography 
was carried out on silica gel (Sorbent Technologies, 40–63 mm). Pre-coated silica gel plates 
(Sorbent Technologies Silica XG 200 mm) were used for TLC analyses. Anhydrous THF and 
dichloromethane (DCM) were obtained by the distillation of a degassed commercially available 
HPLC-grade inhibitor-free solvent over calcium hydride and stored over 4 Å molecular sieves 
under nitrogen. Commercial potassium tert-butoxide was sublimed under vacuum prior to use. 
The syntheses of new bromocyclopropanes starting materials 180a–m are described in chapter 
3.5.2. 2-Bromo-1-methylcyclopropane-1-carbonyl chloride was synthesized according to the 
procedure previously published by our group115 and had physical and spectral properties identical 
to those earlier reported. All other reagents and solvents were purchased from commercial vendors 
and used as received. 
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3.5.2 Syntheses of bromocyclopropanes  
 
 N,N-Dibenzyl-2-bromo-1-methylcyclopropane-1-carboxamide (180a), 
Typical procedure: 2-Bromo-1-methylcyclopropane-1-carbonyl chloride 
(494 mg, 2.50 mmol) in anhydrous DCM (7 mL) was added dropwise to a 
solution of dibenzylamine (493 mg, 2.50 mmol) and triethylamine (706 µL, 
512 mg, 5.07 mmol) in anhydrous DCM (4 mL) stirred in a flame dried Schlenk flask under a 
nitrogen atmosphere. The reaction was stirred overnight at rt. The solvent was then evaporated in 
vacuum, and the residue was triturated with THF (7 mL). The precipitate was removed by suction 
filtration and the filter cake was rinsed with THF (2 x 4 mL). Then the precipitate was dissolved 
in H2O (20 mL) and extracted with EtOAc (2 x 4 mL). The combined organic phases were washed 
with brine (20 mL, dried with MgSO4, combined with the THF filtrate, and concentrated. The 
product was isolated by column chromatography eluting with a hexanes/EtOAc mixture (6:1) as 
a yellow oil (Rf 0.29). Yield 553.4 mg (1.54 mmol, 61%). 
1H NMR (500 MHz, CDCl3) δ [7.51–
7.48 (m), 7.42–7.27 (m), 7.25–7.06 (m), ∑10H], [5.25 (d, J = 14.5 Hz), 4.98 (d, J = 16.6 Hz), 
4.73–7.46 (m), 4.37 (d, J = 16.7 Hz), 3.91 (d, J = 14.5 Hz), ∑4H], [3.24 (dd, J = 8.2, 4.9 Hz), 3.00 
(dd, J = 7.5, 4.7 Hz), ∑1H], [1.81 (dd, J = 8.2, 6.7 Hz), 1.76–1.73 (m), ∑1H], [1.53 (s), 1.40 
(s), ∑3H], [1.25 (t, J = 7.1 Hz), 0.95 (dd, J = 6.7, 4.9 Hz), ∑1H]; 13C NMR (126 MHz, CDCl3) 
δ (172.5, 171.3, 1C), (136.7, 136.1, 2C), (129.1, 128.9, 4C), (128.3, 127.1, 4C), (127.6, 127.4, 
2C), (49.8, 47.5, 1C), [49.6 (br.), 47.1 (br.), 1C], 28.0 (1C), (27.3, 26.1, 1C), (22.7, 21.9, 1C), 
(22.1, 19.8, 1C); FT IR (NaCl, cm-1): 3062, 3030, 2929, 1643, 1495, 1453, 1421, 1325, 1299, 
1205, 1185, 1079, 1029, 1013, 749, 698; HRMS (TOF ES): found 358.0810, calculated for 
C19H21BrNO (M + H) 358.0807 (0.8 ppm); EA found C 63.83, 63.58, H 5.43, 5.93, N 4.14, 3.90, 
calculated for C19H20BrNO: C 63.70, H 5.63; N 3.91. 
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2-Bromo-N-butyl-N-(4-(tert-butyl)benzyl)-1-methylcyclopropane-1-
carbox- amide (180b). This compound was synthesized according to 
Typical procedure employing 2-bromo-1-methylcyclopropane-1-
carbonyl chloride (545 mg, 2.76 mmol), N-(4-(tert-butyl)benzyl)butan-
1-amine (605 mg, 2.76 mmol), and triethylamine (1.40 mL, 1.02 g, 10.5 mmol). The reaction 
mixture was stirred at room temperature overnight. After standard aqueous workup and extraction, 
the material was filtered through a silica plug to give a pale-yellow glass, yield 882 mg (2.32 mmol, 
84%). This material had purity by GC c.a. 98% and could be used in the cyclization step as is 
without additional purification. If desired, diastereomeric bromocyclopropanes can be additionally 
purified and separated by preparative column chromatography on Silica gel eluting with a 
CH2Cl2/EtOAc mixture (40:1). Individual isomers were isolated as colorless crystals (trans-180b) 
and colorless glass (cis-180b), respectively. NMR spectra of both diastereomers showed signals 
of two rotamers. Analysis of signals in proton spectra of cis-180b is complicated by severe 
broadening of the lines, which can be partially resolved by measuring 1H NMR spectrum in 
benzene-d6 at 75 °C. trans-180b: mp 93.3-93.8 °C; Rf 0.37 (CH2Cl2/EtOAc 40:1); 
1H NMR (500 
MHz, CDCl3) δ [7.38 (d, J = 8.2 Hz), 7.30 (d, J = 8.2 Hz), ∑2H], [7.21 (d, J = 8.2 Hz), 7.17 
(d, J = 8.1 Hz), 7.09 (d, J = 8.2 Hz), ∑2H], [5.04 (d, J = 16.8 Hz), 4.81 (d, J = 15.0 Hz), 4.63 
(br.m), 4.46 (d, J = 16.3 Hz) , ∑2H], [3.80 (ddd, J = 14.2, 10.8, 5.6 Hz), 3.53 (ddd, J = 13.9 11.5, 
4.9 Hz), 3.25 (ddd, J = 14.1, 11.4, 4.9 Hz), 3.04–2.95 (m), 2.75 (ddd, J = 13.3, 10.0, 5.4 Hz) , 
∑3H], [1.80–1.70 (m), 1.71–1.64 (m), 1.63– 1.52 (m), 1.52– 1.43 (m), 1.26– 1.16 (m), ∑6H], 
[1.42 (s), 1.32 (s), ∑3H], [1.32 (s), 1.29 (s), ∑9H], [0.92 (t, J = 7.4 Hz), 0.86 (t, J = 7.3 Hz), ∑3H]; 
13C NMR (126 MHz, CDCl3) δ (170.7, 170.6, 1C), (150.5, 150.1, 1C), (134.2, 133.8, 1C), (127.8, 
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126.5, 2C), (125.8, 125.3, 2C), (50.5, 47.3, 1C), (46.7, 45.4, 1C), (34.6, 34.6, 1C), 31.5 (3C), 
(30.5, 28.7, 1C), (28.2, 28.1, 1C), (26.3, 26.2, 1C), (22.7, 22.6, 1C), 22.1, 20.4, (14.0, 14.0 1C). 
cis-180b: Rf 0.27 (CH2Cl2/EtOAc 40:1); 
1H NMR (500 MHz, C6D6 at 75 °C) δ 7.26 (d, J = 8.3 Hz, 
2H), 7.07 (br. s, 2H), 4.51 (br. s, 1H), 4.44 (d, J = 15.2 Hz, 1H), 3.29–3.04 (br. m, 3H), 1.70 (dd, 
J = 8.1, 6.5 Hz, 1H), [1.36 (s), 1.22 (s), ∑9H], 1.40–1.28 (m, 4H), 1.23 (br. s, 1H), 1.13–1.01 (m, 
2H), 0.76 (t, J = 7.4 Hz, 3H), 0.65 (dd, J = 6.6, 4.9 Hz, 1H). 1H NMR (500 MHz, CDCl3 at RT) δ 
7.38–7.30 (br. m, 2H), [7.28–7.25 (br.m), 7.13–7.05 (br. m), ∑2H], [4.65 (br.d, J = 16.3 Hz), 
4.43 (br. d, J = 15.2 Hz), ∑2H], 3.35–3.14 (br.m, 3H), [1.76 (br.m), 1.68 (br.m), 1.57 (br.m), 1.50 
(br.s), ∑6H], 1.32 (br.s, 11H), 1.00–0.78 (br.m, 4H); 13C NMR (126 MHz, CDCl3 at RT) δ 172.1, 
(150.7, 150.3, 1C), (134.2, 133. 5, 1C), (127.5, 126.5, 2C), (125.9, 125.7, 2C), (50.3, 46.7, 1C), 
(46.3, 44.6, 1C), 34.6, 31.5 (3C), (30.2, 29.0, 1C), (27.8, 27.7, 1C), (26.3, 26.2, 1C), 21.9, 
(20.3, 20.2, 1C), (20.0, 19.9, 1C), 14.0. HRMS (TOF ES): found 402.1416, calculated for 
C20H30BrNONa (M + Na) 402.1408 (2.0 ppm). EA found C 63.05, 63.27, H 7.78, 8.03, N 3.87, 
3.59, calculated for C20H30BrNO: C 63.15, H 7.95; N 3.68. 
 
2-Bromo-N-butyl-N-(4-methoxybenzyl)-1-methylcyclopropane-1-
carboxamide (180c). This compound was synthesized according to 
Typical procedure employing 2-bromo-1-methylcyclopropane-1-
carbonyl chloride (584 mg, 2.96 mmol), N-(4-methoxybenzyl)butan-1-amine (572 mg, 2.96 
mmol), and triethylamine (1.40 mL, 1.02 g, 10.5 mmol). The reaction mixture was stirred at room 
temperature overnight. After standard aqueous workup and extraction, the material was filtered 
through a silica plug to give a pale orange oil, yield 912 mg (2.58 mmol, 87%). This material had 
purity by GC c.a. 98% and could be used in the cyclization step as is without additional purification. 
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If desired, it can be additionally purified by preparative column chromatography on Silica gel 
eluting with a CH2Cl2/EtOAc mixture (20:1) to isolated inseparable mixture of diastereomeric 
bromo- cyclopropanes 180c as colorless oil, Rf 0.45 (CH2Cl2/EtOAc 20:1). 
1H NMR (500 MHz, 
CDCl3) δ [7.22 (d, J = 8.6 Hz), 7.17 (d, J = 8.5 Hz), 7.09 (br.m), ∑2H], [6.91 (d, J = 8.6 Hz), 6.95–
6.79 (br.m), 6.82 (d, J = 8.6 Hz), ∑2H], [5.00 (d, J = 16.5 Hz), 4.86 (d, J = 14.7 Hz), 4.61 (br.m), 
4.44 (d, J = 16.6 Hz), 4.40 (br.m), 4.34 (d, J = 14.8 Hz), ∑2H], [3.81 (s), 8.80 (br.s), 3.78 (s), ∑3H], 
[3.78–3.69 (m), 3.51 (ddd, J = 14.1, 11.6, 4.9 Hz), 3.27 (br.m), 3.22–3.15 (m), 3.00 (ddd, J = 7.3, 
4.7, 2.5 Hz), 2.76 (ddd, J = 13.4, 10.0, 5.4 Hz), ∑2H], [1.80–1.70 (m), 1.70–1.64 (m), 1.62–
1.49 (m), 1.46–1.41 (m), 1.33–1.15 (m), ∑7H], [1.48 (s), 1.40 (s), 1.33 (s), ∑3H], [0.93 (t, J 
= 7.4 Hz), 0.86 (t, J = 7.4 Hz), ∑3H]; 13C NMR (126 MHz, CDCl3) δ (172.0, 170.7, 1C), 
(159.1, 158.9, 1C), (129.7, 129.3, 128.1, 2C), (129.5, 128.7, 128.0, 1C), (114.4, 114.3, 114.1, 
113.8, 2C), (55.4, 55.4, 55.3, 1C), (50.3, 50.1, 46.9, 46.5, 1C), (46.4, 46.1, 45.2, 44.5, 1C), 
(30.4, 30.2, 29.0, 28.7, 1C), (28.2, 28.2, 1C), (27.8, 27.6, 26.3, 26.2, 1C), (22.7, 22.6, 21.8, 
1C), (22.0, 20.0, 19.8, 1C), (20.4, 20.3, 1C), (14.0, 14.0, 14.0, 1C); HRMS (TOF ES): found 
376.0900, calculated for C17H24BrNO2Na (M + Na) 376.0888 (3.2 ppm). EA found C 57.83, 57.57, 
H 6.58, 6.96, N 3.94, 4.01, calculated for C17H24BrNO2: C 57.63, H 6.83; N 3.95. 
 
2-Bromo-N-butyl-1-methyl-N-(4-
(trifluoromethyl)benzyl)cyclopropane-1-carboxamide (180d). This 
compound was synthesized according to Typical procedure employing 
2-bromo-1-methylcyclopropane-1-carbonyl chloride (1.00 g, 5.06 mmol), N-(4-
(trifluoromethyl)benzyl)butan-1-amine (1.17 g, 5.06 mmol), and triethylamine (1.39 mL, 1.01 g, 
10.0 mmol). The reaction mixture was stirred at room temperature overnight. The product was 
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isolated by column chromatography eluting with a hexanes/EtOAc mixture (3:1) as a colorless oil 
(Rf 0.34). Yield: 1.73 g (4.40 mmol, 87%). 
1H NMR (500 MHz, CDCl3) δ [7.64 (d, J = 7.9 Hz), 
7.54 (d, J = 7.9 Hz), ∑2H], 7.39 (m, 2H), [5.11 (d, J = 17.3 Hz), 4.90 (d, J = 15.3 Hz), 4.56 (d, 
J = 17.4 Hz), 4.47 (d, J = 15.3 Hz), ∑2H], [3.83 (ddd, J = 13.7, 10.2, 5.6 Hz), 3.60 (ddd, J = 14.3, 
11.7, 4.9 Hz), 3.22 (ddd, J = 14.3, 11.5, 4.8 Hz), 3.02 (ddd, J = 15.6, 7.5, 4.7 Hz), 2.70 (ddd, J 
= 13.6, 10.1, 5.2 Hz), ∑3H], [1.76–1.70 (m), 1.67 (t, J = 5.8 Hz), 1.63–1.44 (m), 1.42 (s), 1.36–
1.28 (m), 1.26 (s), 1.25–1.17 (m), ∑9H], [0.93 (t, J = 7.3 Hz), 0.86 (t, J = 7.3 Hz), ∑3H]; 13C 
NMR (126 MHz, CDCl3) δ (171.0, 170.8, 1C), (141.7, 141.3, 1C), [129.6 (q, 
2JCF = 32.6 Hz), 
129.4 (q, 2JCF = 32.4 Hz), 1C], (128.3, 127.1, 2C), [126.0 (q, 
3JCF = 3.8 Hz), 125.4 (q, 
3JCF = 3.8 
Hz), 2C], [125.3 (q, 1JCF = 272.5 Hz), 124.2 (q, 
1JCF = 271.4 Hz), 1C], (50.5, 47.7, 1C), (47.3, 
45.7, 1C), (30.6, 28.6, 1C), (28.11, 28.05, 1C), (26.2, 26.0, 1C), (22.7, 22.6, 1C), (21.9, 21.8, 
1C), 20.4 (1C), (13.98, 13.95, 1C); 19F NMR (376 MHz, CDCl3) δ -62.45, -62.51; FT IR (NaCl, 
cm-1): 2962, 2935, 2874, 1644, 1416, 1326, 1164, 1125, 1067, 1018, 824; HRMS (TOF ES): 
found 414.0636, calculated for C17H21BrF3NONa (M + Na) 414.0656 (4.8 ppm); EA found C 
52.25, 51.88, H 5.64, 5.28, N 3.28, 3.70, calculated for C17H21BrF3NO: C 52.05, H 5.40, N 
3.57. 
 
2-Bromo-N,1-dimethyl-N-(4-nitrobenzyl)cyclopropane-1-
carboxamide (180e). This compound was synthesized according to 
Typical procedure employing 2-bromo-1-methylcyclopropane-1-
carbonyl chloride (494 mg, 2.50 mmol), N-methyl-1-(4- nitrophenyl)methanamine (415 mg, 2.50 
mmol), and triethylamine (886 µL 642 mg, 6.35 mmol). The reaction mixture was stirred at room 
temperature overnight. The product was isolated by column chromatography eluting with a 
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hexanes/EtOAc mixture (1:3) as a yellow oil (Rf 0.38). Yield: 458 mg (1.40 mmol, 56%). 
1H NMR 
(500 MHz, CDCl3) δ 8.30–8.14 (m, 2H), [7.52 -7.44 (m), 7.37 (d, J = 8.7 Hz), ∑2H], [5.24 (d, J 
= 17.4 Hz), 4.93 (d, J = 14.7 Hz), 4.70–4.54 (m), 4.50 (d, J = 14.7 Hz), ∑2H], [3.24–3.18 
(m), 3.14 (s), 3.09–3.02 (m), 2.92 (s), ∑4H], [1.78 (dd, J = 8.2, 6.8 Hz), 1.67 (dd, J = 6.8, 4.7 Hz), 
∑1H], [1.52 (s), 1.45 (s), 1.32 (s), ∑3H], [1.25 (t, J = 7.2 Hz), 0.97 (t, J = 5.9 Hz), ∑1H]; 13C 
NMR (126 MHz, CDCl3) δ (172.2, 170.9, 1C), (147.4, 144.8, 1C), (128.9, 128.5, 2C), (127.4, 
124.2, 1C), (124.1, 123.8, 2C), (51.1, 50.8, 1C), (35.5, 35.3, 1C), (27.7, 27.2, 1C), (26.0, 25.7, 
1C), (22.4, 18.9, 1C), (21.8, 20.9, 1C); FT IR (NaCl, cm-1): 2932, 2360, 1643, 1519, 1488, 1402, 
1346, 1108, 935, 859, 737, 692. HRMS (TOF ES): found 349.0174, calculated for 
C13H15BrN2O3Na (M + Na) 349.0164 (1.0 ppm); EA found C 47.43, 47.81, H 4.58, 4.90, N 8.57, 
8.72, calculated for C13H15BrN2O3: C 47.72, H 4.62, N 8.56. 
 
N-Benzyl-2-bromo-N-butyl-1-methylcyclopropane-1-carboxamide 
(180f). This compound was synthesized according to Typical procedure 
employing 2-bromo-1-methylcyclopropane-1-carbonyl chloride (634 mg, 
3.21 mmol), N-benzylbutyl-1-amine (524 mg, 3.21 mmol), and triethylamine (1.40 mL, 1.02 g, 
10.5 mmol). The reaction mixture was stirred at room temperature overnight. After standard 
aqueous workup and extraction, the material was filtered through a silica plug to give a colorless 
oil, yield 895 mg (2.76 mmol, 86%). This material had purity by GC c.a. 95% and could be used 
in the cyclization step as is without additional purification. If desired, it can be additionally purified 
by preparative column chromatography on Silica gel eluting with a CH2Cl2/EtOAc mixture (40:1) 
to isolated inseparable mixture of diastereomeric bromocyclopropanes 180f as colorless oil, Rf 
0.45 (CH2Cl2/EtOAc 40:1). 
1H NMR (500 MHz, CDCl3) δ 7.40–7.22 (m, 4H), 7.16 (d, J = 7.2 Hz, 
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1H), [5.08 (d, J = 16.9 Hz), 4.88 (d, J = 14.9 Hz), 4.68 (br. m), 4.53–4.42 (m), ∑2H], [3.81 (dddd, 
J = 13.3, 10.1, 5.5, 1.5 Hz), 3.54 (ddd, J = 14.2, 11.8, 4.9 Hz), 3.36–3.14 (m), 3.04–2.97 (m), 2.75 
(ddd, J = 13.4, 10.1, 5.4 Hz), ∑3H], [1.80–1.71 (m), 1.70–1.65 (m), 1.63–1.52 (m), 1.52–1.43 
(br.m), 1.36–1.16 (m), ∑6H], [1.42 (s), 1.30 (s), ∑3H], [0.92 (t, J = 7.3 Hz), 0.86 (t, J = 7.4 Hz), 
∑3H]; 13C NMR (126 MHz, CDCl3) δ (172.2, 170.7, 1C), (137.5, 137.4, 137.0, 136.7, 1C), (129.0, 
128.9, 128.8, 128.5, 2C), (128.3, 127.9, 127.7, 127.6, 1C), (127.5, 127.3, 126.8, 126.7, 2C), (50.8, 
50.6, 47.7, 47.2, 1C), (46.7, 46.4, 45.5, 44.8, 1C), (30.5, 30.2, 29.0, 28.7, 1C), (28.2, 28.1, 1C), 
(27.7, 27.5, 26.3, 26.2, 26.1, 1C), (22.7, 22.6, 21.8, 1C), (22.0, 22.0, 20.0, 19.8, 1C), (20.4, 20.3, 
1C), (14.0, 14.0, 1C); HRMS (TOF ES): found 346.0797, calculated for C16H22BrNONa (M + Na) 
346.0782 (4.3 ppm). EA found C 59.34, 59.19, H 6.68, 6.91, N 4.14, 4.43, calculated for 
C16H22BrNO: C 59.27, H 6.84; N 4.32. 
 
 N-Benzyl-2-bromo-N-isopropyl-1-methylcyclopropane-1-carboxamide 
(180g). This compound was synthesized according to Typical procedure 
employing 2-bromo-1-methylcyclopropane-1-carbonyl chloride (667 mg, 
3.38 mmol), N-benzylpropan-2-amine (504 mg, 3.38 mmol), and triethylamine (1.40 mL, 1.02 g, 
10.5 mmol). The reaction mixture was stirred at room temperature overnight. After standard 
aqueous workup and extraction, the material was filtered through a silica plug to give a yellow oil, 
yield 860 mg (2.77 mmol, 82%). This material had purity by GC c.a. 98% and could be used in 
the cyclization step as is without additional purification. If desired, it can be additionally purified 
by preparative column chromatography on Silica gel eluting with a CH2Cl2/EtOAc mixture (20:1) 
to isolated inseparable mixture of diastereomeric bromocyclopropanes 180g as colorless oils, Rf 
0.42 (CH2Cl2/EtOAc 20:1). It should be pointed out, that one of the diastereomers shows in NMR 
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spectra two sets of signals due to restricted rotation. 1H NMR (400 MHz, CDCl3) δ 7.41–7.10 
(m, 5H), [5.09 (d, J = 17.4 Hz), 4.63–4.32 (m), 3.93 (sept, J = 6.7 Hz), ∑3H], [3.25 (br.dd, J 
= 8.3, 5.0 Hz), 3.07 (dd, J = 7.6, 4.8 Hz), 2.98 (dd, J = 7.5, 4.7 Hz), ∑1H], [1.77 (t, J = 7.5 Hz), 
1.71 (dd, J = 6.5, 5.0 Hz), ∑1H], [1.68 (s), 1.54 (br.s), 1.45 (s), 1.40 (s), ∑3H], [1.38–1.24 
(m), 1.25–1.11 (m), 1.25–1.11 (m), 0.96–0.90 (m), ∑7H]. 13C NMR (126 MHz, CDCl3) δ (172.1, 
171.3, 170.5, 1C), (139.6, 139.3, 138.5, 1C), (128.7, 128.5, 128.3, 2C), (127.4, 126.8, 1C), 
(127.1, 126.8, 126.6, 2C), (50.4, 49.0, 48.9, 1C), (50.3, 44.7, 44.0, 1C), (29.0, 28.6, 1C), (27.4, 
26.4, 26.1, 1C), (23.3, 22.8, 21.8, 1C), (22.9, 22.3, 1C), (22.2, 22.1, 21.4, 1C), (20.2, 19.9, 19.7, 
1C); HRMS (TOF ES): found 332.0638, calculated for C15H20BrNONa (M + Na) 332.0626 (3.6 
ppm). EA found C 58.30, 58.03, H 6.63, 6.54, N 4.28, 4.60, calculated for C15H20BrNO: C 58.07, 
H 6.50; N 4.51. 
 
N-Benzyl-2-bromo-N-cyclohexyl-1-methylcyclopropane-1-carboxamide 
(180h). This compound was synthesized according to Typical procedure 
employing 2-bromo-1-methylcyclopropane-1-carbonyl chloride (592 mg, 
3.00 mmol), N-benzylcyclohexylamine (568 mg, 3.0 mmol), and triethylamine (1.40 mL, 1.02 g, 
10.5 mmol). The reaction mixture was stirred at room temperature overnight. After standard 
aqueous workup and extraction, the material was filtered through a silica plug to give a pale-yellow 
oil, yield 893 mg (2.55 mmol, 85%). This material had purity by GC c.a. 96% and could be used 
in the cyclization step as is without additional purification. If desired, it can be additionally purified 
by preparative column chromatography on Silica gel eluting with a CH2Cl2/EtOAc mixture (40:1) 
to isolated inseparable mixture of diastereomeric bromocyclopropanes 180h as colorless oils, Rf 
0.40 (CH2Cl2/EtOAc 40:1). It should be pointed out, that one of the diastereomers shows in NMR 
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spectra two sets of signals due to restricted rotation. 1H NMR (400 MHz, CDCl3) δ 7.40–7.12 (m, 
5H), [5.09 (d, J = 17.6 Hz), 4.61 (s), 4.57 (s), 4.44 (d, J = 17.6 Hz), 4.36 (d, J = 15.6 Hz), ∑2H], 
[3.95 (tt, J = 11.4, 3.1 Hz), 3.88–3.76 (m), ∑1H], [3.23 (dd, J = 8.1, 4.9 Hz), 3.08 (dd, J = 7.6, 4.8 
Hz), 2.96 (dd, J = 7.5, 4.6 Hz), ∑1H], [2.02 (br.d, J = 11.8 Hz), 1.89–1.75 (m), 1.74–1.62 (m), 
1.62–1.29 (m), 1.26–1.20 (m), 1.17–0.90 (m), ∑12H], [1.43 (s), 1.27 (s) ∑3H]; 13C NMR (126 
MHz, CDCl3) δ (172.2, 171.3, 170.6, 1C), (139.6, 139.3, 138.9, 1C), (128.6, 128.4, 128.3, 2C), 
(127.3, 126.8, 1C), (127.2, 126.7, 126.6, 2C), (58.2, 58.2, 57.8, 1C), (49.7, 45.8, 45.1, 1C), (33.5, 
32.5, 30.4, 1C), (32.8, 32.2, 30.0, 1C), (28.9, 28.7, 1C), (27.6, 26.3, 26.2, 1C), (26.3, 26.2, 26.2, 
26.1, 26.1, 2C), (25.7, 25.5, 25.5, 1C), (23.5, 23.1, 21.6, 1C), (22.3, 22.2, 20.0, 1C); HRMS (TOF 
ES): found 372.0947, calculated for C18H24BrNONa (M + Na) 372.0939 (2.1 ppm). EA found C 
61.53, 61.91, H 7.03, 7.11, N 4.09, 4.15, calculated for C18H24BrNO: C 61.72, H 6.91; N 4.00. 
 
N-Benzyl-2-bromo-N-(tert-butyl)-1-methylcyclopropane-1-carboxamide 
(180i). This compound was synthesized according to Typical procedure 
employing 2-bromo-1-methylcyclopropane-1-carbonyl chloride (640 mg, 
3.24 mmol), N-benzyl-2-methylpropan-2-amine (529 mg, 3.24 mmol), and triethylamine (1.40 
mL, 1.02 g, 10.5 mmol). The reaction mixture was stirred at room temperature overnight. After 
standard aqueous workup and extraction, the material was filtered through a silica plug to afford a 
pale-yellow glass, yield 830 mg (2.56 mmol, 79%). This material had purity by GC c.a. 98% and 
could be used in the cyclization step as is without additional purification. If desired, diastereomeric 
bromocyclopropanes can be additionally purified and separated by preparative column 
chromatography on Silica gel eluting with a CH2Cl2/EtOAc mixture (40:1). HRMS (TOF ES): 
found 346.0786, calculated for C16H22BrNONa (M + Na) 346.0782 (1.2 ppm). Individual isomers 
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were isolated as colorless glass (trans-180i) and colorless crystalline solid (cis-180i), respectively. 
trans-180i: Rf 0.42 (CH2Cl2/EtOAc 40:1); 
1H NMR (500 MHz, CDCl3) δ 7.34 (t, J = 7.5 Hz, 2H), 
7.25 (t, J = 7.3 Hz, 1H), 7.19 (d, J = 7.5 Hz, 2H), 4.78 (q, J = 17.8 Hz, 2H), 3.20 (dd, J = 8.2, 4.9 
Hz, 1H), 1.71 (dd, J = 8.2, 6.7 Hz, 1H), 1.42 (s, 3H), 1.36 (s, 9H), 0.82 (dd, J = 6.7, 5.0 Hz, 
1H); 13C NMR (126 MHz, CDCl3) δ 173.5, 140.0, 128.8 (2C), 127.1, 125.9 (2C), 58.3, 49.5, 
28.6 (3C), 28.5, 27.9, 22.2, 20.3. cis-180i: mp 165-166 °C; Rf 0.35 (CH2Cl2/EtOAc 40:1); 
1H 
NMR (400 MHz, CDCl3) δ 7.49– 7.10 (m, 5H), 5.10 (d, J = 18.3 Hz, 1H), 4.61 (d, J = 18.3 Hz, 
1H), 2.95 (dd, J = 7.5, 4.6 Hz, 1H), 1.67 (dd, J = 6.7, 4.6 Hz, 1H), 1.39 (s, 9H), 1.22 (s, 3H), 
1.12 (dd, J = 7.5, 6.7 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 171.7, 140.8, 128.6 (2C), 126.9, 
126.1 (2C), 59.0, 49.9, 30.4, 28.6 (3C), 26.9, 23.8, 22.4. EA found C 59.50, 59.03, H 7.01, 6.94, 
N 4.52, 4.19, calculated for C16H22BrNO: C 59.27, H 6.84; N 4.32. 
 
2-Bromo-N-(4-fluorobenzyl)-N,1-dimethylcyclopropane-1-
carboxamide (180j). This compound was synthesized according to 
Typical procedure employing 2-bromo-1-methylcyclopropane-1-carbonyl 
chloride (340 mg, 1.72 mmol), 1-(4- fluorophenyl)-N-methylmethanamine (239 mg, 1.72 mmol), 
and triethylamine (988 µL 717 mg, 7.08 mmol). The reaction mixture was stirred at room 
temperature overnight. The product was isolated by column chromatography eluting with a 
hexanes/EtOAc mixture (1:1) as a yellow oil (Rf 0.37). Yield: 413 mg (1.37 mmol, 80%). 
1H NMR 
(500 MHz, CDCl3) δ [7.31–7.27 (m), 7.27–7.94 (m), ∑4H], 5.14–4.36 (m, 2H), [3.20 (dd, J = 
8.2, 4.9 Hz), 3.10–2.85 (m), ∑4H], [1.82–1.73 (m), 1.69–1.63 (m), ∑1H], [1.49 (s), 1.42 (s), 1.35 
(s), ∑3H], [1.22 (t, J = 7.1 Hz), 0.94 (dd, J = 6.7, 4.9 Hz), ∑1H]; 13C NMR (126 MHz, CDCl3) δ 
(171.2, 170.5, 1C), [162.23 (d, 1JCF = 246.1 Hz), 162.19 (d, 
1JCF = 246.0 Hz), 1C], [132.9 (d, 
4JCF 
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= 3.5 Hz), 132.7 (br. s), 1C], [130.0 (d, 3JCF = 8.2 Hz), 128.3 (d, 
3JCF = 7.9 Hz), 2C], [115.8 (d, 
2JCF = 23.5 Hz), 115.3 (d, 
2JCF = 21.7 Hz), 2C], (52.7, 50.7, 1C), (35.0, 33.5, 1C), (27.8, 25.8, 
1C), [27.5 (br), 26.0, 1C], (25.8, 20.9, 1C), [21.8, 18.9 (br), 1C]; 19F NMR (376 MHz, CDCl3) δ -
114.9, - 115.3; FT IR (NaCl, cm-1): 2930, 2360, 2342, 1700, 1684, 1645, 1540, 1508, 1403, 
1222, 1106, 924, 817, 668, 650; HRMS (TOF ES): found 322.0217, calculated for 
C13H15BrFNONa (M + Na) 322.0219 (0.6 ppm); EA found C 51.98, 52.10, H 5.24, 4.82, N 
4.95, 4.69, calculated for C13H15BrFNO: C 52.02, H 5.04, N 4.67. 
 
2-Bromo-N-(2,4-difluorobenzyl)-N,1-dimethylcyclopropane-1-
carboxamide (180k). This compound was synthesized according to 
Typical procedure employing 2-bromo-1-methylcyclopropane-1-
carbonyl chloride (400 mg, 2.03 mmol), 1-(2,4-difluorophenyl)-N-methylmethanamine (319 mg, 
2.03 mmol), and triethylamine (710 µL, 515 mg, 5.09 mmol). The reaction mixture was stirred at 
room temperature overnight. The product was isolated by column chromatography eluting with a 
CH2Cl2/MeOH mixture (40:1) as a pale-yellow oil (Rf 0.43). Yield: 490 mg (1.54 mmol, 76%). 
1H 
NMR (500 MHz, CDCl3) δ [7.44–7.39 (m), 7.36 (s), 7.27–7.17 (m), ∑1H], 6.95–6.75 (m, 2H), 
5.08–4.45 (m, 2H), 3.23–2.83 (m, 4H), [1.75 (dd, J = 8.2, 6.6 Hz), 1.69–1.61 (m), ∑1H], [1.48 
(s), 1.41 (s), 1.32 (s), ∑3 H], [1.21 (t, J = 7.2 Hz), 0.93 (dd, J = 6.7, 4.9 Hz), ∑1H]; 13C NMR (126 
MHz, CDCl3) δ (172.0, 170.7, 1C), [162.4 (dd, 
1JCF = 249.0 Hz, 
3JCF = 11.8 Hz), 162.2 (dd, 
1JCF 
= 247.6 Hz, 3JCF = 11.9 Hz), 1C), [161.1 (dd, 
1JCF = 248.2 Hz, 
3JCF = 11.9 Hz), 1C], [131.8 (dd, 
3JCF = 9.5 Hz, 
3JCF = 5.7 Hz), 131.4 (br. s), 1C], [120.0 (dd, 
2JCF = 15.0 Hz, 
4JCF = 3.9 Hz), 119.9 
(br. s), 1C], [111.7 (dd, 2JCF = 21.2 Hz, 
4JCF = 3.9 Hz), 111.5 (dd, 
2JCF = 20.8 Hz, 
4JCF = 3.7 Hz), 
1C], [104.3 (t, 2JCF = 25.2 Hz, 
4JCF = 3.9 Hz), 103.5 (t, 
2JCF = 25.5 Hz), 1C], [46.8 (d, 
3JCF = 4.8 
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Hz), 44.2 (t, 3JCF = 3.6 Hz), 1C], (35.4, 35.1, 1C), (27.8, 27.4 (br), 1C), (25.9, 25.8, 1C), (21.80, 
21.77, 1C), (20.9, 18.9, 1C); 19F NMR (376 MHz, Chloroform-d) δ - 111.0 (d, 4JFF = 7.3 Hz), -
111.1 (d, 4JFF = 7.4 Hz), -114.0 (d, 
4JFF = 7.2 Hz), -115.1 (d, 
4JFF = 7.4 Hz). FT IR (NaCl, cm
-
1): 2933, 2360, 2341, 1645, 1505, 1487, 1430, 1403, 1269, 1139, 1106, 1091, 964, 850, 668, 
621. HRMS (TOF ES): found 318.0309, calculated for C13H15BrF2NO (M + H) 318.0305 (1.3 
ppm); EA found C 48.81, 49.33, H 4.64, 4.20, N 4.28, 4.32, calculated for C13H14BrF2NO: C 49.08, 
H 4.44, N 4.40. 
 
2-Bromo-N-(2-chlorobenzyl)-N,1-dimethylcyclopropane-1-
carboxamide (180l). This compound was synthesized according to Typical 
procedure employing 2-bromo-1-methylcyclopropane-1-carbonyl chloride 
(494 mg, 2.50 mmol), 1-(2- chlorophenyl)-N-methylmethanamine (389 mg, 2.50 mmol), and 
triethylamine (886 µL 642 mg, 6.35 mmol). The reaction mixture was stirred at room temperature 
overnight. The product was isolated by column chromatography eluting with a hexanes/EtOAc 
mixture (3:2) as a colorless glass (Rf 0.33). Yield: 586 mg (1.85 mmol, 74%). 
1H NMR (500 MHz, 
CDCl3) δ [7.45–7.28 (m), 7.24–7.19 (m), 7.12 (br. s), ∑4H], 5.12–4.52 (m, 2H), 3.26–2.88 (m, 
4H), [1.77 (br. s), 1.69–1.65 (m), 1.52 (br. s), 1.45 (s), 1.26–1.16 (m), 0.94 (br. s), ∑5H]; 13C 
NMR (126 MHz, CDCl3) δ (171.6, 170.7, 1C), (134.4, 134.2, 1C), (133.7, 132.8, 1C), (129.5, 
128.8, 128.60, 128.56, 127.23, 127.18, 127.1, 127.0, 4C), (51.3, 48.7, 1C), (35.5, 34.5, 1C), 
(28.0, 26.0, 1C), (25.9, 25.6, 1C), (22.5, 21.8, 21.5, 21.0, 2C); FTIR (NaCl, cm-1): 2932, 1644, 
1486, 1443, 1402, 1093, 1050, 752; HRMS (TOF ES): found 322.0196, calculated for 
C13H15BrClNOLi (M + Li) 322.0186 (3.1 ppm); EA found C 49.55, 49.04, H 4.64, 5.05, N 4.57, 
4.30, calculated for C13H15BrClNO: C 49.32, H 4.78, N 4.42. 
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2-Bromo-N-(4-bromo-2-fluorobenzyl)-N,1-dimethylcyclopropane-1-
carboxamide (180m). This compound was synthesized according to 
Typical procedure employing 2-bromo-1-methylcyclopropane-1-
carbonyl chloride (494 mg, 2.50 mmol), 1-(4-bromo-2-fluorophenyl)-N-methylmethanamine 
(545 mg, 2.50 mmol), and triethylamine (886 µL 642 mg, 6.35 mmol). The reaction mixture was 
stirred at room temperature overnight. The product was isolated by column chromatography 
eluting with a hexanes/EtOAc mixture (3:2) as a pale-yellow oil (Rf 0.23). Yield: 853 mg (2.25 
mmol, 90%). 1H NMR (500 MHz, CDCl3) δ [7.36–7.27 (m), 7.28–7.08 (m), ∑3H], 5.05–4.47 (m, 
2H), 3.21–2.86 (m, 4H), [1.75 (dd, J = 8.2, 6.7 Hz), 1.64 (dd, J = 6.9, 4.7 Hz), ∑1H], [1.48 (s), 
1.41 (s), 1.30 (s), ∑3H], [1.21 (t, J = 7.1 Hz), 0.93 (dd, J = 6.7, 4.9 Hz), ∑1H]; 13C NMR (126 
MHz, CDCl3) δ [172.0, 170.8, 1C], 160.8 (d, 
1JCF = 250.8 Hz, 1C), [131.9 (d, 
3JCF = 4.6 Hz), 
131.5 (br. s), 1C], [127.9 (d, 4JCF = 3.4 Hz), 127.7 (d, 
4JCF = 3.6 Hz), 1C], [123.3 (d, 
2JCF = 15.2 
Hz), 123.1 (br. s), 1C], [121.7 (br. s), 121.4 (d, 3JCF = 9.2 Hz), 1C], [119.2 (br. s), 118.8 (d, 
2JCF 
= 22.4 Hz), 1C], [47.0 (br. s), 44.3 (d, 3JCF = 3.7 Hz), 1C], (35.5, 35.2, 1C), (27.8, 27.3, 1C), 
(25.9, 25.8, 1C), (21.79, 21.76, 1C), (20.9, 18.9, 1C); 19F NMR (376 MHz, CDCl3) δ -115.3, -
116.4; FT IR (NaCl, cm-1): 2932, 1644, 1605, 1484, 1401, 1218, 1103, 875, 814, 611; HRMS 
(TOF ES): found 399.9341, calculated for C13H14Br2FNONa (M + Na) 399.9324 (4.3 ppm); EA 
found C 41.48, 41.39, H 3.52, 3.61, N 3.56, 3.76, calculated for C13H14Br2FNO: C 41.19, H 3.72, 
N 3.70. 
 
3.5.3 Cyclization of bromocyclopropanes  
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 (1R*,5S*)-3-Benzyl-1-methyl-4-phenyl-3-azabicyclo[3.1.0]hexan2-one 
(182a). Typical procedure: an oven-dried Wheaton vial equipped with a Teflon 
septum cap was charged with freshly sublimed t-BuOK (315 mg, 2.80 mmol) 
and 18-crown-6 ether (18.5 mg, 0.07 mmol) in a nitrogen-filled glovebox. 
Anhydrous THF (2.22 mL) was then added to this vial and the solution was stirred to premix for 
30 minutes. A solution of N,N-dibenzyl-2-bromo-1-methylcyclopropane-1-carboxamide (180a) 
(251 mg, 0.70 mmol) in anhydrous THF (1.48 mL) was added dropwise to the stirred reaction 
mixture, which was then stirred at 30 °C until starting materials were consumed (10 min for the 
reaction of 182a). The reaction was then quenched by pouring the mixture into brine (35 mL). The 
aqueous layer was extracted with EtOAc (2 × 20 mL). The combined organic phases were washed 
with brine (20 mL), dried with MgSO4, gravity filtered, and concentrated in vacuo. The crude 
material contains a mixture of diastereomers 45 : 55 (endo : exo). Purification by column 
chromatography eluting with a mixture of hexanes/EtOAc (2 : 1) afforded the titled product as a 
pale yellow oil (Rf 0.38). Yield 156 mg (0.56 mmol, 80%). endo-182a: 
1H NMR (400 MHz, CDCl3) 
δ 7.42–7.32 (m, 3H), 7.31–7.21 (m, 3H), 7.20–7.14 (m, 2H), 7.09–7.01 (m, 2H), 5.06 (d, J = 15.0 
Hz, 1H), 4.57 (d, J = 6.0 Hz, 1H), 3.50 (d, J = 14.5 Hz, 1H), 1.93–1.86 (m, 1H), 1.42 (s, 3H), 1.05 
(t, J = 4.5 Hz, 1H), 0.64 (dd, J = 7.8, 5.0 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 177.6, 138.5, 
136.6, 128.9 (2C), 128.9 (2C), 128.7 (2C), 128.0, 127.6, 127.0 (2C), 59.6, 44.2, 27.1, 26.6, 16.4, 
15.2. exo-182a: 1H NMR (400 MHz, CDCl3) δ 7.42–7.32 (m, 3H), 7.31–7.21 (m, 3H), 7.20–7.14 
(m, 2H), 7.09–7.01 (m, 2H), 5.00 (d, J = 14.9 Hz, 1H), 4.12 (s, 1H), 3.36 (d, J = 14.7 Hz, 1H), 
1.58 (dd, J = 7.5, 3.9 Hz, 1H), 1.48 (s, 3H), 0.72 (t, J = 4.3 Hz, 1H), 0.92 (dd, J = 7.5, 4.6 Hz, 1H); 
13C NMR (126 MHz, CDCl3) δ 176.5, 140.8, 137.2, 129.2 (2C), 128.8 (2C), 128.5, 128.5 (2C), 
127.6, 127.0 (2C), 61.8, 43.9, 26.4, 25.6, 19.3, 15.1. FTIR (NaCl, cm−1): 3063, 3030, 2961, 2928, 
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2869, 1694, 1495, 1454, 1414, 1357, 1301, 1200, 1151, 1078, 1029, 941, 747, 761, 701, 622; 
HRMS (TOF ES): found 300.1378, calculated for C19H19NONa (M + Na) 300.1364 (4.7 ppm); 
EA found C 82.12, 82.00, H 6.76, 6.74, N 5.19, 5.12, calculated for C19H19NO: C 82.28, H 6.90, 
N 5.05. 
 
(1R*,5S*)-3-Butyl-1-methyl-4-(4-(trifluoromethyl)phenyl)-
3azabicyclo[3.1.0]hexan-2-one (182d). This compound was synthesized 
according to the Typical procedure employing 2-bromo-N-butyl-1-methyl-
N-(4(trifluoromethyl)benzyl)cyclopropane-1-carboxamide (180d) (67 mg, 
0.171 mmol), 18-crown-6 ether (4.5 mg, 0.017 mmol), and t-BuOK (77 mg, 0.68 mmol). The 
reaction mixture was stirred at rt for 5 min and then quenched with a saturated solution of 
ammonium chloride. The crude material contains an inseparable mixture of diastereomers 15 : 85 
(endo : exo). Purification by column chromatography eluting with a mixture of hexanes/EtOAc (2 : 
1) afforded the titled product as a colorless oil (Rf 0.33). Yield: 12.4 mg (0.046 mmol, 27%). endo-
182d: 1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.2 Hz, 2H), 7.24 (d, J = 8.1 Hz, 2H), 4.90 (d, J 
= 6.2 Hz, 1H), 3.66 (ddd, J = 13.9, 8.9, 7.1 Hz, 1H), 2.50–2.43 (m, 1H), 1.96 (ddd, J = 7.7, 6.1, 
4.0 Hz, 1H), 1.41 (s, 3H), 1.36–1.25 (m, 2H), 1.25–1.15 (m, 2H), 0.89 (t, J = 4.5 Hz, 1H), 0.85 (t, 
J = 7.3 Hz, 3H), 0.62 (dd, J = 7.8, 5.0 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 177.2, 143.0, 130.0 
(q, 2JCF = 40.0 Hz), 126.9 (2C), 125.8 (q, 
3JCF = 3.7 Hz, 2C), 124.0 (q, 
1JCF = 271.9 Hz), 59.7, 40.2, 
28.8, 28.2, 26.6, 20.1, 16.1, 15.0, 13.8. exo-182d: 1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.2 
Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 4.43 (s, 1H), 3.59 (dt, J = 14.0, 7.8 Hz, 1H), 2.46 (ddd, J = 13.8, 
7.8, 5.5 Hz, 1H), 1.57 (dd, J = 7.5, 4.0 Hz, 1H), 1.43 (s, 3H), 1.36–1.25 (m, 2H), 1.25–1.15 (m, 
2H), 1.00 (dd, J = 7.5, 4.7 Hz, 1H), 0.85 (t, J = 7.3 Hz, 3H), 0.80 (t, J = 4.3 Hz, 1H); 13C NMR 
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(126 MHz, CDCl3) δ 176.5, 145.4, 130.6 (q, 
2JCF = 32.7 Hz), 126.9 (2C), 126.1 (q, 
3JCF = 3.9 Hz, 
2C), 124.0 (q, 1JCF = 271.9 Hz), 62.2, 40.0, 29.6, 26.4, 25.8, 19.9, 19.9, 14.9, 13.7. 
19F NMR (376 
MHz, chloroform-d) δ −62.5, −62.6; FTIR (NaCl, cm−1): 2961, 2933, 2873, 1676, 1645, 1459, 
1414, 1326, 1294, 1246, 1166, 1125, 1067, 1018, 959, 846, 756, 608; HRMS (TOF ES): found 
312.1578, calculated for C17H21NOF3 (M + H) 312.1575 (1.0 ppm); EA found C 65.70, 65.45, H 
6.38, 6.65, N 4.39, 4.78, calculated for C17H20F3NO: C 65.58, H 6.48, N 4.50.  
 
(1R*,5S*)-3-Butyl-1-methyl-4-phenyl-3-azabicyclo[3.1.0]hexan-2-one 
(182f). This compound was synthesized according to the Typical procedure 
employing N-benzyl-2-bromo-N-butyl-1-methylcyclopropane-1-
carboxamide (180f) (229 mg, 0.70 mmol), 18-crown-6 ether (18.5 mg, 0.07 mmol), and t-BuOK 
(314 mg, 2.80 mmol). The reaction mixture was stirred overnight at 30 °C. The crude material 
contains an inseparable mixture of diastereomers 53 : 47 (endo : exo). Purification by column 
chromatography eluting with a mixture of hexanes/EtOAc (3 : 1) afforded the titled product as a 
yellow oil (Rf 0.30). Yield 119.2 mg (0.49 mmol, 70%). endo-182f: 
1H NMR (400 MHz, CDCl3) 
δ 7.41–7.29 (m, 3H), 7.15–7.09 (m, 2H), 4.85 (d, J = 6.0 Hz, 1H), 3.63 (ddd, J = 13.8, 8.6, 7.3 Hz, 
1H), 2.50 (m, 1H), 1.93 (ddd, J = 7.7, 6.0, 3.9 Hz, 1H), 1.40 (s, 3H), 1.38–1.12 (m, 4H), 0.99–0.91 
(m, 1H), 0.84 (t, J = 7.3 Hz, 3H), 0.59 (dd, J = 7.7, 5.0 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 
177.4, 138.8, 128.8 (2C), 127.9, 126.8 (2C), 60.2, 40.2, 29.0, 26.9, 26.7, 20.2, 16.2, 15.2, 13.9. 
exo-182f: 1H NMR (400 MHz, CDCl3) δ 7.41–7.29 (m, 3H), 7.22–7.17 (m, 2H), 4.35 (s, 1H), 3.55 
(dt, J = 13.9, 7.7 Hz, 1H), 2.50 (m, 1H), 1.59 (dd, J = 7.5, 3.9 Hz, 1H), 1.42 (s, 3H), 1.38–1.12 (m, 
4H), 0.99–0.91 (m, 1H), 0.84 (t, J = 7.3 Hz, 3H), 0.76 (t, J = 4.2 Hz, 1H); 13C NMR (126 MHz, 
CDCl3) δ 176.6, 141.3, 129.1 (2C), 128.3, 126.7 (2C), 62.8, 39.9, 29.8, 26.7, 25.9, 20.0 (2C), 15.1, 
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13.8. FTIR (NaCl, cm−1): 2960, 2931, 2872, 1692, 1457, 1417, 1372, 1219, 1051, 756, 701. HRMS 
(TOF ES): found 266.1514, calculated for C16H21NONa (M + Na) 266.1521 (2.6 ppm); EA found 
C 78.81, 79.23, H 8.42, 8.50, N 5.92, 5.55, calculated for C16H21NO: C 78.97, H 8.70, N 5.76. 
 
(1R*,5S*)-3-Isopropyl-1-methyl-4-phenyl-3-azabicyclo[3.1.0]hexan-2-one 
(182g). This compound was synthesized according to the Typical procedure 
employing N-benzyl-2-bromo-N-isopropyl-1-methylcyclopropane-1-
carboxamide (180g) (217 mg, 0.70 mmol), 18-crown-6 ether (18.5 mg, 0.07 mmol), and t-BuOK 
(314 mg, 2.80 mmol). The reaction mixture was stirred at 30 °C for 3 h. The crude material contains 
a mixture of diastereomers 50 : 50 (endo : exo). Purification by column chromatography eluting 
with a mixture of hexanes/EtOAc (3 : 1) afforded the titled product as a pale yellow glass (Rf 0.36, 
0.30). Yield 104.3 mg (0.455 mmol, 65%). Analytical samples of individual diastereomers were 
obtained by column chromatography on silica gel eluting with a CH2Cl2/EtOAc mixture (10 : 1). 
endo-182g: 1H NMR (400 MHz, CDCl3) δ 7.42–7.32 (m, 3H), 7.26–7.21 (m, 2H), 4.86 (d, J = 5.8 
Hz, 1H), 3.47 (p, J = 6.8 Hz, 1H), 1.91 (ddd, J = 7.7, 5.9, 3.9 Hz, 1H), 1.38 (s, 3H), 1.32 (d, J = 
6.9 Hz, 3H), 1.15 (d, J = 6.8 Hz, 3H), 1.08 (t, J = 4.4 Hz, 1H), 0.62 (dd, J = 7.7, 4.8 Hz, 1H); 13C 
NMR (126 MHz, CDCl3) δ 178.2, 140.4, 128.7 (2C), 128.0, 126.9 (2C), 61.4, 46.1, 27.3, 26.8, 
20.0, 19.6, 16.2, 15.1. exo-182g: 1H NMR (500 MHz, CDCl3), δ 
1H NMR (500 MHz, CDCl3) δ 
7.38–7.33 (m, 2H), 7.33–7.28 (m, 1H), 7.27–7.21 (m, 2H), 4.36 (s, 1H), 4.02 (p, J = 6.9 Hz, 1H), 
1.49 (dd, J = 7.3, 3.9 Hz, 1H), 1.44 (s, 3H), 1.08 (d, J = 6.8 Hz, 3H), 0.91 (dd, J = 7.3, 4.6 Hz, 1H), 
0.77 (d, J = 6.9 Hz, 3H), 0.66 (t, J = 4.2 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 176.8, 143.6, 
128.9 (2C), 128.2, 126.7 (2C), 61.5, 44.7, 26.6, 26.2, 21.3, 20.4, 19.5, 15.0. FTIR (NaCl, cm−1): 
2970, 2931, 1685, 1456, 1412, 1380, 1345, 1223, 1028, 956, 763, 738, 702. HRMS (TOF ES): 
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found 252.1353, calculated for C15H19NONa (M + Na) 252.1364 (4.4 ppm); EA found C 78.47, 
78.68, H 8.55, 8.18, N 6.07, 6.40, calculated for C15H19NO: C 78.56, H 8.35, N 6.11. 
 
(1R*,5S*)-3-Cyclohexyl-1-methyl-4-phenyl-3-azabicyclo[3.1.0]hexan-2-
one (182h). This compound was synthesized according to the Typical 
procedure employing N-benzyl-2-bromo-N-cyclohexyl-1-
methylcyclopropane-1-carboxamide (180h) (245 mg, 0.70 mmol), 18-crown-
6 ether (18.5 mg, 0.07 mmol), and t-BuOK (314 mg, 2.80 mmol). The reaction mixture was stirred 
overnight at 30 °C. The crude material contains an inseparable mixture of diastereomers 45 : 55 
(endo : exo). Purification by column chromatography eluting with a mixture of hexanes/EtOAc (3 : 
1) afforded the titled product as a colorless glass (Rf 0.38). Yield 141.3 mg (0.525 mmol, 75%). 
endo-182h 1H NMR (400 MHz, CDCl3) δ 7.41–7.27 (m, 3H), 7.25–7.18 (m, 2H), 4.85 (d, J = 6.0 
Hz, 1H), 3.10 (tt, J = 12.2, 3.5 Hz, 1H), 2.04–1.90 (m, 1H), 1.87 (ddd, J = 7.8, 6.0, 3.9 Hz, 1H), 
1.67 (dd, J = 22.8, 11.2 Hz, 4H), 1.57–1.44 (m, 2H), 1.35 (s, 3H), 1.17–0.92 (m, 4H), 0.57 (dd, J 
= 7.8, 4.8 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 178.2, 140.6, 128.6 (2C), 127.9, 126.8 (2C), 
61.2, 54.5, 30.1, 29.6, 27.5, 26.8, 26.3, 26.0, 25.5, 16.2, 15.1. exo-182h: 1H NMR (400 MHz, 
CDCl3) δ 7.41–7.27 (m, 3H), 7.25–7.18 (m, 2H), 4.37 (s, 1H), 3.65 (tt, J = 12.1, 3.8 Hz, 1H), 1.73–
1.59 (m, 1H), 1.55–1.42 (m, 5H), 1.42 (s, 3H), 1.43–1.33 (m, 1H), 1.30–1.21 (m, 2H), 1.18–1.00 
(m, 1H), 1.00–0.70 (m, 2H), 0.64 (t, J = 4.2 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 176.9, 143.9, 
128.9 (2C), 128.0, 126.6 (2C), 61.6, 52.7, 31.9, 30.9, 26.8, 26.3, 25.9, 25.9, 25.5, 19.6, 15.0. FTIR 
(NaCl, cm−1): 2931, 2855, 1684, 1453, 1414, 1360, 1205, 1028, 894, 751, 736, 702, 624. HRMS 
(TOF ES): found 292.1664, calculated for C18H23NONa (M + Na) 292.1677 (4.4 ppm); EA found 
C 80.31, 80.34, H 8.89, 8.86, N 4.95, 5.14, calculated for C18H23NO: C 80.26, H 8.61, N 5.20. 
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(1R*,5S*)-3-(tert-Butyl)-1-methyl-4-phenyl-3-azabicyclo[3.1.0]hexan-2-one 
(182i). This compound was synthesized according to the Typical procedure 
employing N-benzyl-2-bromo-N-(tert-butyl)-1-methylcyclopropane-1-
carboxamide (180i) (227 mg, 0.70 mmol), 18-crown-6 ether (18.5 mg, 0.07 mmol), and t-BuOK 
(314 mg, 2.80 mmol). The reaction mixture was stirred overnight at 30 °C. The crude material 
contains an inseparable mixture of diastereomers 47 : 53 (endo : exo). Purification by column 
chromatography eluting with a mixture of hexanes/EtOAc (3 : 1) afforded the titled product as a 
colorless glass (Rf 0.44). Yield 109 mg (0.448 mmol, 64%). endo-182i: 
1H NMR (500 MHz, CDCl3) 
δ 7.39–7.26 (m, 4H), 7.28–7.14 (m, 1H), 4.97 (d, J = 6.5 Hz, 1H), 1.88 (ddd, J = 7.9, 6.5, 3.7 Hz, 
1H), 1.34 (s, 3H), 1.26 (s, 9H), 0.98 (t, J = 4.3 Hz, 1H), 0.49 (dd, J = 7.9, 4.8 Hz, 1H); 13C NMR 
(126 MHz, CDCl3) δ 178.8, 144.7, 128.5 (2C), 127.1, 125.5 (2C), 61.1, 54.4, 28.3 (3C), 28.3, 28.3, 
16.1, 15.7. exo-182i: 1H NMR (500 MHz, CDCl3) δ 7.39–7.26 (m, 4H), 7.28–7.14 (m, 1H), 4.57 
(s, 1H), 1.40 (dd, J = 7.2, 3.9 Hz, 1H), 1.38 (s, 3H), 1.24 (s, 9H), 0.84 (dd, J = 7.2, 4.3 Hz, 1H), 
0.66 (t, J = 4.1 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 177.8, 143.7, 128.9 (2C), 127.7, 126.1 
(2C), 62.7, 55.5, 28.1 (3C), 26.4, 26.0, 19.2, 14.9. FTIR (NaCl, cm−1): 2963, 2929, 2869, 1664, 
1493, 1455, 1396, 1383, 1359, 1343, 1221, 1198, 1141, 950, 762, 740, 705; HRMS (TOF ES): 
found 266.1528, calculated for C16H21NONa (M + Na) 266.1521 (2.6 ppm); EA found C 79.05, 
79.07, H 8.60, 8.95, N 5.92, 5.57, calculated for C16H21NO: C 78.97, H 8.70, N 5.76. 
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(1R*,5S*)-4-(4-Fluorophenyl)-1,3-dimethyl-3-azabicyclo[3.1.0]hexan-2-
one (182j). This compound was synthesized according to the Typical 
procedure employing 2-bromo-N-(4-fluorobenzyl)-N,1-
dimethylcyclopropane-1-carboxamide (180j) (51 mg, 0.171 mmol), 18-
crown-6 ether (4.5 mg, 0.017 mmol), and t-BuOK (76 mg, 0.68 mmol). The reaction mixture was 
stirred at rt for 4 h. The crude material contains an inseparable mixture of diastereomers 60 : 40 
(endo : exo). Purification by column chromatography eluting with a mixture of hexanes/EtOAc (3 : 
1) afforded the titled product as a colorless glass (Rf 0.36). Yield 21.6 mg (0.099 mmol, 58%). 
endo-182j: 1H NMR (400 MHz, CDCl3) δ 7.11–7.02 (m, 4H), 4.68 (d, J = 5.9 Hz, 1H), 2.61 (s, 
3H), 1.93 (ddd, J = 7.7, 5.9, 4.0 Hz, 1H), 1.40 (s, 3H), 0.90 (t, J = 4.6 Hz, 1H), 0.63 (dd, J = 7.8, 
5.0 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 176.4, 162.4 (d, 
1JCF = 246.1 Hz), 136.5 (d, 
4JCF = 3.5 
Hz), 128.0 (d, 3JCF = 8.1 Hz, 2C), 115.7 (d, 
2JCF = 21.2 Hz, 2C), 62.2, 28.1, 26.9, 25.7, 16.3, 14.9. 
exo-182j: 1H NMR (400 MHz, CDCl3) δ 7.21–7.13 (m, 2H), 7.11–7.02 (m, 2H), 4.23 (s, 1H), 2.57 
(s, 3H), 1.57 (dd, J = 7.6, 3.9 Hz, 1H), 1.42 (s, 3H), 0.96 (dd, J = 7.6, 4.7 Hz, 1H), 0.81 (t, J = 4.3 
Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 176.4, 162.6 (d, 
1JCF = 247.0 Hz), 136.5 (d, 
4JCF = 3.5 
Hz), 128.1 (d, 3JCF = 8.2 Hz, 2C), 116.0 (d, 
2JCF = 21.7 Hz, 2C), 64.5, 27.9, 26.6, 25.7, 20.0, 15.1. 
19F NMR (376 MHz, CDCl3) δ−113.8, −114.6; FTIR (NaCl, cm
−1): 2929, 1683, 1509, 1481, 1398, 
1223, 1158, 1007, 845, 819, 752, 668, 647. HRMS (TOF ES): found 242.0960, calculated for 
C13H14NOFNa (M + Na) 242.0957 (1.2 ppm); EA found C 71.35, 71.27, H 6.18, 6.34, N 6.26, 
6.33, calculated for C13H14FNO: C 71.21, H 6.44, N 6.39. Slow crystallization of the purified 
material from hexane afforded a crop of crystals of exo-182j suitable for X-ray analysis (CCDC 
#1575277). 
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(1R*,5S*)-4-(2,4-Difluorophenyl)-1,3-dimethyl-3-azabicyclo[3.1.0]hexan-
2-one (182k). This compound was synthesized according to the Typical 
procedure employing 2-bromo-N-(2,4-difluorobenzyl)-N,1-
dimethylcyclopropane-1-carboxamide (180k) (54 mg, 0.171 mmol), 18-
crown-6 ether (4.5 mg, 0.017 mmol), and t-BuOK (76 mg, 0.68 mmol). The reaction mixture was 
stirred at rt for 5 min and then quenched with a saturated solution of ammonium chloride. The 
crude material contains an inseparable mixture of diastereomers 69 : 31 (endo : exo). Purification 
by column chromatography eluting with a mixture of hexanes/EtOAc (2 : 3) afforded the titled 
product as a colorless oil (Rf 0.38). Yield 30.2 mg (0.127 mmol, 75%). endo-182k: 
1H NMR (500 
MHz, CDCl3) δ 6.93–6.79 (m, 3H), 4.95 (d, J = 5.9 Hz, 1H), 2.64 (s, 3H), 2.06 (ddd, J = 7.8, 5.9, 
4.0 Hz, 1H), 1.38 (s, 3H), 0.77 (t, J = 4.5 Hz, 1H), 0.64 (dd, J = 7.8, 5.0 Hz, 1H); 13C NMR (126 
MHz, CDCl3) δ 177.9, 162.3 (dd, 
1JCF = 249.2 Hz, 
3JCF = 13.2 Hz), 160.7 (dd, 
1JCF = 248.8 Hz, 
3JCF 
= 12.0 Hz), 127.8 (dd, 3JCF = 9.4 Hz, 
3JCF = 5.8 Hz), 122.1 (dd, 
2JCF = 13.2 Hz, 
4JCF = 3.9 Hz), 111.3 
(dd, 2JCF = 21.0 Hz, 
4JCF = 3.6 Hz), 104.3 (t, 
2JCF = 25.5 Hz), 56.0 (d, 
3JCF = 4.5 Hz), 28.5, 26.5, 
25.6, 16.5, 14.9. exo-182k: 1H NMR (500 MHz, CDCl3) δ 7.14–7.07 (m, 1H), 6.93–6.79 (m, 2H), 
4.57 (s, 1H), 2.59 (s, 3H), 1.60 (dd, J = 7.6, 3.9 Hz, 1H), 1.40 (s, 3H), 0.98 (dd, J = 7.5, 4.7 Hz, 
1H), 0.82 (t, J = 4.3 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 176.5, 162.7 (dd, 
1JCF = 249.7 Hz, 
3JCF = 12.2 Hz), 160.8 (dd, 
1JCF = 249.7 Hz, 
3JCF = 12.2 Hz), 128.8 (dd, 
3JCF = 9.9 Hz, 
3JCF = 5.5 
Hz), 123.5 (dd, 2JCF = 13.2 Hz, JCF = 3.9 Hz), 112.0 (dd, JCF = 21.0 Hz, JCF = 3.7 Hz), 104.4 (t, 
2JCF 
= 25.5 Hz), 58.2 (d, 3JCF = 3.5 Hz), 27.9, 25.7, 25.6, 20.0, 14.9. 
19F NMR (376 MHz, CDCl3) δ 
−109.9 (d, 4JFF = 7.5 Hz), −111.1 (d, 
4JFF = 7.3 Hz),
 −115.97 (d, 4JFF = 7.8 Hz), −116.03 (d, 
4JFF = 
7.3 Hz); FTIR (NaCl, cm−1): 2932, 1694, 1617, 1503, 1430, 1397, 1269, 1234, 1140, 1092, 974, 
961, 850, 765, 610. HRMS (TOF ES): found 260.0862, calculated for C13H13NOF2Na (M + Na) 
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260.0863 (0.4 ppm); EA found C 65.92, 65.51, H 5.60, 5.67, N 6.14, 5.82, calculated for 
C13H13F2NO: C 65.81, H 5.52, N 5.90. 
 
(1R*,5S*)-4-(2-Chlorophenyl)-1,3-dimethyl-3-azabicyclo[3.1.0]hexan-2-
one (182l). This compound was synthesized according to the Typical 
procedure employing 2-bromo-N-(2-chlorobenzyl)-N,1-
dimethylcyclopropane-1-carboxamide (180l) (54 mg, 0.171 mmol), 18-crown-6 ether (4.5 mg, 
0.017 mmol), and t-BuOK (77 mg, 0.68 mmol). The reaction mixture was stirred at rt for 2 min 
and then quenched with a saturated solution of ammonium chloride. The crude material contains 
an inseparable mixture of diastereomers 70 : 30 (endo : exo). Purification by column 
chromatography eluting with a mixture of hexanes/EtOAc (2 : 3) afforded the titled product as a 
colorless oil (Rf 0.45). Yield 27.7 mg (0.118 mmol, 69%). endo-182l: 
1H NMR (400 MHz, CDCl3) 
δ 7.47–7.39 (m, 1H), 7.33–7.22 (m, 2H), 6.86 (dd, J = 6.9, 2.4 Hz, 1H), 5.07 (d, J = 5.9 Hz, 1H), 
2.67 (s, 3H), 2.24 (ddd, J = 7.8, 5.9, 4.0 Hz, 1H), 1.41 (s, 3H), 0.75 (t, J = 4.5 Hz, 1H), 0.60 (dd, J 
= 7.8, 5.0 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 178.3, 136.4, 133.1, 130.2, 128.8, 127.1, 127.0, 
59.9, 28.8, 26.6, 24.9, 16.5, 15.2. exo-182l: 1H NMR (400 MHz, CDCl3) δ 7.47–7.39 (m, 1H), 
7.33–7.22 (m, 2H), 7.11 (dd, J = 7.3, 2.1 Hz, 1H), 4.80 (s, 1H), 2.64 (s, 3H), 1.60 (dd, J = 7.5, 4.0 
Hz, 1H), 1.38 (s, 3H), 0.99 (dd, J = 7.5, 4.7 Hz, 1H), 0.86 (t, J = 4.3 Hz, 1H); 13C NMR (126 MHz, 
CDCl3) δ 177.1, 138.0, 133.1, 130.2, 129.3, 127.7, 127.0, 61.3, 28.4, 25.2, 26.0, 20.1, 15.1. FTIR 
(NaCl, cm−1): 2929, 1698, 1471, 1445, 1395, 1384, 1340, 1232, 1035, 972, 757, 698; HRMS (TOF 
ES): found 258.0660, calculated for C13H14NOClNa (M + Na) 258.0662 (0.8 ppm); EA found C 
66.21, 66.16, H 5.92, 6.10, N 5.64, 6.22, calculated for C13H14ClNO: C 66.24, H 5.99, N 5.94.  
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(1R*,5S*)-4-(4-Bromo-2-fluorophenyl)-1,3-dimethyl-3-
azabicyclo[3.1.0]hexan-2-one (182m). This compound was synthesized 
according to the Typical procedure employing 2-bromo-N-(4-bromo-2-
fluorobenzyl)-N,1-dimethylcyclopropane-1-carboxamide (180m) (65 mg, 
0.171 mmol), 18-crown-6 ether (4.5 mg, 0.017 mmol), and t-BuOK (77 mg, 0.69 mmol). The 
reaction mixture was stirred at rt for 2 min and then quenched with a saturated solution of 
ammonium chloride. The crude material contains an inseparable mixture of diastereomers 72 : 28 
(endo : exo). Purification by column chromatography eluting with a mixture of hexanes/ EtOAc 
(1 : 1) afforded the titled product as a colorless oil (Rf 0.35). Yield 37.8 mg (0.127 mmol, 74%). 
endo-182m: 1H NMR (400 MHz, CDCl3) δ 7.33–7.19 (m, 2H), 6.74 (t, J = 8.2 Hz, 1H), 4.89 (d, J 
= 5.9 Hz, 1H), 2.60 (s, 3H), 2.03 (ddd, J = 8.0, 5.8, 3.9 Hz, 1H), 1.34 (s, 3H), 0.71 (t, J = 4.5 Hz, 
1H), 0.60 (dd, J = 7.8, 5.0 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 178.0, 160.5 (d, J = 250.9 Hz), 
128.2 (d, J = 4.7 Hz), 127.7 (d, J = 3.6 Hz), 125.6 (d, J = 12.8 Hz), 121.6 (d, J = 9.9 Hz), 119.6 (d, 
J = 24.5 Hz), 56.2 (d, J = 4.4 Hz), 28.6, 26.7, 25.5, 16.6, 15.0. exo-182m: 1H NMR (400 MHz, 
CDCl3) δ 7.33–7.19 (m, 2H), 6.96 (t, J = 8.0 Hz, 1H), 4.52 (s, 1H), 2.56 (s, 3H), 1.55 (dd, J = 7.5, 
3.9 Hz, 1H), 1.35 (s, 3H), 0.95 (dd, J = 7.5, 4.8 Hz, 1H), 0.78 (t, J = 4.4 Hz, 1H); 13C NMR (126 
MHz, CDCl3) δ 176.6, 160.6 (d, J = 253.3 Hz), 129.0 (d, J = 5.1 Hz), 128.3 (d, J = 4.7 Hz), 126.9 
(d, J = 13.0 Hz), 122.3 (d, J = 9.8 Hz), 119.8 (d, J = 23.9 Hz), 58.3 (d, J = 3.6 Hz), 28.1, 25.8, 
25.6, 20.1, 14.9. 19F NMR (376 MHz, chloroform-d) δ −116.4, −117.3; FTIR (NaCl, cm−1): 2961, 
2930, 1695, 1605, 1574, 1483, 1396, 1220, 1077, 973, 883, 850, 757. HRMS (TOF ES): found 
320.0056, calculated for C13H13NOFBrNa (M + Na) 320.0062 (1.9 ppm); EA found 52.21, 52.44, 
H 4.29, 4.57, N 4.90, 4.64, calculated for C13H13BrFNO: C 52.37, H 4.40, N 4.70. 
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3.5.4 Syntheses of cyclopropenes 
 
N-Butyl-N-(4-(tert-butyl)benzyl)-1-methylcycloprop-2-ene-1-
carboxamide (185b). This compound was synthesized according to the 
Typical procedure employing 2-bromo-N-butyl-N-(4-(tert-
butyl)benzyl)-1-methylcyclopropane-1-carboxamide (180b) (266 mg, 
0.70 mmol), 18-crown-6 ether (18.5 mg, 0.07 mmol), and t-BuOK (314 mg, 2.80 mmol). The 
reaction mixture was stirred at 25 °C for 47 h. The product was isolated by column chromatography 
eluting with a mixture of hexanes/EtOAc (3 : 2) as a yellow oil (Rf 0.39). Yield 72.2 mg (0.315 
mmol, 45%). 1H NMR (500 MHz, CDCl3) δ 7.33 (br. s, 3H), 7.22 (br. s, 1H), 7.08 (br. s, 2H), 
4.81–4.48 (m, 2H), 3.44–3.18 (m, 2H), [1.95 (br. s), 1.53–1.35 (m), ∑5H], 1.37 (br. s, 11H), 1.31 
(br. s, 3H); 13C NMR (126 MHz, CDCl3) δ 176.3, (150.4, 149.9, 1C), (134.6, 134.2, 1C), (127.4, 
126.5, 2C), 125.6 (2C), 115.8 (2C), (50.3, 44.0, 1C), 46.4, 34.5, 31.4 (3C), (30.6, 29.1, 1C), 24.1, 
23.2, 20.1, 13.9; FTIR (NaCl, cm−1): 2960, 2869, 1625, 1514, 1463, 1410, 1365, 1269, 1104, 1005, 
927, 819, 732, 617; HRMS (TOF ES): found 322.2147, calculated for C20H29NONa (M + Na) 
322.2147 (0.0 ppm); EA found C 80.07, 80.50, H 9.75, 9.95, N 4.93, 4.97, calculated for C20H29NO: 
C 80.22, H 9.76, N 4.68. 
 
N-Butyl-N-(4-methoxybenzyl)-1-methylcycloprop-2-ene-1-
carboxamide (185c). This compound was synthesized according to the 
Typical procedure employing 2-bromo-N-butyl-N-(4-methoxybenzyl)-
1-methylcyclopropane-1-carboxamide (180c) (248 mg, 0.70 mmol), 18-crown-6 ether (18.5 mg, 
0.07 mmol), and t-BuOK (314 mg, 2.80 mmol). The reaction mixture was stirred at 25 °C for 27 
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h. The product was isolated by column chromatography eluting with a hexane/EtOAc mixture (1 : 
1) as a yellow oil (Rf 0.39). Yield 105.3 mg (0.385 mmol, 55%). 
1H NMR (500 MHz, CDCl3) δ 
[7.30 (br. s), 7.24 (br. s), 7.07 (br. s), ∑4H], 6.86 (br. s, 2H), 4.75–4.46 (m, 2H), 3.79 (s, 3H), 3.41–
3.16 (m, 2H), [1.47 (br. s), 1.37 (s), 1.26 (br. s), ∑7H], 0.90 (br. s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 176.2, 158.9, 129.1, 128.0, 115.8, 114.04 (2C), 55.3, 50.1, 46.1, 43.8, 30.5, 29.0, 24.0, 
23.2, 20.1, 13.9; FTIR (NaCl, cm−1): 2958, 2933, 2872, 1615, 1513, 1464, 1417, 1302, 1247, 1175, 
1104, 1033, 815, 621. HRMS (TOF ES): found 296.1637, calculated for C17H23NO2Na (M + Na) 
296.1626 (3.7 ppm); EA found C 74.72, 74.89, H 8.75, 8.39, N 4.89, 5.19, calculated for 
C17H23NO2: C 74.69, H 8.48, N 5.12. 
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Chapter 4. Intramolecular nucleophilic addition of tethered alkoxides to 
cyclopropenes 
4.1 Introduction 
 
The cyclopropene double bond is characterized by enhanced strain energy and much greater 
electrophilicity as compared to normal olefins.  This feature allows for the utilization of strain-
release driven addition of various nucleophilic entities across the C=C bond of cyclopropenes. 
Advances in base-assisted additions of heteroatom-based nucleophiles to cyclopropenes 
provided access to novel stereodefined cyclopropyl scaffolds,116 possessing oxygen,111,114,119 
nitrogen,107,114,120 sulfur,121 Both intermolecular (Scheme 54a and Scheme 54b) and intramolecular 
(Scheme 54c) diastereoselective addition of achiral tethered oxygen-based nucleophiles affording 
racemic products has been reported.123a,133 
 
Scheme 54 
 
 
In previously published work from our group an efficient synthesis of medium cyclic ethers 
190 via a formal nucleophilic cyclization of bromocyclopropanes 188 (Scheme 54c),133a was 
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described. This reaction proceeds through an in-situ base-assisted generation of reactive 
cyclopropene 189, which, once formed, is immediately trapped by a tethered alkoxide. 
Computational studies suggested that the mechanism of this strain-release-driven reaction involves 
a transition state where the potassium ion is coordinated to both alkoxide and amide oxygen, as 
well as to the carbon atom bearing a partial negative charge (C-8) (TS1 in Scheme 54). 
It was expected and confirmed experimentally that the templating effect induced constraints on 
the rotors in the tether, making the cyclization pathway more favorable compared to oligo- and 
polymerization. Furthermore, the rigidity of such activated complexes allowed for high 
diastereoselectivity of the newly formed stereogenic centers when chiral amino alcohol-tethered 
prochiral cyclopropenes are used as substrates. 
Intramolecular nucleophilic addition of tethered chiral alkoxides to prochiral cyclopropene 
moieties has not been fully explored.  To date, only two examples were communicated by our 
group,111c using cyclopropene 192 generated in situ via 1,2-elimination of bromocyclopropane 191 
(Scheme 55). Highly stereoselective formation of bicyclic products 193 was observed in both 
cases, while diastereomers 194 were never detected. 
 
Scheme 55 
 
Further exploration of this approach has met with synthetic challenges and was essentially 
unrewarded. Numerous experimentations proved that only 1-methyl-2-bromocyclopropane 
carboxylic acid is fairly suitable for the preparation of starting amides 191.115 In situ generation of 
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cyclopropenyl amides 192 via 1,2-dehydrohalogenation using analogues of 191 with substituents 
at the quaternary cyclopropene carbon other than methyl has severe limitations (conditions for the 
synthesis of other bromocyclopropane starting materials have not been found) rendering this 
synthetic pathway impractical. 
These difficulties warranted further studies to adapt this methodology to more stable, isolable 
cyclopropenes accessible via the metal-catalyzed cyclopropenation reactions. 
 
4.2 Addition of achiral tethered oxygen-based nucleophiles to cyclopropenes 
 
In order to broaden the scope of base-assisted intermolecular cyclizations of oxygen-based 
nucleophiles to cyclopropenes we focused on an alternative route to cyclopropenyl amide starting 
materials 196, via the Rh(II)-catalyzed [2+1]-cycloaddition of diazoacetates 195 with 
trimethylsilylacetylene,134 which was improved and tailored to our systems (Method B in Scheme 
56).135 
 
Scheme 56 
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The efficiency of this approach was initially tested using racemic cyclopropene amides 198 
derived from achiral amino alcohols 197. Thus, readily available 1-arylcycloprop-2-ene-1-
carboxylic acids 196134,135 were derivatized with N-protected 2-aminoethanols (197, m = 1) and 3-
aminopropanols (197, m = 2) to afford the corresponding amides 198, which were used crude in 
the subsequent base-assisted cyclization (Scheme 57). We first probed the cyclization of amide 
198aa, which reacted smoothly affording oxazabicyclo[5.1.0]octanone 199aa as a sole product in 
good yield (Scheme 57). 
With the positive initial results in hand, we moved on to evaluate the effect of substituents at 
nitrogen (R) and sp3 - hybridized carbon of cyclopropene (Ar) on the cyclization propensity of 
cyclopropenyl amides 198. We were pleased to see that N-methyl (199ab, 199bb, 199cb) and 
various N-benzyl 2-oxa-5-azabicyclo[5.1.0]octan-6-ones (199ac, 199ad, 199af, 199ba, 199ca) 
were efficiently obtained via this approach (Scheme 57). N-Phenyl derivative 199af was produced 
only in poor yield, which was attributed to a facile base-assisted hydrolysis of the C−N bond in 
anilides, as noted previously.115 This side reaction is suppressed in electron-rich anilides, so 
cyclization of p-anisidine derivatives proceeded smoother, affording better yields of oxazepanones 
199ag and 199bg (Scheme 57). Tethered 3-aminopropanols underwent 8-exo-trig cyclization 
efficiently under the same reaction conditions to give oxazocanones 199ah, 199bh, 199bi, and 
199ch (Scheme 57). 
Having mapped the substrate scope, we next investigated the possibility of a diastereoselective 
nucleophilic 7-exo-trig cyclization of tethered chiral alkoxides with prochiral cyclopropenes. 
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Scheme 57 
 
 
4.3 Stereoselective addition of tethered oxygen-based nucleophiles to cyclopropenes 
 
The two-carbon-atom tether allows for independent installation of two stereogenic centers, 
which gives rise to four different modes depicted in Scheme 58. Thus, derivatives of chiral 
aminoethanols with (S)-configuration at C-2 (200) can potentially produce two products: 
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(1S,4S,7S)-201 or (1R,4S,7R)-202 (mode I in Scheme 58). Likewise, (R)-configuration at C-1 in 
the amino alcohol tether of 203 would give rise to diastereomers (1S,3R,7S)-204 or (1R,3R,7R)-
205, respectively (mode II in Scheme 58). Two additional modes are possible when the 
diastereoselectivity is induced in the presence of two contiguous chiral centers at C-1 and C-2 of 
the amino alcohol tether. Thus, threo-(206) could potentially afford products (1S,3S,4S,7S)-207 or 
(1R,3S,4S,7R)-208 (mode III in Scheme 58), while erythro-(209) could provide (1S,3R,4S,7S)- 210 
and (1R,3R,4S,7R)-211, respectively (mode IV in Scheme 58). The following discussion addresses 
all the above-mentioned cyclization modes in detail. 
 
Scheme 58 
 
 
To probe mode I, a set of condensation reactions between 1-arylcycloprop-2-ene-1-carboxylic 
acids (196a−c) and chiral amino alcohols 214b−d were carried out, and thus obtained chiral 
122 
 
cyclopropenes 200 were used crude in the cyclization (Scheme 59) under the standard reaction 
conditions described above (Scheme 57). We were very pleased to find that, in all cases, the 
enantiomerically pure (1S,4S,7S)-2-oxa-5-azabicyclo[5.1.0]octan-6-ones 201 were obtained as 
sole products (1R,4R,7R enantiomer was obtained for 201bc, originated from (R)-phenylglycinol). 
None of these reactions produced any detectable amounts of the diastereomers 202. The relative 
and absolute configuration of compound 201bd was unambiguously confirmed by single-crystal 
X-ray crystallography (CCDC #1823183).3 
 
Scheme 59 
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Scheme 60 
 
 
Our rationale for the origins of the high diastereoselectivity obtained in cyclization mode I is 
shown in Scheme 60. Computational studies performed on achiral models suggested that the 
transition state in 7-exo-trig cyclization (TS1) has a very rigid pseudoboat conformation, stabilized 
by a three-center coordinated potassium cation bound through the alkoxide and carbonyl oxygens 
as well as the anionic carbon atom.123b Assuming the same transition state model is realized for 
the chiral substrates in the present studies, a nucleophilic attack at the now diastereotopic C-7 or 
C-8 would result in two nonequivalent reaction pathways a and b, respectively (Scheme 60). Path 
a, affording product 201, operates via a lower-energy transition state TS2a, in which substituent 
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R1 at C-4 assumes the thermodynamically more favored, pseudoequatorial (bowsprit) 
conformation. The alternative, higher-energy transition state TS2b, resulting from nucleophilic 
attack b, forces the R1 group into a pseudoaxial (flagpole) position where it experiences a strong 
syn-pentane interaction with hydrogen at C-8, which disfavors formation of product 202. 
 
To test mode II, (R)-2-(benzylamino)-1-phenylethan-1-ol (215) was condensed with 
cyclopropenyl carboxylic acid 196b, and the resulting amide 203b was subjected to the base-
assisted cyclization. A 1:4 ratio of two isomeric products, 204b and 205b, was obtained (Scheme 
61). Configurations of both products were unambiguously assigned by 2D NOESY experiments.3 
 
Scheme 61 
 
 
A mechanistic scenario consistent with the observed marginal diastereoselectivity is outlined 
in Scheme 62. It is believed that the unfavorable 1,3-diaxial interaction between substituent R2 at 
C-5 and the R group at nitrogen in the seven-membered complex TS3a (resulting from path a) is 
not as prohibitive as in cyclohexyl analogues. As a result, 204 is produced as a minor product. An 
alternative, major pathway b proceeding via transition state TS3b, in which substituent R2 at the 
stereogenic center is free of the unfavorable interactions, gives rise to major product 205. 
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Scheme 62 
 
 
Next, we tested modes III and IV on cyclopropenyl carboxamide derivatives prepared from 
cyclopropene carboxylic acids 196a−d and (+)- or (−)-pseudoephedrine (214 or ent-214) and (−)-
ephedrine (215). Cyclization of these substrates provided oxazepanones 207 (or ent-207) and 210, 
respectively, as sole products in excellent yields (Scheme 63). 
Single-crystal X-ray diffraction analysis unambiguously confirmed the absolute configurations 
of products 207c (CCDC # 1823195) and 210c (CCDC # 1823181).3 
 
Scheme 63 
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Scheme 63 (continued) 
 
 
The origins of high diastereoselectivity in the 7-exo-trig nucleophilic cyclization producing 207 
(mode III) are analyzed in Scheme 64. It is believed that the nucleophilic attack at C-7 (path a) is 
highly preferred due to a more favored transition state TS4a, in which both substituents R1 and R2 
occupy a pseudoequatorial position. A complementary path b would lead to a much more energetic 
transition state TS4b, in which substituent R1 in a flagpole orientation is experiencing steric 
repulsions with hydrogen at C-8, similar to that described above for mode I (Scheme 60). The 1,3-
diaxial interaction between substituents R and R2 could be another contributing factor to 
destabilization of TS4b. This effect, however, is not expected to be significant for small N-
substituents, such as a methyl group. 
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Scheme 64 
 
 
Finally, the high selectivity observed in cyclization mode IV is rationalized as follows (Scheme 
65). Transition state TS5a resulting from the nucleophilic attack at C-7 (path a) is rather favorable, 
since the 1,3-diaxial interaction between substituents R and R2, as was stated above, is quite 
insignificant for nonbulky R groups. The alternative transition state TS5b, resulting from an attack 
at C-8 (path b), experiences prohibitive steric interactions with a flagpole substituent R1. Arguably, 
in all four cyclization modes analyzed above, the stereoselectivity is greatly influenced by 
configuration of the stereogenic center at C-4 and the R1 group, while the C-5 substituent R2 plays 
a modest role, at least for derivatives with a nonencumbered substituent on the nitrogen. The strong 
cation-templating effect elicits conformational rigidity of the transition state and amplifies the 
asymmetric induction arising from a rather remote chiral center, which ultimately allows for the 
efficient desymmetrization of the cyclopropenyl moiety. 
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Scheme 65 
 
 
4.5 Biological evaluation of antimicrobial and anticancer activities of 
azabicyclo[5.1.0]octanones 
 
It should be pointed out that fused oxazepanes are a very important class of biologically active 
molecules that display diverse pharmacological activities (see Chapter1.3). This class of 
compounds is known for its antibiotic, anticancer, and antipsychotic bioactivities.6 Development 
of new approaches to these important molecules, especially stereoselective, can lead to the 
discovery of new privilege medicinal structures.  
In the preliminary biological studies performed in the collaborative project with the group of 
Prof. Frolova (New Mexico Institute of Mining and Technology, Socorro, New Mexico), 
enantiopure 2-oxa-5-azabicyclo[5.1.0]octan-6-ones were shown to be very attractive biological 
probes.3 This unique heterocyclic scaffold just recently emerged on the chemical space map and it 
revealed promising antimicrobial activity against mycobacterium abscessus,136 a rapid growing 
highly virulent chemotherapy-resistant mycobacterial pathogen. 
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Preliminary biological evaluation of a few representative compounds for antimicrobial and 
anticancer activities was performed by the group of Prof. Frolova. The antiproliferative activity 
was assessed by using the cancer cell line, HeLa, as a model for human cervical adenocarcinoma, 
through the measurements of mitochondrial dehydrogenase activities using the MTT method.137 
In addition, the synthesized compounds were tested against staphylococus epidermidis and 
escherichia coli, where minimum inhibitory concentrations (MICs) were determined by the broth 
microdilution method using MTT assay.138 Since the described compounds bear some similarity 
with azepanes known to possess activity against mycobacteria,139 products 201, 207, and 210 were 
also tested against mycobacterium abscessus by MTT assay. The potency of synthesized 
compounds against yeasts was also evaluated using candida albicans.  
 
Figure 14. Biological activity of selected 2-oxa-5-azabicyclo[5.1.0]octan-6-ones 
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This preliminary tests revealed that none of these compounds demonstrated any activity against 
candida albicans, staphylococus epidermidis, or escherichia coli up to 100 μM nor significant 
cytotoxicity on HeLa cells. However, promising activity against mycobacterium abscessus was 
observed for selected 2-oxa-5-azabicyclo[5.1.0]octan-6-ones (Figure 14). The latter finding, 
coupled with apparent low general toxicity against cultured human cells, set the grounds for further 
SAR studies. 
See section A1 of Appendix for experimental data. 
 
4.6 Conclusion 
 
The development of a synthetic approach that allows for modular assembly of enantiopure 
cyclopropane-fused oxazepanones is reported. A strain-release-driven, cation-templated 
intramolecular nucleophilic addition of tethered alkoxides to prochiral cyclopropenes has been 
developed. The scope of this cyclization and the mechanism of enantiomeric induction were 
investigated on a series of tethered chiral alkoxides. Three out of four tested chiral cyclization 
modes provided a highly efficient asymmetric induction. It was shown that the chiral center at C-
4 plays a crucial role in controlling desymmetrization of the cyclopropenyl moiety, instigated by 
a profound potassium-templated effect. 
The obtained optically active 2-oxa-5-azabicyclo[5.1.0]octan-6-ones were tested against 
representative mycobacterial infection-causing organisms as well as other bacteria, pathogenic 
fungi, and human cancer cell lines. The biological profile exhibited by some of these unique chiral 
cyclopropane-fused medium-sized heterocycles is characterized by promising activity against 
mycobacterium abscessus coupled with apparent low general toxicity against cultured human cells. 
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4.7 Experimental 
4.7.1 General information 
 
NMR spectra were recorded on a Bruker Avance DRX- 500 (500 MHz) with a dual 
carbon/proton cryoprobe (CPDUL), Bruker III (400 MHz) equipped with BBO probe. 13C NMR 
spectra were registered with broadband decoupling. The (+) and (−) designations represent 
positive and negative intensities of signals in 13C DEPT-135 experiments. IR spectra were recorded 
on a ThermoFisher Nicolet iS 5 FT-IR spectrometer. HRMS was carried out on an LCT Premier 
(Micromass Technologies) instrument employing ESI TOF detection techniques. Glassware used 
in moisture-free syntheses was flame-dried in a vacuum prior to use. Column chromatography was 
carried out on silica gel (Sorbent Technologies, 40− 63 mm). Silica gel plates (Sorbent 
Technologies Silica XG 200 mm) were used for TLC analyses. Anhydrous dichloromethane was 
obtained by passing degassed commercially available HPLC-grade inhibitor-free solvent 
consecutively through two columns filled with activated alumina and stored over molecular sieves 
under nitrogen. Water was purified by dual-stage deionization followed by dual-stage reverse 
osmosis. Anhydrous THF was obtained by refluxing commercially available solvent over calcium 
hydride followed by distillation in a stream of dry nitrogen. 1-Phenylcycloprop-2-ene-1-carboxylic 
acid (196a), 140  1-(4-fluorophenyl)-cycloprop-2-ene-1-carboxylic acid (196b),117k and (S)-2-
(benzylamino)-4-methylpentan-1-ol (214d) 141  were synthesized according to the previously 
published procedures and had physical and spectral properties identical to those earlier reported. 
Syntheses of 1-(2,4-dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (196c), 1-(naphthalen-1-
yl)cycloprop-2-ene-1-carboxylic acid (196d), and 2-((5-bromo-2-fluorobenzyl)amino)ethan-1-ol 
(197e) are described in Chapter 4.7.3. All other reagents and solvents were purchased from 
commercial vendors and used as received.  
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4.7.2 Biological Studies: Materials and Methods 
 
All culture cell lines were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA, USA). 
Cell Culture. HeLa cells were cultured in DMEM supplemented with 10% fetal bovine serum 
(FBS). To evaluate antiproliferative properties of the synthesized compounds, the cells were 
trypsinized and seeded at 4 · 103 cells per well into 96-well microtiter plates. The cells were grown 
for 24 h before treatment. 
Fungal Culture. Candida albicans (ATCC 26555) was grown overnight in Difco YM Broth at 
37 °C in a shaking incubator. 
Bacterial Cultures. Mycobacterium abscessus (ATCC 19977) was inoculated in Middlebrook 
7H9 medium supplemented with 1% ADC enrichment and incubated at 37 °C in T25 tissue culture 
flasks for 72 h.  
Staphylococus epidermidis and escherichia coli were incubated in Tryptic Soy Broth (TSB) for 
6 h at 37 °C. 
MTT assay for HeLa (ATCC CCL-2). All compounds were dissolved in DMSO at a 
concentration of either 100 or 50 mM prior to cell treatment. The cells were treated at 
concentrations ranging from 0.004  to 100 μM and incubated for 48 h in 200 μL of media. An 
amount of 20 μL of MTT reagent in serum-free medium (5 mg/mL) was added to each well and 
incubated further for 2 h. Media was removed, and the resulting formazan crystals were solubilized 
in 100 μL of DMSO. A490 was measured using a Thermomax Molecular Device plate reader. The 
experiments were performed in quadruplicate and repeated at least twice for each compound per 
cell line. Cells treated with 0.1% DMSO were used as a vehicle control, and phenyl arsine oxide 
(PAO) was used as a positive killing control. 
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MTT assay for candida albicans (ATCC 26555). Cells were diluted 1:20 in YM Broth. 2-Fold 
serial dilutions were prepared as follows: 1000 μL of cells was added to the first well of each 24-
well plate, and 500 μL of cells was added to the proceeding wells. Compounds were added at a 
final concentration of 100 μM. 2-Fold dilutions were continued across all remaining wells. Cells 
were incubated for 24 h at 37 °C and then treated with 100 μL of MTT (5 mg/mL) and incubated 
for 3 h. An equal volume of premixed solution of 50% dimethylformamide with 20% sodium 
dodecyl sulfate (solubilization solution) was added to dissolve the formazan crystals and incubated 
further for 15 min. The experiments were performed in triplicate. Amphotericin B was used as 
positive kill control, and untreated cells served as negative controls. 
MTT assay for staphylococus epidermidis (ATCC 35984) and Escherichia coli (ATCC 25922). 
An overnight cell growth was diluted to an optical density of 0.100 at A595; cells were further 
diluted 1:100 in TSB. An amount of 1000 μL of the dilution was added to each well of a 12-well 
plate (except the first well, which received only TSB). Each well received one compound at a final 
concentration of 100 μM. Plates were incubated for 24 h at 37 °C. Cells were subsequently treated 
with 100 μL of MTT (5 mg/mL) and incubated at 37 °C for 15 min. Solubilization solution was 
added to dissolve the formazan crystals and incubated further for 15 min. An amount of 50 μg/mL 
of colistin (PME) was used as a positive kill control for E. coli; 50 μg/mL of vancomycin was used 
as a positive kill control for S. epidermidis; and untreated cells served as negative controls. The 
experiments were performed in triplicate. 
MTT assay for mycobacterium abscessus (ATCC 19977). Approximately 5.5 · 105 mycobacteria 
per mL or a dilution of 1:500 from an overnight growth were plated at a final volume of 400 
μL/well in 48-well plates. Compounds were initially screened at a concentration of 100 μM on M. 
abscessus. Compounds with antimycobacterial activity at 100 μM were screened for further 
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activity by adding the selected compounds to cells at a concentration of 50 μM and 2-fold serially 
diluting. The plates were incubated in a shaking incubator for 48 h at 37 °C. Following the 
incubation, 40 μL or 10% w/v of MTT reagent (5 mg/mL) was added to each of the wells. The 
plates were incubated for 2 h at 37 °C. An amount of 650 μL of solubilization solution was added 
to each of the wells, and the plate was incubated at 37 °C for an additional 12 h. An amount of 100 
μL from each well was transferred into a clear 96-well microtiter plate, and A595 was read in a 
Thermomax Molecular Device plate reader. Wells containing Middlebrook 7H9 medium and 
nontreated cells served as negative controls, and a well containing 10 μM PAO-treated cells served 
as a positive kill control. The experiments were performed in triplicate. 
 
4.7.3 Synthesis of Starting Materials 
 
1-(2,4-Dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (196c) 
Solution methyl 1-(2,4-dichlorophenyl)-2-(trimethylsilyl)cycloprop-2-ene-
1-carboxylate (3.71 g, 11.77 mmol, 1.00 equiv.) in a 1 : 1 mixture of 
methanol : THF (100 mL) was stirred at 0 °C. A 1.5 M aqueous solution of NaOH (102 mL, 153.0 
mmol, 13.0 equiv.) was added dropwise and the mixture was stirred for 18 h. Organic solvents 
were then removed under vacuum and the remaining aqueous solution was washed with 
dichloromethane (3 × 50 mL). The remaining aqueous phase was acidified to pH 2 with 1 N 
aqueous HCl and extracted with dichloromethane (3 × 50 mL). The combined organic phases were 
washed with brine, dried with MgSO4, filtered, and concentrated. The product was isolated by 
column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless solid (Rf 0.27, 
mp 194-195 oC). Yield 2.10 g (9.16 mmol, 78 %). 1H NMR (400 MHz, CDCl3) δ 11.88 (s, 1H), 
7.36 (d, J = 2.0 Hz, 1H), 7.28 (s, 2H), 7.19 (dd, J = 8.2, 2.1 Hz, 1H), 7.13 (d, J = 8.2 Hz, 1H). 13C 
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NMR (126 MHz, CDCl3) δ 180.9, 137.9, 135.9, 133.9, 131.2 (+), 129.4 (+), 127.5 (+), 108.0 (+, 
2C), 29.4. FTIR (NaCl, cm-1): 3155, 3115, 2975, 2835, 1697, 1661, 1472, 1302, 1267, 1113, 985, 
934, 805, 630. HRMS (TOF ES): found 226.9671, calculated for C10H5Cl2O2 (M–H) 226.9667 
(1.8 ppm). 
 
1-(Naphthalen-1-yl)cycloprop-2-ene-1-carboxylic acid (196d) Solution of 
methyl 1-(naphthalen-1-yl)-2-(trimethylsilyl)cycloprop-2-ene-1-carboxylate 
(3.82 g, 12.9 mmol, 1.00 equiv.) in a 1 : 1 mixture of methanol : THF (100 
mL) was stirred at 0 °C. A 1.5 M aqueous solution of NaOH (112 mL, 167.7 mmol, 13.0 equiv.) 
was added dropwise and the mixture was stirred for 18 h. Organic solvents were then removed 
under vacuum and the remaining aqueous phase was washed with dichloromethane (3 × 50 mL). 
The remaining aqueous solution was acidified to pH 2 with 1 N aqueous HCl and extracted with 
dichloromethane (3 × 50 mL). The combined organic phases were washed with brine, dried with 
MgSO4, filtered, and concentrated. The product was isolated by column chromatography eluting 
with a hexanes/EtOAc mixture (2:1) as a colorless solid (Rf 0.27, mp 144-145 
oC). Yield 2.23 g 
(10.6 mmol, 82 %). 1H NMR (500 MHz, CDCl3) δ 11.42 (br. s, 1H), 8.08 (d, J = 8.3 Hz, 1H), 7.85 
(d, J = 7.9 Hz, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.55–7.46 (m, 2H), 7.45 (s, 2H), 7.41 (t, J = 7.7 Hz, 
1H), 7.34 (d, J = 6.9 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 181.9, 138.1, 133.9, 132.0, 128.9 
(+), 128.2 (+), 126.3 (+), 126.0 (+), 125.9 (+), 125.8 (+), 124.3 (+), 108.8 (+, 2C), 29.1. FTIR 
(NaCl, cm-1): 3162, 3122, 3048, 2975, 1691, 1656, 1410, 1264, 1237, 1120, 990, 775, 733, 640. 
HRMS (TOF ES): found 209.0593, calculated for C14H9O2 (M–H) 209.0603 (4.8 ppm). 
 2-((5-bromo-2-fluorobenzyl)amino)ethan-1-ol (197e). 5-Bromo-2-
fluorobenzaldehyde (2 mL, 3.42 g, 16.8 mmol, 1.0 equiv.), 2-
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aminoethan-1-ol (1.12 mL, 1.13 g, 18.5 mmol, 1.1 equiv.), and 30 mL of anhydrous methanol were 
combined and stirred at RT overnight. Reaction mixture was cooled to 0 °C, NaBH4 (955 mg, 25.3 
mmol, 1.5 equiv.) was added in portions, and reaction mixture was stirred for 2 hours at RT. 
Reaction mixture was concentrated in vacuum and partitioned between 10 mL of water and 10 mL 
of dichloromethane. The aqueous phase was then extracted with dichloromethane (2 × 10 mL). 
The combined organic phases were washed with brine (10 mL), dried with MgSO4, filtered, and 
concentrated to yield the title compound as a colorless solid (mp 75-76 °C). Yield 3.34 g (13.5 
mmol, 80%). 1H NMR (400 MHz, CDCl3) δ 7.48 (dd, J = 6.6, 2.5 Hz, 1H), 7.38–7.31 (m, 1H), 
6.98–6.88 (m, 1H), 3.83 (s, 3H), 3.70–3.64 (m, 2H), 2.83–2.76 (m, 2H), 1.95 (br. s, 2H);  13C NMR 
(126 MHz, CDCl3) δ 160.3 (d, J = 246.1 Hz), 133.1 (d, J = 5.0 Hz, +), 131.7 (d, J = 8.2 Hz, +), 
129.5 (d, J = 16.4 Hz), 117.3 (d, J = 23.6 Hz, +), 116.8 (d, J = 3.6 Hz), 61.1 (–), 50.4 (–), 46.6 (d, 
J = 2.7 Hz, –). FTIR (NaCl, cm-1): 33020 (br), 2924, 2843, 1483, 1236, 1171, 1069, 814, 621; 
HRMS (TOF ES): found 248.0092, calculated for C9H12BrFNO (M + H) 248.0086 (2.4 ppm). 
4.7.4 Cyclization of Achiral Substrates 
 
 5-Benzyl-7-phenyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one (199aa). 
Typical Procedure:  Flame-dried round bottom flask was charged with 1-
phenylcycloprop-2-ene-1-carboxylic acid (196a) (500 mg, 3.12 mmol, 
1.0 equiv.), DMF (2 drops) and freshly distilled anhydrous dichloromethane (7 mL) under nitrogen 
atmosphere. Oxalyl chloride (400 μL, 592 mg, 4.68 mmol, 1.5 equiv.) was then added dropwise 
and the mixture was stirred at room temperature for 2 h. The solution was concentrated in a stream 
of nitrogen; the residue was subjected to a high vacuum, dissolved in anhydrous dichloromethane 
(2.0 mL) and added dropwise to a stirred solution of 2-(benzylamino)ethan-1-ol (197a) (708 mg, 
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4.68 mmol, 1.5 equiv.) and triethylamine (1.3 mL, 948 mg, 9.36 mmol, 3.0 equiv.) in anhydrous 
dichloromethane (3.0 mL). The reaction mixture was stirred at room temperature for 18 hours and 
then partitioned between water (15 mL) and dichloromethane (20 mL). The aqueous phase was 
acidified with 5 mL of 2N HCl. The organic phase was then washed with 2N HCl (3 x 10 mL). 
The combined aqueous layers were back-extracted once with 10 mL of dichloromethane, which 
was combined with other organic phases, washed with brine, dried with MgSO4, filtered, and 
concentrated. The product, N-benzyl-N-(2-hydroxyethyl)-1-phenylcycloprop-2-ene-1-
carboxamide (198aa) was filtered through a silica plug using EtOAc, and was used at the 
cyclization step as is without additional purification.  An oven-dried 1 mL Wheaton vial was 
charged with powdered KOH (7.6 mg, 0.136 mmol, 2.0 equiv) and anhydrous THF (400 μL).  
Crude amide 198aa (20 mg, 0.068 mmol) was added as a solution in anhydrous THF (400 μL). 
The mixture was vigorously stirred at 30 °C for 18 h, then the reaction mixture was filtered through 
short plug of Silica gel eluting with EtOAc, and the eluate was concentrated in vacuum. The 
product was isolated by column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a 
colorless oil (Rf 0.25). Yield 17.6 mg (0.060 mmol, 88%).  
1H NMR (500 MHz, CDCl3) δ 7.36–
7.26 (m, 7H), 7.25–7.21 (m, 1H), 7.10–7.08 (m, 2H), 4.71 (q, J = 14.7 Hz, 2H), 3.92 (ddd, J = 
15.5, 12.6, 5.1 Hz, 1H), 3.53 (dd, J  = 11.2, 5.1 Hz, 1H), 3.43 (dd, J = 6.3, 3.7 Hz, 1H), 3.41–3.36 
(m, 1H), 3.03 (dt, J = 23.2, 11.6 Hz, 1H), 1.75 (dt, J = 24.0, 12.0 Hz, 1H), 1.49 (dd, J = 6.9, 6.4 
Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 170.7, 138.0, 137.3, 128.9 (+, 2C), 128.8 (+, 2C), 128.4 
(+, 2C), 127.8 (+), 126.8 (+), 124.7 (+, 2C), 64.4 (–), 59.0 (+), 49.8 (–), 44.9 (–), 34.9, 22.5 (–). 
FTIR (NaCl, cm-1): 3026, 2967, 1651, 1497, 1408, 1209, 1057, 1028, 748, 696; HRMS (TOF ES): 
found 294.1501, calculated for C19H20NO2 (M + H) 294.1494 (2.4 ppm). 
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5-Methyl-7-phenyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one (199ab). This 
compound was synthesized according to Typical Procedure from 1-
phenylcycloprop-2-ene-1-carboxylic acid (196a) (200 mg, 1.25 mmol, 1.0 equiv.), and 2-
(methylamino)ethan-1-ol (197b) (141 mg, 1.88 mmol, 1.5 equiv.). After extraction and filtration 
through a silica plug crude N-(2-hydroxyethyl)-N-methyl-1-phenylcycloprop-2-ene-1-carbox-
amide (198ab) was used at the cyclization step as is without additional purification  To this end, 
amide 198ab (20 mg, 0.092 mmol) was treated with powdered KOH (10.3 mg, 0.184 mmol). The 
product was isolated by column chromatography eluting with a hexanes/EtOAc mixture (1:1) as a 
colorless glass (Rf 0.21). Yield 17.6 mg (0.081 mmol, 88%). 
1H  NMR (500 MHz, CDCl3) δ 7.34–
7.27 (m, 2H), 7.25–7.19 (m, 1H), 7.05 (d, J = 7.9 Hz, 2H), 4.06 (ddd, J = 15.4, 12.7, 5.0 Hz, 1H), 
3.82 (td, J = 11.9, 4.6 Hz, 1H), 3.64 (dd, J = 11.2, 5.0 Hz, 1H), 3.40 (dd, J = 6.2, 3.6 Hz, 1H), 3.08 
(s, 3H), 3.03 (dd, J = 15.4, 4.7 Hz, 1H), 1.66 (dd, J = 6.9, 3.5 Hz, 1H), 1.45 (t, J = 6.6 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 170.6, 137.9, 128.9 (+, 2C), 126.8 (+), 124.7 (+, 2C), 63.3 (–), 58.8 
(+), 47.6 (–), 34.9, 34.3 (+), 22.3 (–). FTIR (NaCl, cm-1): 2961, 1651, 1495, 1431, 1395, 1260, 
1169, 1061, 1030, 797, 752, 696. HRMS (TOF ES): found 240.1003, calculated for C13H15NO2Na 
(M + Na) 240.1000 (1.2 ppm). 
 
5-(4-Methoxybenzyl)-7-phenyl-2-oxa-5-azabicyclo[5.1.0]octan-
6-one (199ac). This compound was synthesized according to 
Typical Procedure from 1-phenylcycloprop-2-ene-1-carboxylic 
acid (196a) (200 mg, 1.25 mmol, 1.0 equiv.), and 2-((4-methoxybenzyl)amino)ethan-1-ol (197c) 
(339 mg, 1.88 mmol, 1.5 equiv.). After extraction and filtration through a silica plug crude N-(2-
139 
 
hydroxyethyl)-N-(4-methoxybenzyl)-1-phenylcycloprop-2-ene-1-carboxamide (198ac) was used 
at the cyclization step as is without additional purification.  To this end, amide 198ac (20 mg, 
0.062 mmol) was treated with powdered KOH (6.9 mg, 0.124 mmol). The product was isolated by 
column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless solid (Rf 0.21, 
mp 102-104 °C).  Yield 18.2 mg (0.056 mmol, 91%). 1H NMR (500 MHz, CDCl3) δ 7.33–7.28 
(m, 2H), 7.26–7.20 (m, 3H), 7.09–7.06 (m, 2H), 6.88–6.84 (m, 2H), 4.73 (d, J = 14.5 Hz, 1H), 
4.57 (t, J = 11.7 Hz, 1H), 3.92–3.84 (m, 1H), 3.80 (s, J = 2.5 Hz, 3H), 3.51 (dd, J = 11.1, 5.1 Hz, 
1H), 3.40 (dt, J = 11.1, 5.6 Hz, 1H), 3.34 (ddd, J = 12.5, 11.2, 4.9 Hz, 1H), 3.03 (dd, J = 15.4, 4.8 
Hz, 1H), 1.74 (dd, J = 7.0, 3.6 Hz, 1H), 1.52–1.45 (m, 1H); 13C NMR (126 MHz, CDCl3) δ 170.5, 
159.3, 138.0, 129.7 (+, 2C), 129.4 (+), 128.9 (+, 2C), 126.7 (+), 124.7 (+, 2C), 114.2 (+, 2C), 64.5 
(–), 59.0 (+), 55.4 (+), 49.2 (–), 44.7 (–), 35.0, 22.5 (–); FTIR (NaCl, cm-1): 2957, 2866, 1647, 
1512, 1464, 1437, 1416, 1248, 1177, 1061, 1032, 806, 752, 698. HRMS (TOF ES): found 346.1412, 
calculated for C20H21NO3Na (M + Na) 346.1419 (2.0 ppm). 
 
5-(2-Chlorobenzyl)-7-phenyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one 
(199ad). This compound was synthesized according to the Typical 
Procedure from 1-phenylcycloprop-2-ene-1-carboxylic acid (196a) (200 
mg, 1.25 mmol, 1.0 equiv.), and 2-((2-chlorobenzyl)amino)ethan-1-ol (197d) (348 mg, 1.88 mmol, 
1.5 equiv.). After extraction and filtration through a silica plug crude N-(2-chlorobenzyl)-N-(2-
hydroxyethyl)-1-phenylcycloprop-2-ene-1-carboxamide (198ad) was isolated and used at the 
cyclization step without additional purification. To this end, amide 198ad (20 mg, 0.061 mmol) 
was treated with powdered KOH (6.8 mg, 0.122 mmol).  The titled product was isolated by column 
chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless oil (Rf 0.31). Yield 
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18.4 mg (0.056 mmol, 92%). 1H NMR (500 MHz, CDCl3) δ 7.41 (dd, J = 7.2, 2.1 Hz, 1H), 7.37 
(dd, J = 7.3, 1.9 Hz, 1H), 7.32 (t, J = 7.5 Hz, 2H), 7.28–7.18 (m, 3H), 7.14–7.07 (m, 2H), 4.94 (d, 
J = 15.4 Hz, 1H), 4.77 (d, J = 15.4 Hz, 1H), 3.99 (ddd, J = 15.5, 12.3, 5.4 Hz, 1H), 3.63–3.49 (m, 
2H), 3.47 (dd, J = 6.2, 3.6 Hz, 1H), 3.10 (dd, J = 15.4, 4.5 Hz, 1H), 1.75 (dd, J = 7.0, 3.6 Hz, 1H), 
1.48 (t, J = 6.6 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 170.9, 137.9, 134.9, 133.6, 130.0 (+), 
129.7 (+), 129.0 (+), 129.0 (+, 2C), 127.4, 126.8, 124.8 (+, 2C), 64.4 (–), 58.8 (+), 47.1 (–), 45.4 
(–), 34.9, 22.6 (–). FTIR (NaCl, cm-1): 3059, 2970, 2868, 1655, 1464, 1431, 1417, 1202, 1153, 
1061, 1031, 752, 696. HRMS (TOF ES): found 328.1112, calculated for C19H19ClNO2 (M + H) 
328.1104 (2.4 ppm). 
  
5-(5-Bromo-2-fluorobenzyl)-7-phenyl-2-oxa-5-azabicyclo-
[5.1.0]octan-6-one (199ae).  This compound was synthesized according 
to Typical Procedure from 1-phenylcycloprop-2-ene-1-carboxylic acid 
(196a) (250 mg, 1.56 mmol, 1.0 equiv.), and 2-((5-bromo-2-fluorobenzyl)amino)ethan-1-ol (197e) 
(581 mg, 2.34 mmol, 1.5 equiv.).  After extraction and filtration through a silica plug crude N-(5-
bromo-2-fluorobenzyl)-N-(2-hydroxyethyl)-1-phenylcycloprop-2-ene-1-carboxamide (198ae) 
was isolated and used at the cyclization step without additional purification. To this end, amide 
198ae (20 mg, 0.051 mmol) was treated with powdered KOH (5.7 mg, 0.102 mmol). The product 
was isolated by column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless 
oil (Rf 0.31). Yield 17.4 mg (0.045 mmol, 87%). 
1H NMR (500 MHz, CDCl3) δ 7.56 (dd, J = 6.6, 
2.5 Hz, 1H), 7.40–7.35 (m, 1H), 7.35–7.29 (m, 2H), 7.26–7.20 (m, 1H), 7.07 (dd, J = 5.2, 3.3 Hz, 
2H), 6.95 (t, J = 9.1 Hz, 1H), 4.87 (d, J = 15.2 Hz, 1H), 4.54 (d, J = 15.2 Hz, 1H), 4.00 (ddd, J = 
15.6, 11.4, 6.3 Hz, 1H), 3.66–3.54 (m, 2H), 3.46 (dd, J = 6.2, 3.6 Hz, 1H), 3.13–3.03 (m, 1H), 1.74 
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(dd, J = 7.0, 3.6 Hz, 1H), 1.48 (t, J = 6.6 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 170.9, 160.1 (d, 
J = 246.4 Hz), 137.7, 133.4 (d, J = 4.2 Hz, +), 132.4 (d, J = 8.2 Hz, +), 129.0 (+, 2C), 126.9 (+), 
126.7 (d, J = 16.3 Hz), 124.7 (+, 2C), 117.3 (d, J = 23.5 Hz, +), 117.1 (d, J = 3.4 Hz), 64.2 (–), 
58.8 (+), 45.7 (–),43.2 (d, J = 3.7 Hz, –), 34.8, 22.6 (–). FTIR (NaCl, cm-1): 3055, 2922, 2851, 
1643, 1591, 1478, 1445, 1252, 1113, 1026, 789, 750, 696. HRMS (TOF ES): found 412.0320, 
calculated for C19H17BrFNO2Na (M + Na) 412.0324 (1.0 ppm). 
 
5,7-Diphenyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one (199af). This 
compound was synthesized according to the Typical Procedure from 1-
phenylcycloprop-2-ene-1-carboxylic acid (196a) (200 mg, 1.25 mmol, 1.0 
equiv.), and 2-(phenylamino)ethan-1-ol (197f) (257 mg, 1.88 mmol, 1.5 equiv.). After extraction 
and filtration through a Silica gel plug crude N-(2-hydroxyethyl)-N,1-diphenylcycloprop-2-ene-1-
carboxamide (198af) was isolated and used at the cyclization step without additional purification.  
To this end, amide 198af (20 mg, 0.072 mmol) was treated with powdered KOH (8 mg, 0.144 
mmol). The product was isolated by column chromatography eluting with a hexanes/EtOAc 
mixture (1:1) as a colorless glass (Rf 0.48). Yield 5.8 mg (0.021 mmol, 29%). 
1H NMR (500 MHz, 
CDCl3) δ 7.44–7.39 (m, 2H), 7.38–7.31 (m, 4H), 7.30–7.25 (m, 2H), 7.19–7.16 (m, 2H), 4.37 (ddd, 
J = 15.4, 12.6, 4.9 Hz, 1H), 3.94 (ddd, J = 12.5, 11.5, 4.8 Hz, 1H), 3.76 (dd, J = 11.4, 4.9 Hz, 1H), 
3.54 (dd, J = 6.3, 3.6 Hz, 1H), 3.47 (dd, J = 15.4, 4.7 Hz, 1H), 1.83 (dd, J = 7.1, 3.6 Hz, 1H), 1.55 
(dd, J = 7.0, 6.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 170.4, 142.3, 137.8, 129.4 (+, 2C), 129.0 
(+, 2C), 127.1 (+), 126.9 (+), 126.4 (+, 2C), 124.7 (+, 2C), 64.9 (–), 59.3 (+), 49.1 (–), 35.4, 22.6 
(–). FTIR (NaCl, cm-1): 3057, 2961, 2920, 1663, 1493, 1398, 1231, 1215, 1157, 1055, 757, 698. 
HRMS (TOF ES): found 280.1336, calculated for C18H18NO2 (M + H) 280.1338 (0.7 ppm). 
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5-(4-Methoxyphenyl)-7-phenyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one 
(199ag). This compound was synthesized according to Typical Procedure 
from 1-phenylcycloprop-2-ene-1-carboxylic acid (196a) (200 mg, 1.25 
mmol, 1.0 equiv.), and 2-((4-methoxyphenyl)amino)ethan-1-ol (197g) 
(313 mg, 1.88 mmol, 1.5 equiv.). After extraction and filtration through a silica plug crude N-(2-
hydroxyethyl)-N-(4-methoxyphenyl)-1-phenylcycloprop-2-ene-1-carboxamide (198ag) was used 
at the cyclization step as is without additional purification.  To this end, amide 198ag (20 mg, 
0.065 mmol) was treated with powdered KOH (7.3 mg, 0.13 mmol). The product was isolated by 
column chromatography eluting with a hexanes/EtOAc mixture (1:1) as a colorless glass (Rf 0.26). 
Yield 17 mg (0.055 mmol, 85%). 1H NMR (500 MHz, CDCl3) δ 7.35 (t, J = 7.6 Hz, 2H), 7.29–
7.20 (m, 3H), 7.16 (d, J = 7.6 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 4.34 (ddd, J = 15.4, 12.6, 4.9 Hz, 
1H), 3.92 (td, J = 12.0, 4.7 Hz, 1H), 3.81 (s, 3H), 3.73 (dd, J = 11.3, 4.9 Hz, 1H), 3.52 (dd, J = 6.2, 
3.6 Hz, 1H), 3.38 (dd, J = 15.3, 4.7 Hz, 1H), 1.81 (dt, J = 20.0, 10.0 Hz, 1H), 1.53 (t, J = 6.7 Hz, 
1H). 13C NMR (126 MHz, CDCl3) δ 170.6, 158.4, 137.9, 135.2, 129.0 (+, 2C), 127.7 (+, 2C), 126.8 
(+), 124.6 (+, 2C), 114.7 (+, 2C), 64.6 (–), 59.3 (+), 55.6 (+), 49.4 (–), 35.3, 22.6 (–). FTIR (NaCl, 
cm-1): 2961, 2866, 1661, 1510, 1454, 1400, 1250, 1157, 1055, 1031, 831, 752, 698. HRMS (TOF 
ES): found 332.1275, calculated for C19H19NO3Na (M + Na) 332.1263 (3.6 ppm). 
 
6-Benzyl-8-phenyl-2-oxa-6-azabicyclo[6.1.0]nonan-7-one (199ah). This 
compound was synthesized according to Typical Procedure from 1-
phenylcycloprop-2-ene-1-carboxylic acid (196a) (200 mg, 1.25 mmol, 1.0 
equiv.), and 3-(benzylamino)propan-1-ol (197h) (309 mg, 1.88 mmol, 1.5 equiv.). After extraction 
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and filtration through a silica plug crude N-benzyl-N-(3-hydroxypropyl)-1-phenylcycloprop-2-
ene-1-carboxamide (198ah) was used at the cyclization step as is without additional purification.  
To this end, amide 198ah (20 mg, 0.065 mmol) was treated with powdered KOH (7.3 mg, 0.13 
mmol). The product was isolated by column chromatography eluting with a hexanes/EtOAc 
mixture (2:1) as a colorless solid (Rf 0.31, mp 148-150 °C). Yield 18 mg (0.059 mmol, 90%). 
1H 
NMR (500 MHz, CDCl3) δ 7.29–7.17 (m, 7H), 7.15–7.11 (m, 1H), 7.04–7.00 (m, 2H), 5.33 (dd, J 
= 14.7, 1.2 Hz, 1H), 4.16 (dd, J = 12.7, 5.7 Hz, 1H), 3.97 (d, J = 14.7 Hz, 1H), 3.87–3.76 (m, 2H), 
3.67 (td, J = 12.8, 3.4 Hz, 1H), 3.08 (dd, J = 15.5, 6.7 Hz, 1H), 2.04–1.92 (m, 1H), 1.79 (dd, J = 
7.0, 4.5 Hz, 1H), 1.46 (ddd, J = 15.1, 6.7, 3.3 Hz, 1H), 1.27 (t, J = 7.2 Hz, 1H). 13C NMR (126 
MHz, CDCl3) δ 170.5, 139.4, 137.7, 128.9 (+, 2C), 128.7 (+, 2C), 128.6 (+, 2C), 127.6 (+), 126.6 
(+), 124.8 (+, 2C), 73.4 (-), 68.8 (+), 48.9 (–), 45.7 (–), 35.9, 29.3 (–), 22.5 (–). FTIR (NaCl, cm-
1): 3059, 3030, 2943, 1640, 1495, 1439, 1425, 1221, 1123, 1074, 1013, 750, 698. HRMS (TOF 
ES): found 330.1471, calculated for C20H21NO2Na (M + Na) 330.1470 (0.3 ppm). 
 
5-Benzyl-7-(4-fluorophenyl)-2-oxa-5-azabicyclo[5.1.0]octan-6-one 
(199ba). This compound was synthesized according to Typical 
Procedure from 1-(4-fluorophenyl)cycloprop-2-ene-1-carboxylic acid 
(196b) (200 mg, 1.12 mmol, 1.0 equiv.), and 2-(benzylamino)ethan-1-ol 
(197a) (255 mg, 1.68 mmol, 1.5 equiv.). After extraction and filtration through a silica plug crude 
N-benzyl-1-(4-fluorophenyl)-N-(2-hydroxyethyl)cycloprop-2-ene-1-carboxamide (198ba) was 
used at the cyclization step as is without additional purification.  To this end, amide 198ba (20 mg, 
0.064 mmol) was treated with powdered KOH (7.2 mg, 0.128 mmol). The product was isolated by 
column chromatography eluting with a hexanes/EtOAc mixture (1:1) as a colorless glass (Rf 0.44). 
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Yield 18 mg (0.058 mmol, 90%). 1H NMR (500 MHz, CDCl3) δ 7.36–7.27 (m, 5H), 7.12–7.04 (m, 
2H), 7.00 (t, J = 8.6 Hz, 2H), 4.75–4.63 (m, 2H), 3.96–3.85 (m, 1H), 3.54 (dd, J = 11.2, 5.1 Hz, 
1H), 3.44–3.34 (m, 2H), 3.05 (dd, J = 15.4, 4.8 Hz, 1H), 1.73 (dd, J = 6.9, 3.4 Hz, 1H), 1.41 (t, J 
= 6.6 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 170.6, 161.8 (d, J = 245.8 Hz), 137.2, 133.7 (d, J = 
3.2 Hz, +, 2C), 128.9 (+, 2C), 128.3 (+, 2C), 127.9 (+), 126.5 (d, J = 8.0 Hz, +, 2C), 115.9 (d, J = 
21.4 Hz, 2C, +)., 64.4 (–), 58.5 (+), 49.9 (–), 44.9 (–), 34.4, 22.5 (–). FTIR (NaCl, cm-1): 3063, 
2970, 2868, 1649, 1512, 1468, 1425, 1231, 1200, 1153, 1057, 828, 698. HRMS (TOF ES): found 
334.1207, calculated for C19H18FNO2Na (M + Na) 334.1219 (3.6 ppm). 
 
7-(4-Fluorophenyl)-5-methyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one (199bb). 
This compound was synthesized according to Typical Procedure from 1-(4-
fluorophenyl)cycloprop-2-ene-1-carboxylic acid (196b) (200 mg, 1.12 mmol, 
1.0 equiv.), and 2-(methylamino)ethan-1-ol (197b) (126 mg, 1.68 mmol, 1.5 
equiv.). After extraction and filtration through a silica plug crude 1-(4-fluorophenyl)-N-(2-
hydroxyethyl)-N-methylcycloprop-2-ene-1-carboxamide (198bb) was used at the cyclization step 
as is without additional purification.  To this end, amide 198bb (20 mg, 0.085 mmol) was treated 
with powdered KOH (9.5 mg, 0.17 mmol). The product was isolated by column chromatography 
eluting with EtOAc as a colorless solid (Rf 0.51, mp 104-105 °C). Yield 17.2 mg (0.073 mmol, 
86%). 1H NMR (500 MHz, CDCl3) δ 7.05–6.96 (m, 4H), 4.04 (ddd, J = 15.3, 12.7, 5.0 Hz, 1H), 
3.86–3.76 (m, 1H), 3.69–3.61 (m, 1H), 3.38 (dd, J = 6.3, 3.5 Hz, 1H), 3.06 (s, 3H), 3.05–3.02 (m, 
1H), 1.63 (dd, J = 7.0, 3.5 Hz, 1H), 1.38 (dd, J = 6.9, 6.4 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 
170.5, 161.8 (d, J = 245.6 Hz), 133.6 (d, J = 3.1 Hz), 126.5 (d, J = 8.0 Hz, +, 2C), 115.8 (d, J = 
21.4 Hz, +, 2C), 63.3 (–), 58.4 (+), 47.5 (–), 34.4, 34.3 (+), 22.3 (–). FTIR (NaCl, cm-1): 2959, 
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2870, 1649, 1512, 1481, 1433, 1397, 1231, 1165, 1057, 829, 791. HRMS (TOF ES): found 
236.1094, calculated for C13H15FNO2 (M + H) 236.1087 (3.0 ppm). 
 
7-(4-Fluorophenyl)-5-(4-methoxyphenyl)-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (199bg). This compound was synthesized 
according to Typical Procedure from 1-(4-fluorophenyl)cycloprop-2-
ene-1-carboxylic acid (196b) (200 mg, 1.12 mmol, 1.0 equiv.), and 2-
((4-methoxyphenyl)amino)ethan-1-ol (197g) (282 mg, 1.68 mmol, 1.5 equiv.). After extraction 
and filtration through a silica plug crude 1-(4-fluorophenyl)-N-(2-hydroxyethyl)-N-(4-
methoxyphenyl)cycloprop-2-ene (198bg) was used at the cyclization step as is without additional 
purification.  To this end, amide 198bg (20 mg, 0.061 mmol) was treated with powdered KOH 
(6.9 mg, 0.122 mmol). The product was isolated by column chromatography eluting with a 
hexanes/EtOAc mixture (2:1) as a colorless solid (Rf 0.19, mp 132-133 
oC). Yield 18.4 mg (0.056 
mmol, 92%). 1H NMR (500 MHz, CDCl3) δ 7.23–7.18 (m, 2H), 7.17–7.12 (m, 2H), 7.07–7.01 (m, 
2H), 6.95–6.90 (m, 2H), 4.32 (ddd, J = 15.4, 12.6, 4.9 Hz, 1H), 3.91 (td, J = 11.9, 4.7 Hz, 1H), 
3.81 (s, 3H), 3.74 (dd, J = 11.0, 5.1 Hz, 1H), 3.50 (dd, J = 6.2, 3.5 Hz, 1H), 3.38 (dt, J = 19.4, 9.7 
Hz, 1H), 1.79 (dd, J = 7.1, 3.5 Hz, 1H), 1.45 (t, J = 6.7 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 
170.5, 161.9 (d, J = 245.8 Hz), 158.5, 135.1, 133.6 (d, J = 3.1 Hz), 127.6 (+, 2C), 126.5 (d, J = 8.0 
Hz, +, 2C), 115.9 (d, J = 21.5 Hz, +, 2C), 114.7 (+, 2C), 64.6 (–), 58.9 (+), 55.7 (+), 49.3 (–), 34.8, 
22.6 (–). FTIR (NaCl, cm-1): 3053, 2934, 2870, 1661, 1510, 1456, 1398, 1265, 1250, 1159, 1053, 
1034, 831, 739, 704. HRMS (TOF ES): found 350.1172, calculated for C19H18FNO3Na (M + Na) 
350.1168 (1.1 ppm). 
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 6-Benzyl-8-(4-fluorophenyl)-2-oxa-6-azabicyclo[6.1.0]nonan-7-one 
(199bh). This compound was synthesized according to Typical 
Procedure from 1-(4-fluorophenyl)cycloprop-2-ene-1-carboxylic acid 
(196b) (200 mg, 1.12 mmol, 1.0 equiv.), and 3-(benzylamino)propan-1-ol (197h) (278 mg, 1.68 
mmol, 1.5 equiv.). After extraction and filtration through a silica plug crude N-benzyl-1-(4-
fluorophenyl)-N-(3-hydroxypropyl)cycloprop-2-ene-1-carboxamide (16bh) was used at the 
cyclization step as is without additional purification.  To this end, amide 198bh (20 mg, 0.061 
mmol) was treated with powdered KOH (6.9 mg, 0.122 mmol). The product was isolated by 
column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless solid (Rf 0.19, 
mp 132-133 °C). Yield 17.6 mg (0.054 mmol, 88%). 1H NMR (500 MHz, CDCl3) δ 7.35–7.23 (m, 
5H), 7.10–7.03 (m, 2H), 7.00–6.92 (m, 2H), 5.37 (d, J = 14.7 Hz, 1H), 4.22 (dd, J = 12.7, 5.6 Hz, 
1H), 4.01 (d, J = 14.7 Hz, 1H), 3.90–3.80 (m, 2H), 3.73 (td, J = 12.7, 3.4 Hz, 1H), 3.14 (dd, J = 
15.5, 6.7 Hz, 1H), 2.12–1.97 (m, 1H), 1.83 (dd, J = 7.0, 4.4 Hz, 1H), 1.54 (ddd, J = 15.2, 6.7, 3.2 
Hz, 1H), 1.26 (dd, J = 9.6, 4.9 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 170.3, 161.6 (d, J = 245.7 
Hz), 137.6, 135.1 (d, J = 3.1 Hz), 128.8 (+, 2C), 128.5 (+, 2C), 127.6 (+), 126.6 (d, J = 7.9 Hz, +, 
2C), 115.8 (d, J = 21.5 Hz, +, 2C), 73.4 (–), 68.5 (+), 48.9 (–), 45.7 (–), 35.4, 29.3 (–), 22.4 (–). 
FTIR (NaCl, cm-1): 2963, 1634, 1510, 1477, 1440, 1261, 1165, 1123, 1074, 1015, 817, 752. HRMS 
(TOF ES): found 348.1385, calculated for C20H20FNO2Na (M + Na) 348.1376 (2.6 ppm). 
 
 6-(2-Chlorobenzyl)-8-(4-fluorophenyl)-2-oxa-6-
azabicyclo[6.1.0]nonan-7-one (199bi). This compound was synthesized 
according to Typical Procedure from 1-(4-fluorophenyl)cycloprop-2-
ene-1-carboxylic acid (196b) (200 mg, 1.12 mmol, 1.0 equiv.), and 3-((2-
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chlorobenzyl)amino)propan-1-ol (197i) (336 mg, 1.68 mmol, 1.5 equiv.). After extraction and 
filtration through a silica plug crude N-(2-chlorobenzyl)-1-(4-fluorophenyl)-N-(3-
hydroxypropyl)cycloprop-2-ene-1-carboxamide (198bi) was used at the cyclization step as is 
without additional purification.  To this end, amide 198bi (20 mg, 0.056 mmol) was treated with 
powdered KOH (6.2 mg, 0.112 mmol). The product was isolated by column chromatography 
eluting with a hexanes/EtOAc mixture (2:1) as a colorless glass (Rf 0.19). Yield 18.4 mg (0.051 
mmol, 92%). 1H NMR (500 MHz, CDCl3) δ 7.38–7.33 (m, 1H), 7.30–7.25 (m, 1H), 7.23–7.17 (m, 
2H), 7.15–7.09 (m, 2H), 7.02–6.94 (m, 2H), 5.29 (d, J = 15.4 Hz, 1H), 4.36 (d, J = 15.4 Hz, 1H), 
4.24 (dd, J = 12.8, 5.6 Hz, 1H), 3.94 (dd, J = 15.6, 11.2 Hz, 1H), 3.90 (dd, J = 7.5, 4.4 Hz, 1H), 
3.75 (tt, J = 14.4, 7.2 Hz, 1H), 3.15 (dd, J = 15.5, 6.6 Hz, 1H), 2.17–2.04 (m, 1H), 1.82 (dd, J = 
7.0, 4.4 Hz, 1H), 1.58 (ddd, J = 15.1, 6.5, 3.1 Hz, 1H), 1.24 (t, J = 7.2 Hz, 1H). 13C NMR (126 
MHz, CDCl3) δ 170.6, 161.7f (d, J = 245.7 Hz), 135.0, 134.9 (d, J = 3.2 Hz), 133.8, 129.9 (+), 
129.6 (+), 128.8 (+), 127.2 (+), 126.9 (d, J = 7.8 Hz, +, 2C), 115.8 (d, J = 21.6 Hz, +, 2C), 73.4 
(–), 68.1 (+), 46.3 (–), 46.3 (–), 35.4, 29.5 (–), 22.4 (–). FTIR (NaCl, cm-1): 3066, 2945, 2922, 
1638, 1510, 1474, 1439, 1304, 1223, 1165, 1121, 1074, 1021, 839, 754. HRMS (TOF ES): found 
382.1001, calculated for C20H19ClFNO2Na (M + Na) 382.0986 (3.9 ppm). 
 
 5-Benzyl-7-(2,4-dichlorophenyl)-2-oxa-5-azabicyclo[5.1.0]octan-6-
one (199ca). This compound was synthesized according to Typical 
Procedure from 1-(2,4-dichlorophenyl)cycloprop-2-ene-1-carboxylic 
acid (196c) (200 mg, 0.87 mmol, 1.0 equiv.), and 2-
(benzylamino)ethan-1-ol (197a) (198 mg, 1.31 mmol, 1.5 equiv.). After extraction and filtration 
through a silica plug crude N-benzyl-1-(2,4-dichlorophenyl)-N-(2-hydroxyethyl)cycloprop-2-ene-
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1-carboxamide (198ca) was used at the cyclization step as is without additional purification.  To 
this end, amide 198ca (20 mg, 0.055 mmol) was treated with powdered KOH (6.2 mg, 0.11 mmol). 
The product was isolated by column chromatography eluting with a hexanes/EtOAc mixture (2:1) 
as a colorless oil (Rf 0.29). Yield 16 mg (0.044 mmol, 80%). 
1H NMR (500 MHz, CDCl3) δ 7.70 
(d, J = 8.5 Hz, 1H), 7.37 (d, J = 2.2 Hz, 1H), 7.31–7.19 (m, 6H), 4.81 (d, J = 14.8 Hz, 1H), 4.63 
(ddd, J = 15.6, 12.4, 5.4 Hz, 1H), 4.37 (d, J = 14.8 Hz, 1H), 4.01 (dd, J = 6.3, 3.2 Hz, 1H), 3.71 
(dd, J = 11.3, 5.3 Hz, 1H), 3.42–3.30 (m, 1H), 3.06 (dd, J = 15.5, 5.2 Hz, 1H), 1.72 (dd, J = 6.6, 
3.2 Hz, 1H), 1.34 (t, J = 6.4 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 170.2, 137.2, 134.7, 134.0, 
133.9, 133.8 (+), 130.7 (+), 128.8 (+, 2C), 128.2 (+, 2C), 127.8 (+), 127.6 (+), 64.5 (–), 56.5 (+), 
50.7 (–), 44.5 (–), 34.2, 22.4 (–). FTIR (NaCl, cm-1): 3063, 2963, 1647, 1472, 1414, 1198, 1153, 
1076, 1039, 787, 735, 698. HRMS (TOF ES): found 384.0522, calculated for C19H17Cl2NO2Na 
(M + Na) 384.0534 (3.1 ppm). 
 
  7-(2,4-Dichlorophenyl)-5-methyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one 
(199cb). This compound was synthesized according to Typical Procedure 
from 1-(2,4-dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (196c) (200 
mg, 0.87 mmol, 1.0 equiv.), and 2-(methylamino)ethan-1-ol (197b) (98 mg, 
1.31 mmol, 1.5 equiv.). After extraction and filtration through a silica plug crude 1-(2,4-
dichlorophenyl)-N-(2-hydroxyethyl)-N-methylcycloprop-2-ene-1-carboxamide (198cb) was used 
at the cyclization step as is without additional purification.  To this end, amide 198cb (20 mg, 0.07 
mmol) was treated with powdered KOH (7.8 mg, 0.14 mmol). The product was isolated by column 
chromatography eluting with a hexanes/EtOAc mixture (1:2) as a colorless solid (Rf 0.30, mp 139-
140 °C). Yield 15.8 mg (0.055 mmol, 79%). 1H NMR (500 MHz, CDCl3) δ 7.66 (d, J = 8.5 Hz, 
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1H), 7.34 (d, J = 2.2 Hz, 1H), 7.21 (dd, J = 8.5, 2.2 Hz, 1H), 4.82–4.69 (m, 1H), 4.01 (dd, J = 6.3, 
3.2 Hz, 1H), 3.87–3.80 (m, 2H), 3.05 (ddd, J = 8.1, 5.9, 3.6 Hz, 1H), 2.97 (s, 3H), 1.62 (dd, J = 
6.5, 3.2 Hz, 1H), 1.28 (t, J = 6.4 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 170.0, 134.4, 134.0, 
133.8, 133.7 (+), 130.7 (+), 127.5 (+), 63.4 (–), 56.2 (+), 46.9 (–), 35.1 (+), 34.1, 22.3 (–). FTIR 
(NaCl, cm-1): 3003, 2962, 2926, 1647, 1474, 1435, 1395, 1253, 1215, 1169, 1107, 1080, 1040, 
822, 752, 667. HRMS (TOF ES): found 308.0210, calculated for C13H13Cl2NO2Na (M + Na) 
308.0221 (3.6 ppm). 
 
6-Benzyl-8-(2,4-dichlorophenyl)-2-oxa-6-azabicyclo[6.1.0]nonan-7-
one (199ch). This compound was synthesized according to Typical 
Procedure from 1-(2,4-dichlorophenyl)cycloprop-2-ene-1-carboxylic 
acid (196c) (200 mg, 0.87 mmol, 1.0 equiv.), and 3-
(benzylamino)propan-1-ol (197h) (216 mg, 1.31 mmol, 1.5 equiv.). After extraction and filtration 
through a silica plug crude N-benzyl-1-(2,4-dichlorophenyl)-N-(3-hydroxypropyl)cycloprop-2-
ene-1-carboxamide (198ch) was used at the cyclization step as is without additional purification.  
To this end, amide 198ch (20 mg, 0.053 mmol) was treated with powdered KOH (6 mg, 0.106 
mmol). The product was isolated by column chromatography eluting with a hexanes/EtOAc 
mixture (1:1) as a colorless solid (Rf 0.37, mp 151-153 °C). Yield 17 mg (0.045 mmol, 85%). 
1H 
NMR (500 MHz, CDCl3) δ 7.70 (d, J = 8.5 Hz, 1H), 7.37 (d, J = 2.2 Hz, 1H), 7.26–7.18 (m, 4H), 
7.13–7.03 (m, 2H), 5.23 (d, J = 15.0 Hz, 1H), 4.45–4.35 (m, 2H), 4.19 (dt, J = 25.4, 12.7 Hz, 1H), 
4.05–3.92 (m, 2H), 3.07 (dd, J = 15.5, 6.6 Hz, 1H), 2.06–1.95 (m, 1H), 1.94 (dd, J = 6.7, 4.3 Hz, 
1H), 1.94 (dd, J = 6.7, 4.3 Hz, 1H), 1.16–1.13 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 169.9, 
137.5, 134.7, 134.6, 133.9, 133.5 (+), 130.8 (+), 128.7 (+, 2C), 128.0 (+, 2C), 127.6 (+), 127.4 (+), 
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72.6 (–), 66.2 (+), 49.6 (–), 45.5 (–), 35.7, 29.8 (–), 21.6 (–). FTIR (NaCl, cm-1): 3063, 3028, 2922, 
1643, 1418, 1366, 1219, 1105, 1080, 1013, 789, 733, 698. HRMS (TOF ES): found 398.0709, 
calculated for C20H19Cl2NO2Na (M + Na) 398.0691 (4.5 ppm). 
 
4.7.5 Cyclization of Chiral Substrates 
 
 (+)-(1S,4S,7S)-4-Benzyl-5-methyl-7-phenyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (201aa). This compound was synthesized 
according to typical procedure from 1-phenylcycloprop-2-ene-1-carboxylic 
acid (196a) (200 mg, 1.25 mmol, 1.0 equiv.), and (S)-2-(methylamino)-3-phenylpropan-1-ol 
(214a) (309 mg, 1.88 mmol, 1.5 equiv.). After extraction and filtration through a silica plug crude 
(S)-N-(1-hydroxy-3-phenylpropan-2-yl)-N-methyl-1-phenylcycloprop-2-ene-1-carboxamide 
(200aa) was used at the cyclization step as is without additional purification.  To this end, amide 
200aa (20 mg, 0.065 mmol) was treated with powdered KOH (7.3 mg, 0.13 mmol). The product 
was isolated by column chromatography eluting with a hexanes/EtOAc mixture (1:1) as a colorless 
oil (Rf 0.38). Yield 18.2 mg (0.059 mmol, 91%). [α]D
20 +45.3 (c = 0.8, CHCl3). 
1H  NMR (500 
MHz, CDCl3) δ 7.33–7.23 (m, 6H), 7.03–6.97 (m, 4H), 4.66 (dddd, J = 10.8, 9.6, 5.9, 4.9 Hz, 1H), 
3.66–3.52 (m, 2H), 3.42 (dd, J = 6.2, 3.5 Hz, 1H), 2.93 (s, 3H), 2.91 (dd, J = 15.0, 9.6 Hz, 1H), 
2.80 (dd, J = 14.9, 5.8 Hz, 1H), 1.71 (dd, J = 7.1, 3.6 Hz, 1H), 1.52 (dd, J = 7.1, 6.3 Hz, 1H). 13C 
NMR (126 MHz, CDCl3) δ 171.8, 137.7, 136.7, 128.8 (+, 2C), 128.8 (+, 2C), 128.6 (+, 2C), 127.0 
(+), 126.9 (+), 124.7 (+, 2C), 67.6 (–), 59.8 (+), 54.8 (+), 35.1, 34.1 (–), 27.3 (+), 23.0 (–). FTIR 
(NaCl, cm-1): 2961, 2926, 1649, 1497, 1439, 1397, 1370, 1200, 1150, 1113, 1055, 1030, 750, 696. 
HRMS (TOF ES): found 330.1480, calculated for C20H21NO2Na (M + Na) 330.1470 (3.0 ppm). 
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 (+)-(1S,4S,7S)-4,5-Dibenzyl-7-phenyl-2-oxa-5-azabicyclo[5.1.0]octan-
6-one (201ab). This compound was synthesized according to typical 
procedure from 1-phenylcycloprop-2-ene-1-carboxylic acid (196a) (200 mg, 
1.25 mmol, 1.0 equiv.), and (S)-2-(benzylamino)-3-phenylpropan-1-ol (214b) (452 mg, 1.88 
mmol, 1.5 equiv.). After extraction and filtration through a silica plug crude (S)-N-benzyl-N-(1-
hydroxy-3-phenylpropan-2-yl)-1-phenylcycloprop-2-ene-1-carboxamide (200ab) was used at the 
cyclization step as is without additional purification.  To this end, amide 200ab (20 mg, 0.052 
mmol) was treated with powdered KOH (5.8 mg, 0.104 mmol). The product was isolated by 
column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless glass (Rf 0.31). 
Yield 18.6 mg (0.048 mmol, 93%). [α]D
20 +67.0 (c = 1.1, CHCl3). 
1H  NMR (500 MHz, CDCl3) δ 
7.39–7.22 (m, 11H), 7.13–7.09 (m, 2H), 7.03–6.98 (m, 2H), 5.44 (d, J = 15.8 Hz, 1H), 4.76 (dddd, 
J = 11.7, 9.1, 6.1, 4.5 Hz, 1H), 4.06 (d, J = 15.7 Hz, 1H), 3.50 (dd, J = 6.3, 3.6 Hz, 1H), 3.44 (dd, 
J = 11.1, 4.5 Hz, 1H), 3.07 (t, J = 11.4 Hz, 1H), 2.98 (dd, J = 15.2, 9.2 Hz, 1H), 2.69 (dd, J = 15.2, 
6.1 Hz, 1H), 1.90 (dd, J = 7.1, 3.5 Hz, 1H), 1.58 (dd, J = 7.1, 6.3 Hz, 1H). 13C NMR (126 MHz, 
CDCl3) δ 172.0, 138.9, 137.7, 136.9, 128.9 (+, 2C), 128.9 (+, 2C), 128.7 (+, 2C), 128.3 (+, 2C), 
127.5 (+, 2C), 127.4 (+), 127.0 (+), 127.0 (+), 124.9 (+, 2C), 69.5 (–), 59.9 (+), 54.8 (+), 44.8 (–), 
35.2, 33.5 (–), 23.3 (–). FTIR (NaCl, cm-1): 3059, 3026, 2964, 1649, 1497, 1408, 1377, 1207, 1055, 
1028, 746, 696. HRMS (TOF ES): found 406.1770, calculated for C26H25NO2Na (M + Na) 
406.1783 (3.2 ppm). 
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 (+)-(1S,4S,7S)-5-Benzyl-4-isobutyl-7-phenyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (201ad). This compound was synthesized 
according to typical procedure from 1-phenylcycloprop-2-ene-1-carboxylic 
acid (196a) (200 mg, 1.25 mmol, 1.0 equiv.), and (S)-2-(benzylamino)-4-methylpentan-1-ol 
(214d) (388 mg, 1.88 mmol, 1.5 equiv.). After extraction and filtration through a silica plug crude 
(S)-N-benzyl-N-(1-hydroxy-4-methylpentan-2-yl)-1-phenylcycloprop-2-ene-1-carboxamide 
(200ad) was used at the cyclization step as is without additional purification.  To this end, amide 
200ad (20 mg, 0.057 mmol) was treated with powdered KOH (6.4 mg, 0.114 mmol). The product 
was isolated by column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless 
solid (Rf 0.38, mp 117-118 °C). Yield 18.8 mg (0.054 mmol, 94%). [α]D
20 +83.4 (c = 0.8, CHCl3). 
1H  NMR (500 MHz, CDCl3) δ 7.35–7.20 (m, 8H), 7.12–7.07 (m, 2H), 5.39 (d, J = 15.7 Hz, 1H), 
4.37–4.25 (m, 1H), 4.12 (d, J = 15.5 Hz, 1H), 3.46 (dd, J = 6.2, 3.6 Hz, 1H), 3.35 (dd, J = 11.1, 
4.5 Hz, 1H), 2.99–2.87 (m, 1H), 1.86 (dd, J = 7.1, 3.5 Hz, 1H), 1.65 (ddd, J = 14.2, 9.7, 4.4 Hz, 
1H), 1.57 (dd, J = 7.1, 6.3 Hz, 1H), 1.55–1.46 (m, 1H), 0.98 (ddd, J = 14.3, 9.0, 4.4 Hz, 1H), 0.82 
(d, J = 6.7 Hz, 3H), 0.63 (d, J = 6.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.4, 138.9, 137.9, 
128.9 (+, 2C), 128.6 (+, 2C), 127.7 (+, 2C), 127.3 (+), 126.8 (+), 124.6 (+, 2C), 69.6 (–), 60.0 (+), 
52.9 (+), 44.7 (–), 36.3 (–), 35.2, 25.3 (+), 23.2 (–), 23.1 (+), 21.7 (+). FTIR (NaCl, cm-1): 2955, 
2925, 2866, 1647, 1497, 1437, 1410, 1377, 1219, 1172, 1055, 1029, 748, 698. HRMS (TOF ES): 
found 372.1926, calculated for C23H27NO2Na (M + Na) 372.1939 (3.5 ppm). 
 
 (+)-(1S,4S,7S)-4-Benzyl-7-(4-fluorophenyl)-5-methyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (201ba). This compound was synthesized 
according to typical procedure from 1-(4-fluorophenyl)cycloprop-2-ene-1-
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carboxylic acid (196b) (200 mg, 1.12 mmol, 1.0 equiv.), and (S)-2-(methylamino)-3-
phenylpropan-1-ol (214a) (278 mg, 1.68 mmol, 1.5 equiv.). After extraction and filtration through 
a silica plug crude (S)-1-(4-fluorophenyl)-N-(1-hydroxy-3-phenylpropan-2-yl)-N-
methylcycloprop-2-ene-1-carboxamide (200ba) was used at the cyclization step as is without 
additional purification.  To this end, amide 200ba (20 mg, 0.061 mmol) was treated with powdered 
KOH (6.8 mg, 0.122 mmol). The product was isolated by column chromatography eluting with a 
hexanes/EtOAc mixture (2:1) as a colorless oil (Rf 0.1). Yield 19.2 mg (0.059 mmol, 96%). [α]D
20 
+41.0 (c = 0.9, CHCl3). 
1H  NMR (500 MHz, CDCl3) δ 7.28–7.22 (m, 3H), 7.04–6.92 (m, 6H), 
4.70–4.53 (m, 1H), 3.68–3.51 (m, 2H), 3.39 (dd, J = 6.3, 3.5 Hz, 1H), 2.98–2.89 (m,1H), 2.92 (s, 
3H), 2.80 (dd, J = 14.9, 5.8 Hz, 1H), 1.69 (dd, J = 7.2, 3.5 Hz, 1H), 1.45 (dd, J = 7.2, 6.3 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 171.5, 161.9 (d, J = 245.6 Hz), 136.7, 133.4 (d, J = 3.1 Hz), 128.8 
(+, 2C), 128.5 (+, 2C), 127.1 (+), 126.4 (d, J = 7.9 Hz, +, 2C), 115.7 (d, J = 21.4 Hz, +, 2C), 67.5 
(–), 59.5 (+), 55.1 (+), 34.6, 34.1 (–), 27.3 (+), 23.0 (–). FTIR (NaCl, cm-1): 2961, 2920, 2866, 
1647, 1515, 1454, 1425, 1398, 1368, 1230, 1165, 1111, 1049, 831, 812, 793, 700. HRMS (TOF 
ES): found 348.1390, calculated for C20H20FNO2Na (M + Na) 348.1376 (4.0 ppm). 
 
 (+)-(1S,4S,7S)-4,5-Dibenzyl-7-(4-fluorophenyl)-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (201bb). This compound was synthesized 
according to typical procedure from 1-(4-fluorophenyl)cycloprop-2-ene-1-
carboxylic acid (196b) (200 mg, 1.12 mmol, 1.0 equiv.), and (S)-2-
(benzylamino)-3-phenylpropan-1-ol (214b) (406 mg, 1.68 mmol, 1.5 equiv.). After extraction and 
filtration through a silica plug crude (S)-N-benzyl-1-(4-fluorophenyl)-N-(1-hydroxy-3-
phenylpropan-2-yl)cycloprop-2-ene-1-carboxamide (200bb) was used at the cyclization step as is 
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without additional purification.  To this end, amide 200bb (20 mg, 0.05 mmol) was treated with 
powdered KOH (5.6 mg, 0.1 mmol). The product was isolated by column chromatography eluting 
with a hexanes/EtOAc mixture (2:1) as a colorless glass (Rf 0.31). Yield 18 mg (0.045 mmol, 90%). 
[α]D
20 +53.0 (c = 0.90, CHCl3). 
1H  NMR (500 MHz, CDCl3) δ 7.34–7.30 (m, 4H), 7.28–7.22 (m, 
4H), 7.11–7.02 (m, 4H), 6.99 (dd, J = 7.4, 2.1 Hz, 2H), 5.41 (d, J = 15.7 Hz, 1H), 4.71 (dddd, J = 
11.8, 9.0, 6.2, 4.5 Hz, 1H), 4.06 (d, J = 15.7 Hz, 1H), 3.48 (dd, J = 6.4, 3.6 Hz, 1H), 3.44 (dd, J = 
11.2, 4.6 Hz, 1H), 3.07 (t, J = 11.4 Hz, 1H), 2.99 (dd, J = 15.1, 9.0 Hz, 1H), 2.69 (dd, J = 15.1, 6.2 
Hz, 1H), 1.87 (dd, J = 7.2, 3.5 Hz, 1H), 1.50 (dd, J = 7.1, 6.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) 
δ 171.9, 161.9 (d, J = 245.8 Hz), 138.8, 136.9, 133.5 (d, J = 3.2 Hz), 129.0 (+, 2C), 128.7 (+, 2C), 
128.3 (+, 2C), 127.5 (+), 127.4 (+, 2C), 127.1 (+), 126.6 (d, J = 7.9 Hz, +, 2C), 115.8 (d, J = 21.7 
Hz, +, 2C), 69.5 (–), 59.5 (+), 55.0 (+), 44.9 (–), 34.7, 33.6 (–), 23.3 (–). FTIR (NaCl, cm-1): 2965, 
2864, 1649, 1512, 1416, 1233, 1165, 750, 698. HRMS (TOF ES): found 424.1707, calculated for 
C26H24FNO2Na (M + Na) 424.1689 (4.2 ppm). 
 
 (–)-(1R,4R,7R)-5-Benzyl-7-(4-fluorophenyl)-4-phenyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (201bc). This compound was synthesized 
according to typical procedure from 1-(4-fluorophenyl)cycloprop-2-ene-1-
carboxylic acid (196b) (200 mg, 1.12 mmol, 1.0 equiv.), and (R)-2-
(benzylamino)-2-phenylethan-1-ol (214c) (383 mg, 1.68 mmol, 1.5 equiv.). After extraction the 
(R)-N-benzyl-1-(4-fluorophenyl)-N-(2-hydroxy-1-phenylethyl)cycloprop-2-ene-1-carboxamide 
(200bc) was isolated by column chromatography eluting with a dichloromethane/EtOAc mixture 
(3:1) as a mixture of rotamers in a ratio of 2.2 : 1 as a colorless solid (Rf 0.33, mp 158-159 °C). 
Yield 146.7 mg (0.38 mmol, 34%). [α]D
20 –28.3 (c = 1.0, CHCl3). 
1H NMR (500 MHz, CDCl3) δ 
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[7.44–7.20 (m), Σ8H], [7.10–7.06 (m), 7.01–6.92 (m), 6.80 (br. m), Σ6H], [5.48–5.42 (m), 5.22 
(dd, J = 8.4, 4.6 Hz), Σ1H], [5.11 (d, J = 15.1 Hz), 4.42 (d, J = 16.9 Hz), 4.20 (d, J = 16.9 Hz), 
3.87 (d, J = 15.0 Hz), Σ2H], [4.15–4.08 (m), 4.06–4.00 (m), 3.81–3.65 (br. m), 3.63–3.55 (br. m), 
Σ2H], [1.72 (br.s), 1.40 (br. s), Σ1H]. 13C NMR (126 MHz, CDCl3) δ Major diastereomer: 176.9, 
161.8 (d, J = 245.4 Hz), 138.4 (d, J = 2.7 Hz), 137.7, 137.0, 128.8 (+, 4C), 128.5 (+, 2C), 128.2 
(+),127.8 (d, J = 7.8 Hz, +, 2C), 127. 6 (+), 126.8 (+, 2C), 115.5 (d, J = 21.2 Hz, +, 2C), 110.2 (+), 
109.8 (+), 63.9 (–), 63.1 (+), 50.6 (–), 32.6. Minor diastereomer: 176.1, 161.9 (d, J = 246.1 Hz), 
139.3, 139.0 (d, J = 2.6 Hz), 136.6, 128.9 (+, 4C), 128.1 (+), 127.8 (+, 2C), 127.5 (+), 128.4 (d, J 
= 7.9 Hz, +, 2C), 127.6 (+, 2C), 115.5 (d, J = 21.2 Hz, +, 2C), 111.7 (+), 110.4 (+), 62.5 (+), 62.4 
(–), 45.7 (–), 29.8. FTIR (NaCl, cm-1): 3366 (br), 3063, 3030, 2916, 1605, 1508, 1452, 1414, 1231, 
1159, 829, 752, 700, 621. HRMS (TOF ES): found 410.1512, calculated for C25H22FNO2Na (M + 
Na) 410.1532 (4.9 ppm).  To this end, amide 200bc (20 mg, 0.052 mmol) was treated with 
powdered KOH (5.8 mg, 0.104 mmol). The product was isolated by column chromatography 
eluting with a hexanes/EtOAc mixture (2:1) as a colorless solid (Rf 0.4, mp 192-194 °C). Yield 
17.8 mg (0.046 mmol, 89%). [α]D
20 –82.6 (c = 0.8, CHCl3). 
1H NMR (500 MHz, CDCl3) δ 7.37–
7.31 (m, 1H), 7.32–7.26 (m, 2H), 7.19–7.16 (m, 5H), 7.12–7.06 (m, 2H), 6.96–6.89 (m, 4H), 5.46 
(dd, J = 11.7, 5.1 Hz, 1H), 5.04 (d, J = 15.3 Hz, 1H), 3.82–3.71 (m, 3H), 3.52 (dd, J = 6.3, 3.5 Hz, 
1H), 1.92 (dd, J = 7.2, 3.5 Hz, 1H), 1.59 (dd, J = 7.2, 6.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 
171.1, 161.9 (d, J = 245.8 Hz), 138.3, 133.9 (d, J = 3.0 Hz), 132.6, 129.7 (+, 2C), 129.3 (+), 128.9 
(+, 2C), 128.2 (+, 2C), 127.7 (+, 2C), 127.1 (+), 126.3 (d, J = 7.9 Hz, +, 2C), 116.1 (d, J = 21.5 
Hz, +, 2C), 67.2 (–), 59.9 (+), 58.5 (+), 45.6 (–), 34.7, 23.2 (–). FTIR (NaCl, cm-1): 3032, 2926, 
2862, 1651, 1510, 1416, 1402, 1223, 1165, 1030, 831, 802, 750, 698. HRMS (TOF ES): found 
410.1539, calculated for C25H22FNO2Na (M + Na) 410.1532 (1.7 ppm). 
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 (+)-(1S,4S,7S)-5-Benzyl-7-(4-fluorophenyl)-4-isobutyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (201bd). This compound was synthesized 
according to typical procedure from 1-(4-fluorophenyl)cycloprop-2-ene-1-
carboxylic acid (196b) (200 mg, 1.12 mmol, 1.0 equiv.), and (S)-2-
(benzylamino)-4-methylpentan-1-ol (214d) (349 mg, 1.68 mmol, 1.5 equiv.). After extraction and 
filtration through a silica plug crude (S)-N-benzyl-1-(4-fluorophenyl)-N-(1-hydroxy-4-
methylpentan-2-yl)cycloprop-2-ene-1-carboxamide (200bd) was used at the cyclization step as is 
without additional purification.  To this end, amide 200bd (20 mg, 0.054 mmol) was treated with 
powdered KOH (6.1 mg, 0.108 mmol). The product was isolated by column chromatography 
eluting with a hexanes/EtOAc mixture (2:1) as a colorless solid (Rf 0.35, mp 139-141 °C). Yield 
18.6 mg (0.05 mmol, 93%). [α]D
20 +79.3 (c = 0.7, CHCl3). 
1H  NMR (500 MHz, CDCl3) δ 7.31–
7.21 (m, 5H), 7.12–7.06 (m, 2H), 7.05–6.99 (m, 2H), 5.37 (d, J = 15.5 Hz, 1H), 4.29 (ddt, J = 11.9, 
9.2, 4.5 Hz, 1H), 4.10 (d, J = 15.5 Hz, 1H), 3.45 (dd, J = 6.3, 3.5 Hz, 1H), 3.36 (dd, J = 11.0, 4.5 
Hz, 1H), 2.99–2.89 (m, 1H), 1.84 (dd, J = 7.1, 3.5 Hz, 1H), 1.65 (ddd, J = 14.2, 9.4, 4.6 Hz, 1H), 
1.56–1.46 (m, 1H), 1.49 (dd, J = 7.1, 6.3 Hz, 1H), 1.00 (ddd, J = 14.4, 9.0, 4.5 Hz, 1H), 0.83 (d, J 
= 6.6 Hz, 3H), 0.65 (d, J = 6.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.2, 161.8 (d, J = 245.6 
Hz), 138.7, 133.7 (d, J = 3.2 Hz), 128.6 (+, 2C), 127.7 (+, 2C), 127.4 (+), 126.4 (d, J = 7.9 Hz, +, 
2C), 115.8 (d, J = 21.5 Hz, +, 2C), 69.6 (–), 59.5 (+), 52.9 (+), 44.7 (–), 36.2 (–), 34.7, 25.3 (+), 
23.3 (–), 23.0 (+), 21.8 (+). FTIR (NaCl, cm-1): 2955, 2868, 1647, 1512, 1417, 1352, 1223, 1159, 
1030, 835, 799, 727, 700. HRMS (TOF ES): found 368.2028, calculated for C23H27FNO2 (M + H) 
368.2026 (0.5 ppm). The relative and absolute configuration of compound 201bd was 
unambiguously confirmed by single-crystal X-ray crystallography (CCDC #1823183). 
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 (+)-(1S,4S,7S)-4-Benzyl-7-(2,4-dichlorophenyl)-5-methyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (201ca). This compound was synthesized 
according to typical procedure from 1-(2,4-dichlorophenyl)cycloprop-2-
ene-1-carboxylic acid (196c) (200 mg, 0.87 mmol, 1.0 equiv.), and (S)-2-
(methylamino)-3-phenylpropan-1-ol (214a) (216 mg, 1.31 mmol, 1.5 equiv.). After extraction and 
filtration through a silica plug crude (S)-1-(2,4-dichlorophenyl)-N-(1-hydroxy-3-phenylpropan-2-
yl)-N-methylcycloprop-2-ene-1-carboxamide (200ca) was used at the cyclization step as is without 
additional purification.  To this end, amide 200ca (20 mg, 0.053 mmol) was treated with powdered 
KOH (5.9 mg, 0.106 mmol). The product was isolated by column chromatography eluting with a 
hexanes/EtOAc mixture (1:1) as a colorless oil (Rf 0.5). Yield 16.8 mg (0.045 mmol, 84%). [α]D
20 
+36.5 (c = 0.7, CHCl3). 
1H  NMR (500 MHz, CDCl3) δ 7.63 (d, J = 8.5 Hz, 1H), 7.36 (d, J = 2.2 
Hz, 1H), 7.31–7.19 (m, 4H), 7.15–7.10 (m, 2H), 5.15 (ddt, J = 11.9, 7.7, 3.8 Hz, 1H), 4.07 (dd, J 
= 6.3, 3.2 Hz, 1H), 3.75 (dd, J = 11.4, 4.4 Hz, 1H), 3.54 (t, J = 11.3 Hz, 1H), 3.04 (dd, J = 14.3, 
7.7 Hz, 1H), 2.88 (s, 3H), 2.83 (dd, J = 14.3, 7.7 Hz, 1H), 1.66 (dd, J = 6.7, 3.2 Hz, 1H), 1.39 (t, J 
= 6.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 171.0, 136.9, 133.9, 133.9, 133.7 (+), 133.5, 130.7 
(+), 128.9 (+, 2C), 128.7 (+, 2C), 127.6 (+), 127.1 (+), 67.5 (–), 56.9 (+), 54.4 (+), 35.0 (–), 34.6, 
28.2 (+), 22.9 (–). FTIR (NaCl, cm-1): 3005, 2924, 2866, 1645, 1474, 1397, 1366, 1200, 1152, 
1107, 1069, 1032, 829, 754, 698. HRMS (TOF ES): found 398.0704, calculated for 
C20H19Cl2NO2Na (M + Na) 398.0691 (3.3 ppm). 
 
158 
 
 (+)-(1S,4S,7S)-4,5-Dibenzyl-7-(2,4-dichlorophenyl)-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (201cb). This compound was synthesized 
according to typical procedure from 1-(2,4-dichlorophenyl)cycloprop-2-
ene-1-carboxylic acid (196c) (200 mg, 0.87 mmol, 1.0 equiv.), and (S)-2-
(benzylamino)-3-phenylpropan-1-ol (214b) (316 mg, 1.31 mmol, 1.5 equiv.). After extraction and 
filtration through a silica plug crude (S)-N-benzyl-1-(2,4-dichlorophenyl)-N-(1-hydroxy-3-
phenylpropan-2-yl)cycloprop-2-ene-1-carboxamide (200cb) was used at the cyclization step as is 
without additional purification.  To this end, amide 200cb (20 mg, 0.044 mmol) was treated with 
powdered KOH (4.9 mg, 0.088 mmol). The product was isolated by column chromatography 
eluting with a hexanes/EtOAc mixture (2:1) as a colorless oil (Rf 0.44). Yield 17.4 mg (0.038 
mmol, 87%). [α]D
20 +56.6 (c = 0.7, CHCl3). 
1H  NMR (500 MHz, CDCl3) δ 7.73 (d, J = 8.5 Hz, 
1H), 7.40 (d, J = 2.2 Hz, 1H), 7.34–7.19 (m, 9H), 7.13–7.07 (m, 2H), 5.26 (dt, J = 7.9, 4.0 Hz, 
1H), 5.20 (d, J = 15.8 Hz, 1H), 4.16 (d, J = 15.7 Hz, 1H), 4.10 (dd, J = 6.3, 3.3 Hz, 1H), 3.64 (dd, 
J = 11.3, 4.5 Hz, 1H), 3.13 (t, J = 11.3 Hz, 1H), 3.08 (dd, J = 14.4, 7.3 Hz, 1H), 2.76 (dd, J = 14.4, 
7.9 Hz, 1H), 1.82 (dd, J = 6.6, 3.2 Hz, 1H), 1.43 (t, J = 6.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) 
δ 171.5, 138.7, 137.0, 134.1, 134.0 (+), 133.7, 130.7 (+), 129.0 (+, 2C), 128.7 (+, 2C), 128.5 (+, 
2C), 127.7 (+), 127.4 (+, 2C), 127.4 (+), 127.1 (+), 69.2 (–), 57.3 (+), 54.4 (+), 45.6 (–), 34.6, 34.5 
(–), 23.3 (–). FTIR (NaCl, cm-1): 3026, 2926, 1647, 1495, 1473, 1406, 1371, 1244, 1030, 752, 698. 
HRMS (TOF ES): found 452.1195, calculated for C26H24Cl2NO2 (M + H) 452.1184 (2.4 ppm). 
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 (+)-(1S,4S,7S)-5-Benzyl-7-(2,4-dichlorophenyl)-4-isobutyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (201cd). This compound was synthesized 
according to typical procedure from 1-(2,4-dichlorophenyl)cycloprop-2-
ene-1-carboxylic acid (196c) (200 mg, 0.87 mmol, 1.0 equiv.), and (S)-2-
(benzylamino)-4-methylpentan-1-ol (214d) (272 mg, 1.31 mmol, 1.5 equiv.). After extraction and 
filtration through a silica plug crude (S)-N-benzyl-1-(2,4-dichlorophenyl)-N-(1-hydroxy-4-
methylpentan-2-yl)cycloprop-2-ene-1-carboxamide (200cd) was used at the cyclization step as is 
without additional purification.  To this end, amide 200cd (20 mg, 0.048 mmol) was treated with 
powdered KOH (5.4 mg, 0.096 mmol). The product was isolated by column chromatography 
eluting with a hexanes/EtOAc mixture (2:1) as a colorless solid (Rf 0.53, mp 144-146 °C). Yield 
18 mg (0.043 mmol, 90%). [α]D
20 +77.6 (c = 0.8, CHCl3). 
1H  NMR (500 MHz, CDCl3) δ 7.72 (d, 
J = 8.5 Hz, 1H), 7.37 (d, J = 2.2 Hz, 1H), 7.28–7.19 (m, 6H), 5.28 (d, J = 15.6 Hz, 1H), 4.87 (ddt, 
J = 11.7, 9.5, 4.8 Hz, 1H), 4.15 (dd, J = 6.3, 3.2 Hz, 1H), 4.02 (d, J = 15.6 Hz, 1H), 3.60 (dd, J = 
11.2, 4.7 Hz, 1H), 2.97 (t, J = 11.4 Hz, 1H), 1.81 (dd, J = 6.7, 3.2 Hz, 1H), 1.66 (ddd, J = 14.1, 
9.1, 5.0 Hz, 1H), 1.62–1.50 (m, 1H), 1.41 (t, J = 6.5 Hz, 1H), 1.12 (ddd, J = 13.8, 8.6, 5.0 Hz, 1H), 
0.91 (d, J = 6.6 Hz, 3H), 0.83 (d, J = 6.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.8, 138.7, 
134.2, 133.9, 133.6, 133.6 (+), 130.8 (+), 128.6 (+, 2C), 127.5 (+, 3C), 127.3 (+), 69.6 (–), 57.2 
(+), 52.1 (+), 45.2 (–), 36.7 (–), 34.4, 25.4 (+), 23.2 (–), 23.2 (+), 22.3 (+). FTIR (NaCl, cm-1): 
3063, 3957, 3868, 1647, 1473, 1404, 1371, 1217, 1028, 868, 804, 748, 731, 696. HRMS (TOF 
ES): found 440.1143, calculated for C23H25Cl2NO2Na (M + Na) 440.1160 (3.9 ppm). 
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 (1S,3R,7S)- and (1R,3R,7R)-5-benzyl-7-(4-fluorophenyl)-3-
phenyl-2-oxa-5-azabicyclo[5.1.0]octan-6-one (204b and 205b). These 
compounds were synthesized according to typical procedure from 1-(4-
fluorophenyl)cycloprop-2-ene-1-carboxylic acid (196b) (200 mg, 1.12 
mmol, 1.0 equiv.), and (R)-2-(benzylamino)-1-phenylethan-1-ol (215) 
(383 mg, 1.68 mmol, 1.5 equiv.). After extraction and filtration through a silica plug crude (R)-N-
benzyl-1-(4-fluorophenyl)-N-(2-hydroxy-2-phenylethyl)cycloprop-2-ene-1-carboxamide (203b) 
was used at the cyclization step as is without additional purification.  To this end, amide 203b (20 
mg, 0.052 mmol) was treated with powdered KOH (5.8 mg, 0.104 mmol). The reaction mixture 
was vigorously stirred at 50 °C for 48 h,. The product was isolated by column chromatography 
eluting with a hexanes/EtOAc mixture (2:1) as a mixture of diastereomers in a ratio of 4 : 1 as a 
colorless oil (Rf 0.30). Yield 18.8 mg (0.049 mmol, 94%). 
1H NMR (500 MHz, CDCl3) δ Major 
diastereomer: 7.43–7.19 (m, 10H), 7.12–7.03 (m, 2H), 7.03–6.95 (m, 2H), 4.79 (dd, J = 32.0, 14.8 
Hz, 2H), 4.54 (dd, J = 11.6, 4.4 Hz, 1H), 4.10 (dd, J = 15.2, 11.5 Hz, 1H), 3.58 (dd, J = 6.3, 3.5 
Hz, 1H), 3.47 (dd, J = 15.3, 4.5 Hz, 1H), 1.79 (dd, J = 6.9, 3.5 Hz, 1H), 1.42 (t, J = 6.6 Hz, 1H). 
Minor diastereomer: 7.43–7.19 (m, 10H), 7.12–7.03 (m, 2H), 7.03–6.95 (m, 1H), 6.92–6.90 (m, 
1H), 5.37 (d, J = 14.8 Hz, 1H), 4.85 (d, J = 4.7 Hz, 1H) , 4.15 (dd, J = 15.0, 4.6 Hz, 1H) , 3.71 (dd, 
J = 6.2, 3.5 Hz, 1H) , 3.16 (d, J = 15.3 Hz, 1H), 2.82 (d, J = 14.8 Hz, 1H), 1.95 (dd, J = 7.0, 3.4 
Hz, 1H) , 1.53 (dd, J = 7.1, 6.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ Major diastereomer: 170.6, 
161.8 (d, J = 245.8 Hz), 137.5, 137.1, 133.5 (d, J = 3.2 Hz), 129.0 (+, 2C), 129.0 (+, 2C), 128.4 
(+), 128.4 (+, 2C), 128.0 (+), 126.7 (d, J = 8.1 Hz, +,2C), 126.4 (+, 2C), 115.9 (d, J = 21.6 Hz, +, 
2C), 74.3 (+), 55.1 (+), 50.2 (–), 48.5 (–), 34.5, 22.4 (–). Minor diastereomer: 170.5, 161.8 (d, J = 
246.1 Hz), 140.0, 137.0, 133.7 (d, J = 3.2 Hz), 128.7 (+, 2C), 128.7 (+, 2C), 128.3 (+, 2C), 128.2 
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(+), 127.7 (+), 126.5 (d, J = 7.9 Hz, +, 2C), 125.8 (+, 2C), 115.9 (d, J = 21.4 Hz, +, 2C), 75.8 (+), 
59.1 (+), 50.7 (–), 50.5 (–), 34.5, 22.7 (–). HRMS (TOF ES): found 410.1529, calculated for 
C25H22FNO2Na (M + Na) 410.1532 (0.7 ppm). 
 
 (–)-(1S,3S,4S,7S)-4,5-Dimethyl-3,7-diphenyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (207a). This compound was synthesized 
according to Typical Procedure from 1-phenylcycloprop-2-ene-1-carboxylic 
acid (196a) (200 mg, 1.25 mmol, 1.0 equiv.), and (1S,2S)-(+)-pseudoephedrine hydrochloride 
(214) (378 mg, 1.88 mmol, 1.5 equiv.). After extraction and filtration through a silica plug crude 
N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-1-phenylcycloprop-2-ene-1-carboxamide 
(206a) was used at the cyclization step as is without additional purification.  To this end, amide 
206a (20 mg, 0.065 mmol) was treated with powdered KOH (7.3 mg, 0.13 mmol). The product 
was isolated by column chromatography eluting with a hexanes/EtOAc mixture (3:2) as a colorless 
glass (Rf 0.28). Yield 17.2 mg (0.056 mmol, 86%). [α]D
20 –55.3 (c = 0.80, CHCl3). 
1H NMR (500 
MHz, CDCl3) δ 7.42–7.32 (m, 5H), 7.29–7.24 (m, 3H), 7.14–7.07 (m, 2H), 4.70 (dq, J = 10.8, 6.9 
Hz, 1H), 4.38 (d, J = 10.8 Hz, 1H), 3.68 (dd, J = 6.4, 3.6 Hz, 1H), 3.08 (s, 3H), 1.71 (dd, J = 6.8, 
3.5 Hz, 1H), 1.44 (t, J = 6.7 Hz, 1H), 1.12 (d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
171.5, 138.2, 136.6, 129.2 (+, 2C), 129.1 (+, 2C), 129.1 (+), 128.5 (+, 2C), 126.8 (+), 124.5 (+, 
2C), 80.1 (+), 55.7 (+), 51.5 (+), 35.1, 27.6 (+), 23.4 (–), 15.1 (+). FTIR (NaCl, cm-1): 2983, 2920, 
1646, 1495, 1452, 1425, 1397, 1152, 1049, 1018, 762, 698. HRMS (TOF ES): found 330.1469, 
calculated for C20H21NO2Na (M + Na) 330.1470 (0.3 ppm). 
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 (+)-(1R,3R,4R,7R)-4,5-Dimethyl-3,7-diphenyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (ent-207a). This compound was synthesized 
according to Typical Procedure from 1-phenylcycloprop-2-ene-1-carboxylic 
acid (196a) (200 mg, 1.25 mmol, 1.0 equiv.), and (1R,2R)-(–)-pseudoephedrine hydrochloride 
(ent-214) (378 mg, 1.88 mmol, 1.5 equiv.). After extraction and filtration through a silica plug 
crude N-((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-1-phenylcycloprop-2-ene-1-
carboxamide (ent-206a)was used at the cyclization step as is without additional purification.  To 
this end, amide ent-206a (20 mg, 0.065 mmol) was treated with powdered KOH (7.3 mg, 0.13 
mmol). The product was isolated by column chromatography eluting with a hexanes/EtOAc 
mixture (3:2) as a colorless glass (Rf 0.28). [α]D
20 +55.9 (c = 0.80, CHCl3). Yield 17.6 mg (0.057 
mmol, 88%). 1H NMR (500 MHz, CDCl3) δ 7.41–7.32 (m, 5H), 7.30–7.25 (m, 3H), 7.14–7.10 (m, 
2H), 4.70 (dq, J = 10.8, 7.0 Hz, 1H), 4.38 (d, J = 10.8 Hz, 1H), 3.68 (dd, J = 6.4, 3.5 Hz, 1H), 3.08 
(s, 3H), 1.71 (dd, J = 6.9, 3.5 Hz, 1H), 1.44 (t, J = 6.7 Hz, 1H), 1.12 (d, J = 7.0 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 171.5, 138.2, 136.6, 129.2 (+, 2C), 129.1 (+, 2C), 129.1 (+), 128.5 (+, 2C), 
126.8 (+), 124.5 (+, 2C), 80.1 (+), 55.7 (+), 51.5 (+), 35.1, 27.6 (+), 23.4 (–), 15.1 (+). FTIR (NaCl, 
cm-1): 2984, 2923, 1645, 1495, 1454, 1427, 1397, 1152, 1049, 1018, 762, 698. HRMS (TOF ES): 
found 330.1467, calculated for C20H21NO2Na (M + Na) 330.1470 (0.9 ppm). 
 
 (–)-(1S,3S,4S,7S)-7-(4-Fluorophenyl)-4,5-dimethyl-3-phenyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (207b). This compound was synthesized 
according to Typical Procedure from 1-(4-fluorophenyl)cycloprop-2-ene-1-
carboxylic acid (196b) (200 mg, 1.12 mmol, 1.0 equiv.), and (1S,2S)-(+)-
pseudoephedrine hydrochloride (214) (340 mg, 1.68 mmol, 1.5 equiv.). After extraction and 
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filtration through a silica plug crude 1-(4-fluorophenyl)-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-
yl)-N-methylcycloprop-2-ene-1-carboxamide (206b) was used at the cyclization step as is without 
additional purification.  To this end, amide 206b (20 mg, 0.061 mmol) was treated with powdered 
KOH (6.8 mg, 0.122 mmol). The product was isolated by column chromatography eluting with a 
hexanes/EtOAc mixture (3:1) as a colorless solid (Rf 0.60, mp 73-75 
oC). [α]D
20 –49.5 (c = 0.80, 
CHCl3). Yield 18.6 mg (0.057 mmol, 93%). 
1H NMR (500 MHz, CDCl3) δ 7.39 (dd, J = 5.7, 1.6 
Hz, 3H), 7.26 (s, 2H), 7.12–7.03 (m, 4H), 4.67 (dq, J = 10.8, 6.9 Hz, 1H), 4.38 (d, J = 10.8 Hz, 
1H), 3.64 (dd, J = 6.5, 3.5 Hz, 1H), 3.07 (s, 3H), 1.70 (dd, J = 6.9, 3.5 Hz, 1H), 1.38 (t, J = 6.7 Hz, 
1H), 1.14 (d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.4, 161.8 (d, J = 245.6 Hz), 136.4, 
133.9 (d, J = 3.0 Hz), 129.2 (+, 2C), 129.1 (+), 128.4 (+, 2C), 126.2 (d, J = 8.0 Hz, +, 2C), 116.1 
(d, J = 21.4 Hz, +, 2C), 80.0 (+), 55.4 (+), 51.5 (+), 34.6, 27.6 (+), 23.3 (–), 15.1 (+). FTIR (NaCl, 
cm-1): 2989, 1647, 1510, 1397, 1233, 1152, 1098, 1044, 1017, 829, 804, 762, 702, 637. HRMS 
(TOF ES): found 348.1383, calculated for C20H20FNO2Na (M + Na) 348.1376 (2.0 ppm). 
 
 (+)-(1R,3R,4R,7R)-7-(4-Fluorophenyl)-4,5-dimethyl-3-phenyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (ent-207b). This compound was synthesized 
according to Typical Procedure from 1-(4-fluorophenyl)cycloprop-2-ene-1-
carboxylic acid (196b) (200 mg, 1.12 mmol, 1.0 equiv.), and (1R,2R)-(–)-
pseudoephedrine hydrochloride (ent-214) (340 mg, 1.68 mmol, 1.5 equiv.). After extraction and 
filtration through a silica plug crude 1-(4-fluorophenyl)-N-((1R,2R)-1-hydroxy-1-phenylpropan-
2-yl)-N-methylcycloprop-2-ene-1-carboxamide (ent-206b) was used at the cyclization step as is 
without additional purification.  To this end, amide ent-206b (20 mg, 0.061 mmol) was treated 
with powdered KOH (6.8 mg, 0.122 mmol). The product was isolated by column chromatography 
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eluting with a hexanes/EtOAc mixture (2:1) as a colorless solid (Rf 0.14, mp 74-76 
oC). [α]D
20 
+50.3 (c = 0.90, CHCl3). Yield 19.2 mg (0.059 mmol, 96%). 
1H NMR (500 MHz, CDCl3) δ 7.43–
7.35 (m, 3H), 7.28–7.24 (m, 2H), 7.12–7.02 (m, 4H), 4.67 (dq, J = 10.8, 7.0 Hz, 1H), 4.38 (d, J = 
10.8 Hz, 1H), 3.64 (dd, J = 6.4, 3.5 Hz, 1H), 3.07 (s, 3H), 1.69 (dd, J = 6.9, 3.5 Hz, 1H), 1.38 (t, J 
= 6.7 Hz, 1H), 1.13 (d, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.4, 161.8 (d, J = 245.6 
Hz), 136.4, 133.9 (d, J = 3.1 Hz), 129.2 (+, 2C), 129.1 (+), 128.4 (+, 2C), 126.2 (d, J = 7.8 Hz, +, 
2C), 116.1 (d, J = 21.6 Hz, +, 2C), 80.0 (+), 55.4 (+), 51.5 (+), 34.6, 27.6 (+), 23.3 (–), 15.1 (+). 
FTIR (NaCl, cm-1): 2986, 1647, 1510, 1397, 1233, 1152, 1046, 1018, 831, 804, 760, 702, 637. 
HRMS (TOF ES): found 348.1382, calculated for C20H20FNO2Na (M + Na) 348.1376 (1.7 ppm). 
 
 (–)-(1S,3S,4S,7S)-7-(2,4-Dichlorophenyl)-4,5-dimethyl-3-phenyl-2-
oxa-5-azabicyclo[5.1.0]octan-6-one (207c). This compound was 
synthesized according to Typical Procedure from 1-(2,4-
dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (196c) (200 mg, 0.87 
mmol, 1.0 equiv.), and (1S,2S)-(+)-pseudoephedrine hydrochloride (214) (264 mg, 1.31 mmol, 1.5 
equiv.). After extraction and filtration through a silica plug crude 1-(2,4-dichlorophenyl)-N-
((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methylcycloprop-2-ene-1-carboxamide (206c) was 
used at the cyclization step as is without additional purification.  To this end, amide 206c (20 mg, 
0.053 mmol) was treated with powdered KOH (5.9 mg, 0.106 mmol). The product was isolated by 
column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless solid (Rf 0.54, 
mp 144-146 oC). Yield 16.4 mg (0.043 mmol, 82%). [α]D
20 –85.2 (c = 0.70, CHCl3). 
1H  NMR 
(500 MHz, CDCl3) δ 7.54 (d, J = 8.5 Hz, 1H), 7.48–7.40 (m, 5H), 7.39 (d, J = 2.3 Hz, 1H), 7.28–
7.24 (m, 1H), 5.16 (dq, J = 10.8, 7.0 Hz, 1H), 4.38 (d, J = 10.8 Hz, 1H), 4.22 (dd, J = 6.3, 3.2 Hz, 
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1H), 2.99 (s, 3H), 1.69 (dd, J = 6.7, 3.2 Hz, 1H), 1.54 (t, J = 6.5 Hz, 1H), 1.18 (d, J = 7.0 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 170.8, 136.9, 134.1, 133.8, 133.7, 132.2 (+), 131.2 (+), 129.2 (+, 
2C), 129.1 (+), 128.5 (+, 2C), 127.6 (+), 80.1 (+), 53.6 (+), 51.3 (+), 34.6, 27.9 (+), 22.3 (–), 15.1 
(+). FTIR (NaCl, cm-1): 2922, 2851, 1653, 1471, 1392, 1152, 1107, 1068, 758, 702. HRMS (TOF 
ES): found 376.0854, calculated for C20H20Cl2NO2 (M + H) 376.0871 (4.5 ppm). The relative and 
absolute configuration of compound 207c was unambiguously confirmed by single-crystal X-ray 
crystallography (CCDC # 1823195). 
 
 (+)-(1R,3R,4R,7R)-7-(2,4-Dichlorophenyl)-4,5-dimethyl-3-phenyl-2-
oxa-5-azabicyclo[5.1.0]octan-6-one (ent-207c). This compound was 
synthesized according to typical procedure from 1-(2,4-
dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (196c) (200 mg, 0.87 
mmol, 1.0 equiv.), and (1R,2R)-(–)-pseudoephedrine hydrochloride (ent-214) (264 mg, 1.31 mmol, 
1.5 equiv.). After extraction and filtration through a silica plug crude 1-(2,4-dichlorophenyl)-N-
((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-N-methylcycloprop-2-ene-1-carboxamide (ent-206c) 
was used at the cyclization step as is without additional purification.  To this end, amide ent-206c 
(20 mg, 0.053 mmol) was treated with powdered KOH (5.9 mg, 0.106 mmol). The product was 
isolated by column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless 
solid (Rf 0.54, mp 140-141 
oC). Yield 16.8 mg (0.045 mmol, 84%). [α]D
20 +81.8 (c = 0.70, CHCl3). 
1H  NMR (500 MHz, CDCl3) δ 7.55 (d, J = 8.5 Hz, 1H), 7.47–7.40 (m, 5H), 7.39 (d, J = 2.3 Hz, 
1H), 7.30–7.24 (m, 1H), 5.16 (dq, J = 10.9, 7.0 Hz, 1H), 4.38 (d, J = 10.8 Hz, 1H), 4.22 (dd, J = 
6.3, 3.1 Hz, 1H), 2.99 (s, 3H), 1.69 (dd, J = 6.7, 3.2 Hz, 1H), 1.54 (t, J = 6.5 Hz, 1H), 1.18 (d, J = 
7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 170.8, 136.9, 134.1, 133.8, 133.7, 132.2 (+), 131.2 
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(+), 129.2 (+, 2C), 129.1 (+), 128.5 (+, 2C), 127.6 (+), 80.0 (+), 53.6 (+), 51.3 (+), 34.6, 27.9 (+), 
22.3 (–), 15.1 (+). FTIR (NaCl, cm-1): 2922, 2851, 1653, 1474, 1392, 1152, 1107, 1068, 760, 700. 
HRMS (TOF ES): found 398.0702, calculated for C20H19Cl2NO2Na (M + Na) 398.0691 (2.8 ppm). 
 
 (–)-(1S,3S,4S,7S)-4,5-Dimethyl-7-(naphthalen-1-yl)-3-phenyl-2-
oxa-5-azabicyclo[5.1.0]octan-6-one (207d). This compound was 
synthesized according to typical procedure from 1-(naphthalen-1-
yl)cycloprop-2-ene-1-carboxylic acid (196d) (200 mg, 0.95 mmol, 1.0 equiv.), and (1S,2S)-(+)-
pseudoephedrine hydrochloride (214) (288 mg, 1.43 mmol, 1.5 equiv.). After extraction and 
filtration through a silica plug crude N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-1-
(naphthalen-1-yl)cycloprop-2-ene-1-carboxamide (206d) was used at the cyclization step as is 
without additional purification.  To this end, amide 206d (20 mg, 0.056 mmol) was treated with 
powdered KOH (6.3 mg, 0.112 mmol). The product was isolated by column chromatography 
eluting with a hexanes/EtOAc mixture (2:1) as a colorless solid (Rf 0.30, mp 217-220 °C). Yield 
16.2 mg (0.045 mmol, 81%). [α]D
20 –115.1 (c = 0.70, CHCl3). 
1H  NMR (500 MHz, CDCl3) δ 9.30 
(dd, J = 8.6, 1.0 Hz, 1H), 7.86–7.80 (m, 2H), 7.72 (dd, J = 7.1, 1.1 Hz, 1H), 7.67–7.61 (m, 3H), 
7.57–7.44 (m, 5H), 5.55 (dq, J = 10.8, 7.0 Hz, 1H), 4.48 (d, J = 10.8 Hz, 1H), 3.96 (dd, J = 6.3, 
2.8 Hz, 1H), 2.95 (s, 3H), 1.84 (dd, J = 6.3, 2.8 Hz, 1H), 1.23 (d, J = 7.0 Hz, 3H), 1.20 (t, J = 6.3 
Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 170.8, 137.3, 134.7, 134.6, 133.6, 129.4 (+, 2C), 129.1 
(+), 128.9 (+), 128.5 (+, 2C), 128.2 (+), 127.6 (+), 126.5 (+), 126.5 (+), 125.4 (+), 124.9 (+), 80.0 
(+), 52.4 (+), 51.0 (+), 34.1, 27.9 (+), 21.6 (–), 15.3 (+). FTIR (NaCl, cm-1): 3003, 2918, 1645, 
1454, 1391, 1329, 1233, 1152, 1088, 999, 781, 758, 700. HRMS (TOF ES): found 380.1638, 
calculated for C24H23NO2Na (M + Na) 380.1626 (3.2 ppm). 
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 (+)-(1R,3R,4R,7R)-4,5-Dimethyl-7-(naphthalen-1-yl)-3-phenyl-2-
oxa-5-azabicyclo[5.1.0]octan-6-one (ent-207d). This compound was 
synthesized according to typical procedure from 1-(naphthalen-1-
yl)cycloprop-2-ene-1-carboxylic acid (196d) (200 mg, 0.95 mmol, 1.0 equiv.), and (1R,2R)-(–)-
pseudoephedrine hydrochloride (ent-214) (288 mg, 1.43 mmol, 1.5 equiv.). After extraction and 
filtration through a silica plug crude N-((1R,2R)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-1-
(naphthalen-1-yl)cycloprop-2-ene-1-carboxamide (ent-206d) was used at the cyclization step as is 
without additional purification.  To this end, amide ent-206d (20 mg, 0.056 mmol) was treated 
with powdered KOH (6.3 mg, 0.112 mmol). The product was isolated by column chromatography 
eluting with a hexanes/EtOAc mixture (2:1) as a colorless solid (Rf 0.30, mp 222-224 °C). Yield 
16.8 mg (0.047 mmol, 84%). [α]D
20 +118.5 (c = 0.70, CHCl3). 
1H  NMR (500 MHz, CDCl3) δ 9.30 
(dd, J = 8.6, 1.1 Hz, 1H), 7.87–7.78 (m, 2H), 7.72 (dd, J = 7.2, 1.2 Hz, 1H), 7.69–7.60 (m, 3H), 
7.58–7.44 (m, 5H), 5.55 (dq, J = 10.9, 7.0 Hz, 1H), 4.48 (d, J = 10.8 Hz, 1H), 3.96 (dd, J = 6.3, 
2.8 Hz, 1H), 2.95 (s, 3H), 1.84 (dd, J = 6.2, 2.8 Hz, 1H), 1.23 (d, J = 7.0 Hz, 3H), 1.20 (t, J = 6.3 
Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 170.8, 137.3, 134.7, 134.6, 133.6, 129.4 (+, 2C), 129.1 
(+), 128.9 (+), 128.5 (+, 2C), 128.2 (+), 127.6 (+), 126.5 (+), 126.5 (+), 125.4 (+), 124.9 (+), 80.0 
(+), 52.4 (+), 51.0 (+), 34.1, 27.9 (+), 21.6 (–), 15.3 (+). FTIR (NaCl, cm-1): 3003, 2918, 1645, 
1454, 1392, 1329, 1232, 1151, 1087, 999, 781, 758, 700. HRMS (TOF ES): found 380.1608, 
calculated for C24H23NO2Na (M + Na) 380.1624 (4.7 ppm). 
 
168 
 
 (+)-(1S,3R,4S,7S)-4,5-Dimethyl-3,7-diphenyl-2-oxa-5-
azabicyclo[5.1.0]octan-6-one (210a). This compound was synthesized 
according to Typical Procedure from 1-phenylcycloprop-2-ene-1-carboxylic 
acid (196a) (200 mg, 1.25 mmol, 1.0 equiv.), and (1R,2S)-(–)-ephedrine hydrochloride (215) (378 
mg, 1.88 mmol, 1.5 equiv.). After extraction and filtration through a silica plug crude N-((1R,2S)-
1-hydroxy-1-phenylpropan-2-yl)-N-methyl-1-phenylcycloprop-2-ene-1-carboxamide (209a) was 
used at the cyclization step as is without additional purification.  To this end, amide 209a. (20 mg, 
0.065 mmol) was treated with powdered KOH (7.3 mg, 0.13 mmol). The product was isolated by 
column chromatography eluting with a hexanes/EtOAc mixture (3:2) as a colorless glass (Rf 0.28). 
[α]D
20 +77.0 (c = 0.70, CHCl3). Yield 16.8 mg (0.055 mmol, 84%). 
1H NMR (500 MHz, CDCl3) 
δ 7.36–7.29 (m, 5H), 7.27–7.19 (m, 3H), 7.08–7.03 (m, 2H), 4.64 (qd, J = 7.2, 4.2 Hz, 1H), 4.51 
(d, J = 4.3 Hz, 1H), 3.62 (dd, J = 6.2, 3.4 Hz, 1H), 2.70 (s, 3H), 1.89 (dd, J = 7.0, 3.4 Hz, 1H), 
1.62 (t, J = 6.6 Hz, 1H), 1.08 (d, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.3, 138.2, 
136.5, 129.0 (+, 2C), 128.6 (+), 128.2 (+, 2C), 127.8 (+, 2C), 126.8 (+), 124.6 (+, 2C), 81.2 (+), 
59.4 (+), 52.3 (+), 35.1, 29.0 (+), 22.6 (–), 14.6 (+). FTIR (NaCl, cm-1): 2999, 2923, 1648, 1497, 
1454, 1435, 1397, 1170, 1053, 1020, 756, 713, 700. HRMS (TOF ES): found 330.1484, calculated 
for C20H21NO2Na (M + Na) 330.1470 (4.2 ppm). 
 
 (+)-(1S,3R,4S,7S)-7-(2,4-Dichlorophenyl)-4,5-dimethyl-3-phenyl-2-
oxa-5-azabicyclo[5.1.0]octan-6-one (210c). This compound was 
synthesized according to typical procedure from 1-(2,4-
dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (196c) (150 mg, 0.65 
mmol, 1.0 equiv.), and (1R,2S)-(–)-ephedrine (215) (198 mg, 0.98 mmol, 1.5 equiv.). After 
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extraction and filtration through a silica plug crude 1-(2,4-dichlorophenyl)-N-((1R,2S)-1-hydroxy-
1-phenylpropan-2-yl)-N-methylcycloprop-2-ene-1-carboxamide (209c) was used at the 
cyclization step as is without additional purification.  To this end, amide 209c (60 mg, 0.16 mmol) 
was treated with powdered KOH (18 mg, 0.32 mmol). The product was isolated by column 
chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless solid (Rf 0.26, mp 152-
157 °C). Yield 52.2 mg (0.139 mmol, 87%). [α]D
20 +27.9 (c = 0.7, CHCl3). 
1H  NMR (500 MHz, 
CDCl3) δ 7.7 (d, J = 8.5 Hz, 1H), 7.4 (d, J = 2.3 Hz, 1H), 7.3–7.3 (m, 3H), 7.3–7.2 (m, 3H), 5.4–
5.3 (m, 1H), 4.7 (d, J = 4.4 Hz, 1H), 4.3 (dd, J = 6.2, 3.1 Hz, 1H), 2.6 (s, 3H), 1.8 (dd, J = 6.6, 3.1 
Hz, 1H), 1.5 (t, J = 6.4 Hz, 1H), 1.1 (d, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 170.8, 
136.8, 133.9, 133.9, 133.9 (+), 133.9, 130.7 (+), 128.6 (+), 128.3 (+, 2C), 127.7 (+, 2C), 127.7 (+), 
81.1 (+), 56.6 (+), 51.4 (+), 34.4, 29.5 (+), 22.9 (–), 14.3 (+). FTIR (NaCl, cm-1): 2918, 2848, 1647, 
1474, 1397, 1389, 1354, 1167, 1107, 1026, 826, 756, 706. HRMS (TOF ES): found 398.0676, 
calculated for C20H19Cl2NO2Na (M + Na) 398.0691 (3.8 ppm). The relative and absolute 
configuration of compound 210c was unambiguously confirmed by single-crystal X-ray 
crystallography (CCDC # 1823181). 
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Chapter 5. Intramolecular nucleophilic addition of tethered carbamates 
to cyclopropenes 
5.1 Introduction 
 
Employment of carbon-,125,117, 142  nitrogen-,107,114,120 oxygen-,111,114,119 sulfur-,121 or halogen-
based122  nucleophiles has been demonstrated in the intermolecular mode of the ring-retentive 
addition (Scheme 66). The intramolecular version of this reaction involving nucleophilic species 
tethered to cyclopropenes and leading to the formation of fused bicyclic ring systems is much more 
challenging. 
 
Scheme 66 
 
 
We recently developed methods for transition metal-free intramolecular addition of tethered 
nucleophiles (Scheme 67a and Scheme 67b), employing carbon- and oxygen-based species 
(Chapter 3 and Chapter 4 respectively). During these studies, the resulting novel cyclopropene-
fused scaffolds were identified as attractive biologically active probes possessing promising 
biological activity,3 which justified further synthetic efforts, especially towards medium sized 
cyclic amines 217, that could mimic β- or γ-turns of polypeptides. 
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Scheme 67 
 
 
At first glance, using amine-based nucleophilic entities in intermolecular cyclizations (Scheme 
67c) seemed to be a reasonably straightforward extension of the work previously performed with 
tethered alcohols (Scheme 67b). Unfortunately, decreased nucleophilicity of amines compared to 
alkoxides, paired with lowered acidity of amines compared to alcohols complicated the 
development of direct base assisted addition of tethered amines to cyclopropanes. 
 
5.2 Intramolecular addition of tethered nitrogen-based nucleophiles to cyclopropenes 
 
It should be noted that for successful base-assisted addition of the heteroatom-based entities 
across C=C bond of cyclopropenes, a fine balance between nucleophilicity and acidity must be 
maintained.107,111,114,143  Thus, the ring-retentive reaction of cyclopropenes with primary amines 
(9, NHX = NH2, NHAlk in Scheme 67c) cannot be achieved since the nucleophilicity of these 
neutral amines is much lower that of alkoxides, and their acidity is not sufficient to produce much 
more reactive anionic entities in the presence of typically employed weak bases.  Increasing the 
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strength of the base proved counterproductive, since concurrent deprotonation of acidic C-H bonds 
of cyclopropene occurs, greatly diminishing it’s electrophilicity.  At higher temperature it was 
possible to force a thermally-induced intramolecular nucleophilic attack in substrate 218, but the 
resulting donor-acceptor cyclopropane 219 tended towards facile ring-cleavage 144 , 145  and 
subsequent decomposition of cyclic imine 220 (Scheme 68a, also see Chapter 2). 
 
Scheme 68 
 
Arguably, the best solution to this problem would be the employment of an appropriate 
protecting group at the amine function, acidifying the N-H bond in the precursor and moderating 
the electron-donating character of the nitrogen atom in the cyclic product.  Given the availability 
of the corresponding starting materials we focused our initial investigation on reactivity of Boc-
protected amines 216 (Scheme 68b).  To this end, 1-phenylcycloprop-2-ene-1-carboxylic acid 
196a (Scheme 69) was subjected to the acylation reaction with tert-butyl (2-aminoethyl)carbamate 
220a.  Without purification, the resulting amide 216aa was treated with powdered KOH to afford 
the desired 2,5-diazabicyclo[5.1.0]octan-6-one 217aa as the sole product in 86% overall yield.   
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Scheme 69 
 
This reaction proved to be pretty general for 7-exo-trig cyclization showing high tolerance for 
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substituents at the amide nitrogen and at the quaternary carbon of cyclopropene.  It was shown that 
the starting amines could be protected not only by benzyl or substituted benzyl groups, but also by 
alkyl (220d-f) or 2-picolyl moieties (220g).  The aryl group at the quaternary center of 
cyclopropene can bear alkoxy- (196e), or halogen substituents (196b,c,f,g).  All seven-membered 
bicyclic amides were obtained in very high yields as sole products (Scheme 69). 
Similarly, acylation of cyclopropene-3-carboxylic acids 196 with N-benzylated derivatives of 
(3-aminopropyl)carbamate 220h-j afforded the corresponding tethered carbamates 216 in crude 
form (Scheme 70).  After treatment with a base, the latter underwent smooth 8-exo-trig cyclization 
leading to the formation of  2,6-diazabicyclo[6.1.0]nonan-7-ones 217. 
 
Scheme 70 
 
 
 
5.3 Diastereoselectivity of the intermolecular addition of nitrogen-based nucleophiles to 
cyclopropenes 
 
With positive initial result in hand we studied the effect of additional stereogenic centers on the 
diastereoselectivity of this reaction.  
First, we employed chiral cycloprop-2-enecarboxylic acids 169h,i (in racemic form, Scheme 
71).  Ethanolamines and propanolamines were converted into mono-carbamates 220 uneventfully, 
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and the following condensation afforded tertiary amide species 216, possessing chiral 
cyclopropene units (Scheme 71).  We were pleased to find, that the reaction of these precursors 
proceeded regio- and diastereoselectively, affording in high yields seven- (217ha, 217ia, 217ib) 
and eight-membered (217hh, 217ii) heterocycles as sole products with relative configurations 
(1S*,7S*,8R*) and (1S*,8S*,9R*), respectively.  Overall, the addition of the N-H moiety across 
the C=C bond of cyclopropene proceeded in a formal syn-fashion.   
 
Scheme 71 
 
 
Next, the reaction of tethered carbamate 216bk assembled by acylation of L-valine-derived 
chiral amine 220k with prochiral cycloprop-2-enecarboxylic acid 169b was evaluated (Scheme 
72).  The cyclopropene moiety in 216bk possesses two diastereotopic sites for nucleophilic attack, 
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but only one of them is being involved in the reaction giving rise to product 217bk with (1S,4S,7S)-
configuration and bulky isopropyl group in the more favored bowsprit configuration (as shown by 
X-ray crystallography, CCDC #1854746).  This stereochemical outcome is very similar to the one 
recently reported for assembly of cyclopropane-fused oxazepanones (Chapter 4.3) via 7-exo-trig 
cyclizations of tethered chiral alkoxides.  
 
Scheme 72 
 
 
5.4 Preliminary evaluation of biological activity  
 
The obtained structures constitute very attractive biological probes as this unique heterocyclic 
scaffold just recently emerged on the chemical space map (Chapter 1.3).3 Accordingly, a 
preliminary biological evaluation of a few representative compounds for anticancer activity using 
HeLa cell line (ATCC CCL-2) as a model for human cervical adenocarcinoma, through the 
measurements of mitochondrial dehydrogenase activities using the MTT method137 was performed 
by the group of Prof. Frolova.4 Preliminary tests revealed that some of the compounds possess 
promising anticancer activity, and the level of biological activity is very dependent on the character 
of substituents in designed structures (Figure 15).  For example, the changing of the substituent on 
amide nitrogen from aryl or benzyl groups to alkyl group eliminates the antiproliferative activity 
of synthesized compounds 8 completely. The same effect was observed as a result of the 
replacement of H with Ph at the CH2-group of the cyclopropane ring.  At the same time, significant 
improvement of biological activity (almost three-fold) was achieved after incorporation of Br in 
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the meta-position of the aryl ring at quaternary cyclopropane carbon. Thus, the obtained 
compounds 217gc, 217gj revealed great promise as novel anticancer scaffolds and will be a subject 
of further investigations. 
See section A2 of Appendix for experimental data. 
 
 
Figure 15. Biological activity of selected 2,5-diazabicyclo[5.1.0]octan-6-ones and 2,6-
diazabicyclo[6.1.0]nonan-7-ones 
 
5.5 Conclusion 
 
A novel and highly efficient strain-release-driven cyclization involving potassium-templated 
ring-retentive 7- and 8-exo-trig nucleophilic attack of tethered nitrogen-based nucleophiles (Boc-
protected amines) at cyclopropene double bond was demonstrated.  The described reaction 
proceeds in highly regio- and diastereoselective fashion and provides expedited access to 
previously unknown 2,5-diazabicyclo[5.1.0]octan-6-ones and 2,6-diazabicyclo[6.1.0]nonan-7-
ones as sole products in high yields.  Utilization of chiral diamines derived from natural aminoacids 
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allows to obtain cyclopropane-fused medium-sized nitrogen-based heterocycles in 
enantiomerically pure form.  Preliminary evaluation of bioactivity of these previously unknown 
drug-like scaffold was performed to reveal several structures with promising anti-cancer 
properties. 
 
5.6 Experimental 
5.6.1 General information 
 
NMR spectra were recorded on a Bruker Avance DRX500 (500 MHz) with a dual 
carbon/proton cryoprobe (CPDUL). 13C NMR spectra were registered with broadband decoupling. 
The (+) and (−) designations represent positive and negative intensities of signals in 13C DEPT-
135 experiments. IR spectra were recorded on a ThermoFisher Nicolet iS 5 FT-IR Spectrometer. 
HRMS was carried out on LCT Premier (Micromass Technologies) instrument employing ESI 
TOF detection techniques. Glassware used in moisture-free syntheses was flame-dried in vacuum 
prior to use. Column chromatography was carried out on silica gel (Sorbent Technologies, 40−63 
mm). Silica gel plates (Sorbent Technologies Silica XG 200 mm) were used for TLC analyses. 
Anhydrous dichloromethane was obtained by passing degassed commercially available HPLC-
grade inhibitor-free solvent consecutively through two columns filled with activated alumina and 
stored over molecular sieves under nitrogen. Water was purified by dual stage deionization 
followed by dual stage reverse osmosis. Anhydrous THF was obtained by refluxing commercially 
available solvent over calcium hydride followed by distillation in a stream of dry nitrogen. All 
other reagents and solvents were purchased from commercial vendors and used as received. 
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5.6.2 Biological Studies: Materials and Methods 
 
Biological Studies. Cell culture: HeLa cells were cultured in DMEM supplemented with 10% 
FBS. To evaluate antiproliferative properties of the synthesized compounds, the cells were 
trypsinized and seeded 4 · 103 cells per well into 96-well microtiter plates. The cells were grown 
for 24 h before treatment. MTT assay for HeLa: All compounds were dissolved in DMSO at a 
concentration of either 100 or 50 mM prior to cell treatment. The cells were treated at 
concentrations ranging from 0.004 to 100 μM and incubated for 48 h in 200 μL of media. Twenty 
microliters of MTT reagent in serum-free medium (5 mg/mL) was added to each well and 
incubated further for 2 h. Media was removed, and the resulting formazan crystals were 
resolubilized in 100 μL of DMSO. A490 was measured using a Thermomax Molecular Device 
plate reader. The experiments were performed in quadruplicate and repeated at least twice for each 
compound per cell line. Cells treated with 0.1% DMSO were used as a negative control, and phenyl 
arsine oxide (PAO) was used as a positive killing control. 
5.6.3 Synthesis of Starting Materials 
 
1-(4-Methoxyphenyl)cycloprop-2-ene-1-carboxylic acid (169e). Typical 
procedure: Methyl (4-methoxyphenyl)acetate (6.86 g, 41.3 mmol, 1.00 
equiv.) and tosyl azide (9.0 g, 45.4 mmol, 1.1 equiv.) were stirred in acetonitrile (150 mL) at 0 °C, 
and DBU (7.54 g, 49.5 mmol, 1.2 equiv.) was added dropwise. Upon complete addition the 
reaction was allowed to warm to room temperature and was stirred overnight. The solvent was 
then evaporated and the residue was partitioned between saturated ammonium chloride and 
methylene chloride. The aqueous phase was then extracted with methylene chloride (3 × 30 mL). 
Combined organic phases were then washed with brine, dried with MgSO4, filtered, and 
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concentrated. The recovered material was then mixed with Silica gel (15 g) and filtered through a 
short pad of Silica gel using hexanes. Crude methyl 2-diazo-2-(4-methoxyphenyl)acetate was 
obtained as a red oil. This material was then mixed with trimethylsilylacetylene (2 mL), and added 
via a syringe pump over 18 h to a stirring and refluxing suspension of rhodium(II) acetate dimer 
(27.4 mg, 0.124 mmol, 0.3 mol%) in trimethylsilylacetylene (47 mL, 413 mmol, 10.0 equiv.). 
After complete addition, the reaction was monitored by gas chromatography until complete 
consumption of the starting material was observed. Once this was achieved, the reflux condenser 
was replaced with a distillation head and most of the trimethylsilylacetylene was recovered by 
distillation at ambient pressure. The residual solvent was then removed under vacuum. The 
reaction mixture was then purified by short column chromatography eluting with a mixture of 
hexane : EtOAc (10 : 1). Crude ethyl 1-(4-methoxyphenyl)-2-(trimethylsilyl)cycloprop-2-ene-1-
carboxylate was obtained as a yellowish oil, which was stirred at 0 °C in a mixture of methanol 
and THF (1 : 1, 200 mL). An aqueous solution of sodium hydroxide (2 M, 200 mL) was added 
dropwise and the mixture was stirred for 18 h. Organic solvents were then removed under vacuum 
and the remaining aqueous solution was washed with dichloromethane (3 × 50  mL). The mixture 
was acidified to pH 2 with 2 M aqueous HCl and extracted with dichloromethane (3 × 50 mL). 
The combined organic phases were washed with brine, dried with MgSO4, filtered, and 
concentrated. The obtained product was purified by column chromatography on silica gel eluting 
with a mixture of hexane/EtOAc (2 : 1). The title compound was obtained as an off-white 
crystalline solid (Rf 0.3, mp 115–116 °C). Overall yield 2.198 g (11.6 mmol, 28%). 1H NMR (500 
MHz, CDCl3) δ 7.22 (s, 2H), 7.24–7.19 (m, 2H), 6.87–6.81 (m, 2H), 3.79 (s, 3H). 
13C NMR (126 
MHz, CDCl3) δ 180.7, 158.5, 132.9, 129.5 (+, 2C), 113.8 (+, 2C), 107.6 (+, 2C), 55.4 (+), 29.7. 
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FT IR (NaCl, cm−1): 3440 (br.), 1689, 1659, 1514, 1246, 1030, 773. HRMS (TOF ES): found 
189.0551, calculated for C11H9O3 (M − H)
− 189.0552 (0.5 ppm). 
 
1-(3-Chlorophenyl)cycloprop-2-ene-1-carboxylic acid (169f). This 
compound was obtained from methyl (3-chlorophenyl)acetate (5.65 g, 33.1 
mmol) using the protocol described for the synthesis of 1-(4-methoxyphenyl)cycloprop-2-ene-1-
carboxylic acid (vide supra). The title compound was obtained as an off-white crystalline solid 
(mp 84–86 °C). Yield 4.71 g (24.2 mmol, 73%). 1H NMR (500 MHz, CDCl3) δ 7.28 (td, J = 1.8, 
0.6 Hz, 1H), 7.24–7.22 (m, 1H), 7.21 (t, J = 1.9 Hz, 1H), 7.20 (s, 2H), 7.19–7.17 (m, 1H). 13C 
NMR (126 MHz, CDCl3) δ 180.9, 142.7, 134.1, 129.5 (+), 128.7 (+), 127.1 (+), 126.7 (+), 106.8 
(+, 2C), 30.0. FT IR (NaCl, cm−1): 3160 (br.), 1690, 1674, 1595, 1413, 1269, 1091, 984. HRMS 
(TOF ES): found 193.0057, calculated for C10H6ClO2 (M − H)
− 193.0056 (0.5 ppm). 
 
1-(2,4-Dichlorophenyl)-2-phenylcycloprop-2-ene-1-carboxylic acid (169i). 
This compound was obtained using methyl (2,4-dichlorophenyl)acetate 
(2.11 g, 10.3 mmol) and a solution of ethynylbenzene (3.15 g, 30.9 mmol, 
3.0 equiv.) in 20 mL of CH2Cl2 according to the protocol described for the synthesis of 1-(4-
methoxyphenyl)cycloprop-2-ene-1-carboxylic acid (vide supra). The title compound was obtained 
as a light-beige crystalline solid (mp 153–154 °C). Yield 1.79 g (5.87 mmol, 57%). 1H NMR (500 
MHz, CDCl3) δ 7.73–7.68 (m, 2H), 7.50–7.42 (m, 3H), 7.37 (d, J = 2.1 Hz, 1H), 7.31 (s, 1H), 7.23 
(d, J = 8.2 Hz, 1H), 7.11 (dd, J = 8.2, 2.1 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 180.0, 137.9, 
135.9, 133.9, 131.1 (+), 130.6 (+), 130.1 (+, 2C), 129.5 (+), 129.2 (+, 2C), 127.3 (+), 125.2, 118.1, 
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101.3 (+), 32.8. FT IR (NaCl, cm−1): 3381 (br.), 1685, 1471, 1260,1101, 821, 698. HRMS (TOF 
ES): found 302.9982, calculated for C16H9Cl2O2 (M − H)
− 302.9980 (0.7 ppm). 
 
tert-Butyl (S)-(2-(benzylamino)-3-methylbutyl)carbamate (220k). A 
15 mL autoclave vessel was charged with tert-butyl (S)-(2-amino-3-
methylbutyl)carbamate (300 mg, 1.48 mmol, 1.0 equiv.), benzaldehyde (182 μL, 189 mg, 1.78 
mmol, 1.2 equiv.), 10 wt% palladium on carbon (78.9 mg, 0.074 mmol, 0.05 equiv.), and methanol 
(3 mL). The mixture was stirred under hydrogen gas (1.5 atm.) overnight. The catalyst was 
removed by vacuum filtration through Celite® 545 non-acid-washed filter aid washing with 
methanol, then the resulting mixture was evaporated. The product was isolated by column 
chromatography eluting with a chloroform/methanol mixture (40:1) as a colorless oil (Rf 0.24). 
Yield: 239 mg (0.82 mmol, 55%). [α]D
20 +1.8 (c = 1.5, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 
7.28–7.15 (m, 5H), 4.97 (br. s, 1H), 3.70 (s, 2H), 3.29–3.12 (m, 1H), 2.96 (dt, J = 12.9, 6.2 Hz, 
1H), 2.36 (q, J = 6.2 Hz, 1H), 1.76 (nonet, J = 6.8 Hz, 1H), 1.38 (s, 9H), 0.86 (dd, J = 17.1, 6.8 
Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 156.3, 140.6, 128.5 (+, 2C), 128.2 (+, 2C), 127.0 (+), 
79.0, 62.1 (+), 51.5 (–), 40.5 (–), 28.5 (+, 3C), 19.2 (+, 2C), 18.4 (+). FTIR (NaCl, cm-1): 3350 
(br.), 2963, 1699,1495, 1366, 1171738, 699. HRMS (TOF ES): found 293.222, calculated for 
C17H29N2O2 (M + H) 293.229 (2.4 ppm). 
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5.6.4 Synthesis of Medium-Sized Heterocycles. 
 
tert-Butyl 5-(4-fluorobenzyl)-6-oxo-7-phenyl-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (217ac). This compound 
was synthesized according to Typical Procedure from 1-
phenylcycloprop-2-ene-1-carboxylic acid (169a) (200 mg, 1.25 mmol, 1.0 equiv.), and tert-butyl 
(2-((4-fluorobenzyl)amino)ethyl)carbamate (402 mg, 1.5 mmol, 1.2 equiv.). After extraction and 
filtration through a silica plug crude tert-butyl (2-(N-(4-fluorobenzyl)-1-phenylcycloprop-2-ene-
1-carboxamido)ethyl)carbamate (216ac) was used at the cyclization step as is without additional 
purification. To this end, amide 216ac (60 mg, 0.146 mmol) was treated with powdered KOH 
(20.5 mg, 0.365 mmol). The reaction mixture was vigorously stirred at 35 °C for 16 h. The product 
was isolated by column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless 
solid (Rf 0.26, mp 112-113 
oC). Yield: 53.3 mg (0.13 mmol, 89%). 1H NMR (500 MHz, C6D6) δ 
7.14 (d, J = 7.4 Hz, 2H), 7.09 (dd, J = 8.5, 6.7 Hz, 2H), 7.05–7.00 (m, 1H), 6.93 (dd, J = 8.4, 5.5 
Hz, 2H), 6.75 (t, J = 8.7 Hz, 2H), 4.34 (br.s, 1H), 4.20 (br.s, 1H), 3.51 (br.s, 1H), 3.37 (td, J = 13.2, 
4.1 Hz, 1H), 2.47 (dd, J = 7.1, 4.6 Hz, 1H), 2.44–2.37 (m, 2H), 1.95 (t, J = 5.6 Hz, 1H), 1.50 (t, J 
= 6.9 Hz, 1H), 1.41 (s, 9H). 13C NMR (126 MHz, C6D6) δ 169.9, 162.8 (d, J = 245.3 Hz), 156.5, 
139.2, 134.2 (d, J = 3.5 Hz), 130.1 (d, J = 8.1 Hz, +, 2C), 129.0 (+, 2C), 127.1 (+), 125.8 (+, 2C), 
115.6 (d, J = 21.3 Hz, +, 2C), 80.0, 48.9 (–), 44.5 (–), 43.5 (–), 37.3 (+), 36.3, 28.4 (+, 3C), 26.4 
(–). FTIR (NaCl, cm-1): 2976, 2929, 1701, 1650, 1509, 1365, 1346, 1222, 1146, 853, 765, 697. 
HRMS (TOF ES): found 433.1910, calculated for C24H27FN2O3Na (M + Na) 433.1903 (1.6 ppm). 
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tert-Butyl 5-(4-methoxybenzyl)-6-oxo-7-phenyl-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (217ab). This compound 
was synthesized according to Typical Procedure from 1-
phenylcycloprop-2-ene-1-carboxylic acid (169a) (200 mg, 1.25 mmol, 1.0 equiv.), and tert-butyl 
(2-((4-methoxybenzyl)amino)ethyl)carbamate (420 mg, 1.5 mmol, 1.2 equiv.). After extraction 
and filtration through a silica plug crude tert-butyl (2-(N-(4-methoxybenzyl)-1-phenylcycloprop-
2-ene-1-carboxamido)ethyl)carbamate (216ab) was used at the cyclization step as is without 
additional purification. To this end, amide 216ab (60 mg, 0.142 mmol) was treated with powdered 
KOH (19.9 mg, 0.355 mmol). The reaction mixture was vigorously stirred at 35 °C for 16 h. The 
product was isolated by column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a 
colorless solid (Rf 0.25, mp 134-136 
oC). Yield: 51.7 mg (0.122 mmol, 86%). 1H NMR (500 MHz, 
C6D6) δ 7.21–7.17 (m, 2H), 7.11 (dd, J = 8.5, 6.9 Hz, 2H), 7.09–7.05 (m, 2H), 7.05–6.99 (m, 1H), 
6.76–6.69 (m, 2H), 4.50 (br.s, 1H), 4.31 (br.s, 1H), 3.58 (br.s, 1H), 3.41 (td, J = 13.3, 4.1 Hz, 1H), 
3.32 (s, 3H), 2.59–2.51 (m, 1H), 2.48 (dd, J = 7.1, 4.7 Hz, 1H), 2.43 (dd, J = 12.8, 3.9 Hz, 1H), 
1.99 (t, J = 5.6 Hz, 1H), 1.53 (t, J = 6.8 Hz, 1H), 1.42 (s, 9H). 13C NMR (126 MHz, C6D6) δ 169.8, 
159.8, 156.5, 139.5, 130.4, 129.8 (+, 2C), 129.0(+, 2C), 127.0 (+), 125.8 (+, 2C), 114.5 (+, 2C), 
79.9, 54.8 (+), 49.1 (–), 44.6 (–), 43.3 (–), 37.5 (+), 36.4, 28.4 (+, 3C), 26.4 (–). FTIR (NaCl, cm-
1): 2974, 2923, 1701, 1651, 1513, 1393, 1248, 1146, 1032, 808, 760. HRMS (TOF ES): found 
445.2104, calculated for C25H30N2O4Na (M + Na) 445.2103 (0.2 ppm). 
 
tert-Butyl 5-benzyl-7-(3-bromophenyl)-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (217ga). This compound 
was synthesized according to Typical Procedure from 1-(3-
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bromophenyl)cycloprop-2-ene-1-carboxylic acid (169g) (200 mg, 0.84 mmol, 1.0 equiv.), and tert-
butyl (2-(benzylamino)ethyl)carbamate (251 mg, 1 mmol, 1.2 equiv.). After extraction and 
filtration through a silica plug crude tert-butyl (2-(N-benzyl-1-(3-bromophenyl)cycloprop-2-ene-
1-carboxamido)ethyl)carbamate (216ga) was used at the cyclization step as is without additional 
purification. To this end, amide 216ga (60 mg, 0.127 mmol) was treated with powdered KOH 
(17.9 mg, 0.319 mmol). The reaction mixture was vigorously stirred at 35 °C for 8 h. The product 
was isolated by column chromatography eluting with a hexanes/EtOAc mixture (1:1) as a colorless 
solid (Rf 0.4, mp 151-152 
oC). Yield: 54.6 mg (0.116 mmol, 91%). 1H NMR (500 MHz, C6D6) δ 
7.38 (t, J = 1.9 Hz, 1H), 7.19–7.13 (m, 2H), 7.13–7.01 (m, 5H), 6.73 (t, J = 7.9 Hz, 1H), 4.51 (br.s, 
1H), 4.16 (br.s, 1H), 3.51 (br.s, 1H), 3.20 (td, J = 13.4, 4.1 Hz, 1H), 2.48–2.37 (m, 1H), 2.33 (dd, 
J = 12.9, 4.0 Hz, 1H), 2.29 (dd, J = 7.1, 4.7 Hz, 1H), 1.91 (t, J = 5.7 Hz, 1H), 1.41 (s, 9H), 1.39–
1.35 (m, 1H). 13C NMR (126 MHz, C6D6) δ 169.2, 156.3, 141.9, 138.2, 130.5 (+), 130.2 (+), 128.9 
(+, 2C), 128.7 (+), 128.4 (+, 2C), 127.7 (+), 124.8 (+), 123.4, 80.0, 49.6 (–), 44.3 (–), 43.3 (–), 
37.3 (+), 36.0, 28.4 (+, 3C), 26.6 (–). FTIR (NaCl, cm-1): 2974, 2926, 1702, 1654, 1476, 1393, 
1366, 1344, 1249, 1147, 1062, 994, 777, 754, 697. HRMS (TOF ES): found 493.1109, calculated 
for C24H27BrN2O3Na (M + Na) 493.1103 (1.2 ppm). 
 
tert-Butyl 7-(3-bromophenyl)-5-(4-fluorobenzyl)-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (217gc). This 
compound was synthesized according to Typical Procedure from 
1-(3-bromophenyl)cycloprop-2-ene-1-carboxylic acid (169g) (200 mg, 0.84 mmol, 1.0 equiv.), 
and tert-butyl (2-((4-fluorobenzyl)amino)ethyl)carbamate (269 mg, 1 mmol, 1.2 equiv.). After 
extraction and filtration through a silica plug crude tert-butyl (2-(1-(3-bromophenyl)-N-(4-
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fluorobenzyl)cycloprop-2-ene-1-carboxamido)ethyl)carbamate (216gc) was used at the 
cyclization step as is without additional purification. To this end, amide 216gc (60 mg, 0.123 mmol) 
was treated with powdered KOH (17.2 mg, 0.307 mmol). The reaction mixture was vigorously 
stirred at 35 °C for 8 h. The product was isolated by column chromatography eluting with a 
hexanes/EtOAc mixture (1:1) as a colorless solid (Rf 0.4, mp 156-157 
oC). Yield: 54.1 mg (0.111 
mmol, 90%). 1H NMR (500 MHz, C6D6) δ 7.35 (t, J = 1.9 Hz, 1H), 7.19–7.13 (m, 1H), 7.01–6.96 
(m, 1H), 6.92 (dd, J = 8.4, 5.5 Hz, 2H), 6.80–6.71 (m, 3H), 4.31 (br. s, 1H), 4.11 (br. s, 1H), 3.46 
(br. s, 1H), 3.20 (ddd, J = 15.4, 13.4, 4.2 Hz, 1H), 2.42–2.31 (m, 2H), 2.29 (dd, J = 7.1, 4.7 Hz, 
1H), 1.88 (dd, J = 6.7, 4.7 Hz, 1H), 1.40 (s, 9H), 1.43–1.34 (m, 1H). 13C NMR (126 MHz, C6D6) 
δ 169.2, 162.8 (d, J = 246.0 Hz), 156.3, 141.8, 134.0 (d, J = 3.4 Hz), 130.5 (+), 130.3 (+), 130.1 
(d, J = 8.1 Hz, +, 2C), 128.7 (+), 124.7 (+), 123.4, 115.7 (d, J = 21.3 Hz, +, 2C), 80.1, 48.9 (–), 
44.3 (–), 43.4 (–), 37.3 (+), 35.9, 28.4 (+, 3C), 26.5 (–). FTIR (NaCl, cm-1): 2977, 2931, 1701, 
1652, 1594, 1509, 1477, 1412, 1394, 1344, 1249, 1222, 1201, 1148, 1063, 994, 854, 816, 778, 736, 
693. HRMS (TOF ES): found 511.1001, calculated for C24H26BrFN2O3Na (M + Na) 511.1009 (1.6 
ppm). 
 
tert-Butyl 5-(4-methoxybenzyl)-7-(4-methoxyphenyl)-6-oxo-
2,5-diazabicyclo[5.1.0]octane-2-carboxylate (217eb). This 
compound was synthesized according to Typical Procedure 
from 1-(4-methoxyphenyl)cycloprop-2-ene-1-carboxylic acid 
(169e) (200 mg, 1.05 mmol, 1.0 equiv.), and tert-butyl (2-((4-
methoxybenzyl)amino)ethyl)carbamate (354 mg, 1.26 mmol, 1.2 equiv.). After extraction and 
filtration through a silica plug crude tert-butyl (2-(N-(4-methoxybenzyl)-1-(4-
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methoxyphenyl)cycloprop-2-ene-1-carboxamido)ethyl)carbamate (216eb) was used at the 
cyclization step as is without additional purification. To this end, amide 216eb (60 mg, 0.133 mmol) 
was treated with powdered KOH (18.6 mg, 0.332 mmol). The reaction mixture was vigorously 
stirred at 35 °C for 16 h. The product was isolated by column chromatography eluting with a 
hexanes/EtOAc mixture (1:1) as a colorless glass (Rf 0.43). Yield: 55.9 mg (0.123 mmol, 93%). 
1H NMR (500 MHz, C6D6) δ 7.19–7.16 (m, 2H), 7.07 (d, J = 8.5 Hz, 2H), 6.78–6.70 (m, 4H), 4.57 
(br.s, 1H), 4.26 (br.s, 1H), 3.63 (br.s, 1H), 3.51 (td, J = 13.4, 3.9 Hz, 1H), 3.31 (s, 3H), 3.31 (s, 
3H), 2.62–2.54 (m, 1H), 2.51–2.46 (m, 2H), 1.97 (t, J = 5.5 Hz, 1H), 1.51 (t, J = 6.8 Hz, 1H), 1.43 
(s, 9H). 13C NMR (126 MHz, C6D6) δ 170.1, 159.7, 159.3, 156.6, 131.3, 130.4, 129.7 (+, 2C), 
127.3 (+, 2C), 114.7 (+, 2C), 114.5 (+, 2C), 79.8, 54.9 (+), 54.8 (+), 49.0 (–), 44.6 (–), 43.3 (–), 
36.9 (+), 36.0, 28.5 (+, 3C), 26.1 (–). FTIR (NaCl, cm-1): 2926, 1700, 1649, 1514, 1393, 1248, 
1176, 1146, 1032, 829, 784. HRMS (TOF ES): found 475.2213, calculated for C26H32N2O5Na (M 
+ Na) 475.2209 (0.8 ppm). 
 
tert-Butyl 5-ethyl-6-oxo-7-phenyl-2,5-diazabicyclo[5.1.0]octane-2-
carboxylate (217ae). This compound was synthesized according to Typical 
Procedure from 1-phenylcycloprop-2-ene-1-carboxylic acid (217a) (200 mg, 
1.25 mmol, 1.0 equiv.), and tert-butyl (2-(ethylamino)ethyl)carbamate (282 mg, 1.5 mmol, 1.2 
equiv.). After extraction and filtration through a silica plug crude tert-butyl (2-(N-ethyl-1-
phenylcycloprop-2-ene-1-carboxamido)ethyl)carbamate (216ae) was used at the cyclization step 
as is without additional purification. To this end, amide 216ae (60 mg, 0.182 mmol) was treated 
with powdered KOH (25.5 mg, 0.455 mmol). The reaction mixture was vigorously stirred at 35 °C 
for 8 h. The product was isolated by column chromatography eluting with a hexanes/EtOAc 
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mixture (2:1) as a colorless glass (Rf 0.43). Yield: 51.1 mg (0.155 mmol, 85%). 
1H NMR (500 
MHz, C6D6) δ 7.15–7.07 (m, 4H), 7.04–6.99 (m, 1H), 3.80 (br.t, J = 10.8 Hz, 1H), 3.42–3.28 (m, 
2H), 3.01 (dq, J = 14.1, 7.1 Hz, 1H), 2.56–2.48 (m, 1H), 2.46 (dd, J = 7.1, 4.6 Hz, 1H), 2.30 (dd, 
J = 15.2, 4.6 Hz, 1H), 1.92 (t, J = 5.7 Hz, 1H), 1.48 (t, J = 6.9 Hz, 1H), 1.41 (s, 9H), 0.87 (t, J = 
7.1 Hz, 3H). 13C NMR (126 MHz, C6D6) δ 169.1, 156.6, 139.6, 128.9 (+, 2C), 126.9 (+), 125.7 (+, 
2C), 79.9, 45.0 (–), 43.6 (–), 41.3 (–), 37.7 (+), 36.5, 28.5 (+, 3C), 26.3 (–), 13.5 (+). FTIR (NaCl, 
cm-1): 2973, 2926, 1699, 1652, 1429, 1366, 1346, 1175, 1146, 1065, 757, 697, 614. HRMS (TOF 
ES): found 353.1836, calculated for C19H26N2O3Na (M + Na) 353.1841 (1.4 ppm). 
 
tert-Butyl 7-(3-bromophenyl)-5-ethyl-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (217ge). This compound was 
synthesized according to Typical Procedure from 1-(3-
bromophenyl)cycloprop-2-ene-1-carboxylic acid (169g) (200 mg, 0.84 mmol, 1.0 equiv.), and tert-
butyl (2-(ethylamino)ethyl)carbamate (190 mg, 1 mmol, 1.2 equiv.). After extraction and filtration 
through a silica plug crude tert-butyl (2-(1-(3-bromophenyl)-N-ethylcycloprop-2-ene-1-
carboxamido)ethyl)carbamate (216ge) was used at the cyclization step as is without additional 
purification. To this end, amide 216ge (60 mg, 0.147 mmol) was treated with powdered KOH 
(20.6 mg, 0.367 mmol). The reaction mixture was vigorously stirred at 35 °C for 8 h. The product 
was isolated by column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless 
glass (Rf 0.4). Yield: 52.2 mg (0.128 mmol, 87%). 
1H NMR (400 MHz, C6D6) δ 7.30 (t, J = 1.9 
Hz, 1H), 7.16–7.11 (m, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.70 (t, J = 7.9 Hz, 1H), 3.73 (br.s, 1H), 
3.36–3.20 (m, 1H), 3.16–3.07 (m, 1H), 2.86 (br.s, 1H), 2.40 (dd, J = 13.0, 4.0 Hz, 1H), 2.23 (dd, 
J = 7.2, 4.7 Hz, 1H), 2.15 (dd, J = 15.4, 4.5 Hz, 1H), 1.85 (br.s, 1H), 1.39 (s, 9H), 1.42–1.33 (m, 
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1H), 0.80 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, C6D6) δ 168.5, 156.4, 142.1, 130.5 (+), 130.1 
(+), 128.5 (+), 124.9 (+), 123.3, 80.1, 44.8 (–), 43.5 (–), 41.4 (–), 37.4 (+), 36.2, 28.4 (+, 3C), 26.3, 
13.4 (+). FTIR (NaCl, cm-1): 2973, 2928, 1701, 1652, 1477, 1394, 1366, 1344, 1249, 1147, 856, 
778, 694. HRMS (TOF ES): found 431.0953, calculated for C19H25BrN2O3Na (M + Na) 431.0946 
(1.6 ppm). 
 
tert-Butyl 5-ethyl-7-(4-fluorophenyl)-6-oxo-2,5-diazabicyclo[5.1.0]octane-2-
carboxylate (217be). This compound was synthesized according to Typical 
Procedure from 1-(4-fluorophenyl)cycloprop-2-ene-1-carboxylic acid (217b) 
(200 mg, 1.12 mmol, 1.0 equiv.), and tert-butyl (2-
(ethylamino)ethyl)carbamate (256 mg, 1.35 mmol, 1.2 equiv.). After extraction and filtration 
through a silica plug crude tert-butyl (2-(N-ethyl-1-(4-fluorophenyl)cycloprop-2-ene-1-
carboxamido)ethyl)carbamate (216be) was used at the cyclization step as is without additional 
purification. To this end, amide 216be (60 mg, 0.172 mmol) was treated with powdered KOH 
(24.2 mg, 0.431 mmol). The reaction mixture was vigorously stirred at 35 °C for 8 h. The product 
was isolated by column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless 
solid (Rf 0.45, mp 146-148 
oC). Yield: 52.2 mg (0.15 mmol, 87%). 1H NMR (500 MHz, C6D6) δ 
6.98–6.93 (m, 2H), 6.78–6.71 (m, 2H), 3.87–3.72 (m, 1H), 3.34–3.25 (m, 2H), 2.98 (dq, J = 14.1, 
7.1 Hz, 1H), 2.53 (dd, J = 13.0, 4.0 Hz, 1H), 2.35 (dd, J = 7.1, 4.6 Hz, 1H), 2.30 (dd, J = 15.3, 5.0 
Hz, 1H), 1.85 (t, J = 5.6 Hz, 1H), 1.41 (s, 9H), 1.35 (t, J = 6.8 Hz, 1H), 0.84 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, C6D6) δ 169.0, 162.3 (d, J = 246.0 Hz), 156.6, 135.2 (d, J = 3.6 Hz), 127.5 
(d, J = 8.1 Hz, +, 2C), 115.7 (d, J = 21.7 Hz, +, 2C), 80.0, 45.0 (–), 43.5 (–), 41.4 (–), 37.3 (+), 
35.9, 28.5 (+, 3C), 26.1 (–), 13.5 (+). FTIR (NaCl, cm-1): 2975, 2932, 1699, 1651, 1512, 1476, 
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1395, 1366, 1345, 1250, 1234, 1148, 1064, 834, 778. HRMS (TOF ES): found 371.1756, 
calculated for C19H25FN2O3Na (M + Na) 371.1747 (2.4 ppm). 
 
tert-Butyl 7-(3-bromophenyl)-5-isobutyl-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (217gf). This compound was 
synthesized according to Typical Procedure from 1-(3-
bromophenyl)cycloprop-2-ene-1-carboxylic acid (169g) (200 mg, 0.84 mmol, 1.0 equiv.), and tert-
butyl (2-(isobutylamino)ethyl)carbamate (217 mg, 1 mmol, 1.2 equiv.). After extraction and 
filtration through a silica plug crude tert-butyl (2-(1-(3-bromophenyl)-N-isobutylcycloprop-2-ene-
1-carboxamido)ethyl)carbamate (216ge) was used at the cyclization step as is without additional 
purification. To this end, amide 216ge (60 mg, 0.137 mmol) was treated with powdered KOH 
(19.2 mg, 0.342 mmol). The reaction mixture was vigorously stirred at 35 °C for 8 h. The product 
was isolated by column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless 
solid (Rf 0.48, mp 122-123 
oC). Yield: 56.5 mg (0.129 mmol, 94%). 1H NMR (500 MHz, C6D6) δ 
7.39 (t, J = 1.9 Hz, 1H), 7.18–7.15 (m, 1H), 7.06 (d, J = 7.9 Hz, 1H), 6.76 (t, J = 7.9 Hz, 1H), 3.77 
(br.t, J = 10.3 Hz, 1H), 3.33–3.20 (m, 2H), 2.65 (dd, J = 13.4, 8.2 Hz, 1H), 2.51–2.43 (m, 1H), 
2.37–2.29 (m, 2H), 1.84 (t, J = 5.7 Hz, 1H), 1.67 (dh, J = 8.1, 6.7 Hz, 1H), 1.41 (s, 9H), 1.33 (t, J 
= 7.1 Hz, 1H), 0.75 (dd, J = 6.7, 1.1 Hz, 6H). 13C NMR (126 MHz, C6D6) δ 169.1, 156.4, 142.1, 
130.5 (+), 130.1 (+), 128.7 (+), 124.8 (+), 123.3, 80.1, 53.8 (–), 44.5 (–), 44.4 (–), 37.2 (+), 36.4, 
28.4 (+, 3C), 28.0 (+), 26.6 (–), 20.3 (+), 20.1 (+). FTIR (NaCl, cm-1): 2964, 2928, 2871, 1702, 
1652, 1593, 1562, 1477, 1428, 1367, 1345, 1297, 1248, 1247, 1175, 1062, 856, 777, 693, 664. 
HRMS (TOF ES): found 459.1263, calculated for C21H29BrN2O3Na (M + Na) 459.1259 (0.9 ppm). 
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tert-Butyl 8-(3-bromophenyl)-6-(4-fluorobenzyl)-7-oxo-2,6-
diazabicyclo[6.1.0]nonane-2-carboxylate (217gh). This 
compound was synthesized according to Typical Procedure from 
1-(3-bromophenyl)cycloprop-2-ene-1-carboxylic acid (217g) (200 mg, 0.84 mmol, 1.0 equiv.), 
and tert-butyl (3-((4-fluorobenzyl)amino)propyl)carbamate (283 mg, 1 mmol, 1.2 equiv.). After 
extraction and filtration through a silica plug crude tert-butyl (3-(1-(3-bromophenyl)-N-(4-
fluorobenzyl)cycloprop-2-ene-1-carboxamido)propyl)carbamate (216gh) was used at the 
cyclization step as is without additional purification. To this end, amide 217gh (60 mg, 0.119 
mmol) was treated with powdered KOH (16.7 mg, 0.298 mmol). The reaction mixture was 
vigorously stirred at 35 °C for 8 h. The product was isolated by column chromatography eluting 
with a hexanes/EtOAc mixture (3:1) as a colorless solid (Rf 0.27, mp 119-121 
oC). Yield: 54.1 mg 
(0.107 mmol, 90%). 1H NMR (500 MHz, C6D6) δ 7.32 (s, 1H), 7.11 (d, J = 7.1 Hz, 1H), 6.97 (dd, 
J = 8.1, 5.7 Hz, 2H), 6.86 (d, J = 7.9 Hz, 1H), 6.79 (t, J = 8.6 Hz, 2H), 6.68 (t, J = 7.9 Hz, 1H), 
5.01 (d, J = 14.6 Hz, 1H), 3.86 (d, J = 14.3 Hz, 1H), 3.59 (d, J = 14.6 Hz, 1H), 3.28 (dd, J = 15.5, 
11.2 Hz, 1H), 2.80–2.69 (m, 2H), 2.51 (dd, J = 15.5, 5.9 Hz, 1H), 2.41 (ddd, J = 14.6, 11.5, 3.2 
Hz, 1H), 1.68–1.56 (m, 1H), 1.43 (s, 9H), 1.19 (dd, J = 8.5, 6.6 Hz, 1H), 0.92–0.82 (m, 1H). 13C 
NMR (126 MHz, C6D6) δ 169.2, 162.8 (d, J = 245.3 Hz), 155.2, 143.3, 134.2 (d, J = 3.5 Hz), 130.5 
(+), 130.3 (d, J = 8.1 Hz, +, 2C), 129.9 (+), 128.7 (+), 124.2 (+), 123.5, 115.7 (d, J = 21.1 Hz, +, 
2C), 80.2, 50.3 (–), 48.7 (–), 46.6 (+), 46.2 (–), 37.0, 28.5 (+, 3C), 27.6 (–), 25.2 (–). FTIR (NaCl, 
cm-1): 2973, 2925, 1692, 1639, 1593, 1562, 1509, 1477, 1414, 1383, 1367, 1256, 1221, 1154, 1107, 
969, 858, 819, 769, 689. HRMS (TOF ES): found 525.1165, calculated for C25H28BrFN2O3Na (M 
+ Na) 525.1165 (0.0 ppm). 
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tert-Butyl 6-oxo-7-phenyl-5-(pyridin-2-ylmethyl)-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (217ag). This compound was 
synthesized according to Typical Procedure from 1-phenylcycloprop-2-
ene-1-carboxylic acid (169a) (200 mg, 1.25 mmol, 1.0 equiv.), and tert-butyl (2-((pyridin-2-
ylmethyl)amino)ethyl)carbamate (377 mg, 1.5 mmol, 1.2 equiv.). After extraction and filtration 
through a silica plug crude tert-butyl (2-(1-phenyl-N-(pyridin-2-ylmethyl)cycloprop-2-ene-1-
carboxamido)ethyl)carbamate (216ag) was used at the cyclization step as is without additional 
purification. To this end, amide 216ag (60 mg, 0.152 mmol) was treated with powdered KOH 
(21.4 mg, 0.381 mmol). The reaction mixture was vigorously stirred at 35 °C for 8 h. The product 
was isolated by column chromatography eluting with a hexanes/EtOAc mixture (1:2) as a colorless 
glass (Rf 0.31). Yield: 48.6 mg (0.123 mmol, 81%). 
1H NMR (500 MHz, C6D6) δ 8.37 (d, J = 4.8 
Hz, 1H), 7.16 (s, 4H), 7.12–6.98 (m, 3H), 6.66–6.59 (m, 1H), 4.65 (br.s, 2H), 3.65 (br.s, 1H), 3.51 
(td, J = 14.8, 14.2, 3.8 Hz, 1H), 2.88 (dd, J = 15.2, 4.9 Hz, 1H), 2.47–2.38 (m, 2H), 1.94 (t, J = 5.6 
Hz, 1H), 1.53 (t, J = 6.8 Hz, 1H), 1.39 (s, 9H). 13C NMR (126 MHz, C6D6) δ 169.8, 158.4, 159.4, 
149.3 (+), 139.4, 136.4 (+), 128.9 (+, 2C), 128.1, 126.9 (+), 125.8 (+, 2C), 122.8 (+), 122.3 (+), 
79.8, 52.2 (–), 44.6 (–), 44.6 (–), 37.7 (+), 36.2, 28.4 (+, 3C), 26.3 (–). FTIR (NaCl, cm-1): 2961, 
2924, 2854, 1700, 1654, 1591, 1474, 1435, 1394, 1366, 1345, 1251, 1146, 1066, 756, 698, 610. 
HRMS (TOF ES): found 416.1958, calculated for C23H27N3O3Na (M + Na) 416.195 (1.9 ppm). 
 
tert-Butyl 6-benzyl-7-oxo-8-phenyl-2,6-diazabicyclo[6.1.0]nonane-2-
carboxylate (217ah). This compound was synthesized according to 
Typical Procedure from 1-phenylcycloprop-2-ene-1-carboxylic acid (H-
acid) (200 mg, 1.25 mmol, 1.0 equiv.), and tert-butyl (3-(benzylamino)propyl)carbamate (396 mg, 
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1.5 mmol, 1.2 equiv.). After extraction and filtration through a silica plug crude tert-butyl (3-(N-
benzyl-1-phenylcycloprop-2-ene-1-carboxamido)propyl)carbamate (216ah) was used at the 
cyclization step as is without additional purification. To this end, amide 216ah (60 mg, 0.148 
mmol) was treated with powdered KOH (20.7 mg, 0.369 mmol). The reaction mixture was 
vigorously stirred at 35 °C for 8 h. The product was isolated by column chromatography eluting 
with a hexanes/EtOAc mixture (2:1) as a colorless solid (Rf 0.21, mp 110-112 
oC). Yield: 50.5 mg 
(0.124 mmol, 84%). 1H NMR (500 MHz, C6D6) δ 7.18–7.16 (m, 4H), 7.13–6.98 (m, 6H), 5.19 (d, 
J = 14.7 Hz, 1H), 3.89 (br.d, J = 14.6 Hz, 1H), 3.84 (d, J = 14.7 Hz, 1H), 3.54 (dd, J = 15.3, 11.5 
Hz, 1H), 3.03 (dd, J = 8.8, 6.0 Hz, 1H), 2.80–2.75 (m, 1H), 2.65 (dd, J = 15.4, 5.6 Hz, 1H), 2.59 
(ddd, J = 14.4, 11.3, 3.2 Hz, 1H), 1.76–1.65 (m, 1H), 1.46 (s, 9H), 1.33 (dd, J = 8.8, 6.7 Hz, 1H), 
0.98–0.89 (m, 1H). 13C NMR (126 MHz, C6D6) δ 170.0, 155.3, 140.9, 138.7, 129.0 (+, 2C), 128.8 
(+, 2C), 128.6 (+, 2C), 127.5 (+), 126.7 (+), 125.9 (+, 2C), 80.0, 49.9 (–), 49.4 (–), 46.2 (+), 46.1 
(–), 37.5, 28.5 (+, 3C), 27.6 (–), 24.8 (–). FTIR (NaCl, cm-1): 2925, 2854, 1692, 1640, 1631, 1585, 
1470, 1453, 1416, 1383, 1366, 1288, 1253, 1156, 1105, 1051, 939, 860, 788, 732, 699. HRMS 
(TOF ES): found 429.2164, calculated for C25H30N2O3Na (M + Na) 429.2154 (2.3 ppm). 
 
tert-Butyl 6-benzyl-8-(2,4-dichlorophenyl)-7-oxo-2,6-
diazabicyclo[6.1.0]nonane-2-carboxylate (217ch). This compound 
was synthesized according to Typical Procedure from 1-(2,4-
dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (169c) (200 mg, 0.87 mmol, 1.0 equiv.), and 
tert-butyl (3-(benzylamino)propyl)carbamate (278 mg, 1.05 mmol, 1.2 equiv.). After extraction 
and filtration through a silica plug crude tert-butyl (3-(N-benzyl-1-(2,4-dichlorophenyl)cycloprop-
2-ene-1-carboxamido)propyl)carbamate (216ch) was used at the cyclization step as is without 
194 
 
additional purification. To this end, amide 216ch (60 mg, 0.126 mmol) was treated with powdered 
KOH (17.7 mg, 0.316 mmol). The reaction mixture was vigorously stirred at 35 °C for 8 h. The 
product was isolated by column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a 
colorless solid (Rf 0.24, mp 118-120 
oC). Yield: 51.5 mg (0.108 mmol, 86%). 1H NMR (500 MHz, 
C6D6) δ 7.48 (d, J = 8.5 Hz, 1H), 7.12 (d, J = 2.3 Hz, 1H), 7.04–6.93 (m, 5H), 6.84 (dd, J = 8.4, 
2.2 Hz, 1H), 5.01 (d, J = 14.9 Hz, 1H), 4.11 (t, J = 13.6 Hz, 1H), 3.88–3.73 (m, 2H), 3.20–3.06 
(m, 2H), 2.71–2.63 (m, 1H), 2.30 (t, J = 6.5 Hz, 1H), 1.47 (s, 9H), 1.39–1.31 (m, 1H), 1.12 (dd, J 
= 8.9, 6.5 Hz, 1H), 0.99–0.85 (m, 1H). 13C NMR (126 MHz, C6D6) δ 169.7, 155.3, 138.4, 137.4, 
135.2, 134.2 (+), 134.0, 130.4 (+), 128.8 (+, 2C), 128.2 (+, 2C), 127.5 (+), 127.5 (+), 80.2, 49.9 
(–), 45.2 (+), 44.7 (–), 44.0 (–), 35.7, 28.5 (+, 3C), 27.8 (–), 21.3 (–). FTIR (NaCl, cm-1): 2972, 
2925, 2854, 1690, 1639, 1477, 1454, 1423, 1383, 1366, 1292, 1255, 1159, 1106, 1078, 1059, 968, 
860, 750, 733, 699, 602. HRMS (TOF ES): found 497.1382, calculated for C25H28Cl2N2O3Na (M 
+ Na) 497.1375 (1.4 ppm). 
 
tert-Butyl 6-benzyl-8-(3-bromophenyl)-7-oxo-2,6-
diazabicyclo[6.1.0]nonane-2-carboxylate (217gh). This compound 
was synthesized according to Typical Procedure from 1-(3-
bromophenyl)cycloprop-2-ene-1-carboxylic acid (169g) (200 mg, 0.84 mmol, 1.0 equiv.), and tert-
butyl (3-(benzylamino)propyl)carbamate (267 mg, 1 mmol, 1.2 equiv.). After extraction and 
filtration through a silica plug crude tert-butyl (3-(N-benzyl-1-(3-bromophenyl)cycloprop-2-ene-
1-carboxamido)propyl)carbamate (216gh) was used at the cyclization step as is without additional 
purification. To this end, amide 216gh (60 mg, 0.124 mmol) was treated with powdered KOH 
(17.3 mg, 0.308 mmol). The reaction mixture was vigorously stirred at 35 °C for 8 h. The product 
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was isolated by column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless 
solid (Rf 0.24, mp 121-123 
oC). Yield: 49.8 mg (0.103 mmol, 83%). 1H NMR (500 MHz, C6D6) δ 
7.39 (s, 1H), 7.16–7.11 (m, 5H), 7.06 (t, J = 6.7 Hz, 1H), 6.94 (d, J = 7.9 Hz, 1H), 6.71 (t, J = 7.9 
Hz, 1H), 5.19 (d, J = 14.7 Hz, 1H), 3.87 (br.d, J = 14.3 Hz, 1H), 3.73 (d, J = 14.7 Hz, 1H), 3.32 
(dd, J = 15.5, 11.1 Hz, 1H), 2.80 (dd, J = 8.3, 6.3 Hz, 1H), 2.75 (t, J = 6.3 Hz, 1H), 2.61 (dd, J = 
15.2, 5.7 Hz, 1H), 2.43 (ddd, J = 14.4, 11.6, 3.0 Hz, 1H), 1.73–1.61 (m, 1H), 1.45 (s, 9H), 1.21 
(dd, J = 8.6, 6.7 Hz, 1H), 0.92–0.84 (m, 1H). 13C NMR (126 MHz, C6D6) δ 169.2, 155.2, 143.4, 
138.4, 130.5 (+), 129.9 (+), 128.9 (+, 2C), 128.7 (+), 128.6 (+, 2C), 127.6 (+), 124.3 (+), 123.4, 
80.2, 50.2 (–), 49.4 (–), 46.6 (+), 46.1 (–), 37.1, 28.5 (+, 3C), 27.5 (–), 25.3 (–). FTIR (NaCl, cm-
1): 2972, 2925, 1691, 1639, 1593, 1561, 1476, 1454, 1418, 1383, 1366, 1282, 1256, 1158, 1106, 
1078, 968, 860, 768, 752, 700. HRMS (TOF ES): found 507.1255, calculated for C25H29BrN2O3Na 
(M + Na) 507.1259 (0.8 ppm). 
 
tert-Butyl 5-methyl-6-oxo-7-phenyl-2,5-diazabicyclo[5.1.0]octane-2-
carboxylate (217ad). This compound was synthesized according to Typical 
Procedure from 1-phenylcycloprop-2-ene-1-carboxylic acid (169a) (200 mg, 1.25 
mmol, 1.0 equiv.), and tert-butyl (2-(methylamino)ethyl)carbamate (261 mg, 1.5 mmol, 1.2 equiv.). 
After extraction and filtration through a silica plug crude tert-butyl (2-(N-methyl-1-
phenylcycloprop-2-ene-1-carboxamido)ethyl)carbamate (216ad) was used at the cyclization step 
as is without additional purification. To this end, amide 216ad (60 mg, 0.19 mmol) was treated 
with powdered KOH (26.6 mg, 0.474 mmol). The reaction mixture was vigorously stirred at 35 °C 
for 8 h. The product was isolated by column chromatography eluting with a hexanes/EtOAc 
mixture (2:1) as a colorless solid (Rf 0.42, mp 188-189 
oC). Yield: 54.6 mg (0.173 mmol, 91%). 
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1H NMR (500 MHz, C6D6) δ 7.15–7.06 (m, 4H), 7.03 (dd, J = 8.1, 6.0 Hz, 1H), 3.79 (br.t, J = 11.4 
Hz, 1H), 3.43 (ddd, J = 15.5, 13.7, 3.7 Hz, 1H), 2.58 (s, 3H), 2.52–2.43 (m, 2H), 2.17 (dd, J = 15.4, 
4.7 Hz, 1H), 1.87 (t, J = 5.3 Hz, 1H), 1.46 (t, J = 6.7 Hz, 1H), 1.41 (s, 9H). 13C NMR (126 MHz, 
C6D6) δ 169.5, 156.7, 139.5, 128.9 (+, 2C), 127.0 (+), 125.9 (+, 2C), 80.0, 45.5 (–), 43.6 (–), 37.3 
(+), 36.4, 33.3 (+), 28.5 (+, 3C), 26.3 (–). FTIR (NaCl, cm-1): 2974, 2928, 1698, 1655, 1479, 1432, 
1396, 1357, 1345, 1251, 1175, 1146, 1067, 856, 775, 758, 698, 615. HRMS (TOF ES): found 
339.1696, calculated for C18H24N2O3Na (M + Na) 339.1685 (3.2 ppm). 
 
tert-Butyl 7-(3-bromophenyl)-5-methyl-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (217gd). This compound was 
synthesized according to Typical Procedure from 1-(3-
bromophenyl)cycloprop-2-ene-1-carboxylic acid (169g) (200 mg, 0.84 mmol, 1.0 equiv.), and tert-
butyl (2-(methylamino)ethyl)carbamate (175 mg, 1 mmol, 1.2 equiv.). After extraction and 
filtration through a silica plug crude tert-butyl (2-(1-(3-bromophenyl)-N-methylcycloprop-2-ene-
1-carboxamido)ethyl)carbamate (216gd) was used at the cyclization step as is without additional 
purification. To this end, amide 216gd (60 mg, 0.152 mmol) was treated with powdered KOH 
(21.3 mg, 0.38 mmol). The reaction mixture was vigorously stirred at 35 °C for 8 h. The product 
was isolated by column chromatography eluting with a hexanes/EtOAc mixture (1:1) as a colorless 
solid (Rf 0.39, mp 115-117 
oC). Yield: 54.1 mg (0.137 mmol, 90%). 1H NMR (500 MHz, C6D6) δ 
7.36–7.31 (m, 1H), 7.19–7.15 (m, 1H), 7.06 (d, J = 7.9 Hz, 1H), 6.75 (t, J = 7.9 Hz, 1H), 3.72 (br.t, 
J = 10.6 Hz, 1H), 3.34–3.23 (m, 1H), 2.52 (s, 3H), 2.42 (dd, J = 13.1, 3.8 Hz, 1H), 2.33–2.28 (m, 
1H), 2.13 (dd, J = 15.3, 4.4 Hz, 1H), 1.80 (t, J = 5.6 Hz, 1H), 1.40 (s, 9H), 1.31 (t, J = 7.0 Hz, 1H). 
13C NMR (126 MHz, C6D6) δ 168.9, 156.6, 142.0, 130.5 (+), 130.2 (+), 128.6 (+), 125.1 (+), 123.3, 
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80.1, 45.4 (–), 43.5 (–), 37.0 (+), 36.1, 33.3 (+), 28.4 (+, 3C), 26.4 (–). FTIR (NaCl, cm-1): 2974, 
2928, 1699, 1657, 1593, 1563, 1478, 1394, 1356, 1342, 1250, 1174, 1147, 1082, 1054, 856, 778, 
695, 664. HRMS (TOF ES): found 417.0786, calculated for C18H23BrN2O3Na (M + Na) 417.0790 
(1.0 ppm). 
 
tert-Butyl 7-(2,4-dichlorophenyl)-5-methyl-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (216cd). This compound was 
synthesized according to Typical Procedure from 1-(2,4-
dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (169c) (200 mg, 0.87 mmol, 
1.0 equiv.), and tert-butyl (2-(methylamino)ethyl)carbamate (183 mg, 1.05 mmol, 1.2 equiv.). 
After extraction and filtration through a silica plug crude tert-butyl (2-(1-(2,4-dichlorophenyl)-N-
methylcycloprop-2-ene-1-carboxamido)ethyl)carbamate (216cd) was used at the cyclization step 
as is without additional purification. To this end, amide 216cd (60 mg, 0.156 mmol) was treated 
with powdered KOH (21.8 mg, 0.389 mmol). The reaction mixture was vigorously stirred at 35 °C 
for 8 h. The product was isolated by column chromatography eluting with a hexanes/EtOAc 
mixture (1:1) as a colorless solid (Rf 0.42, mp 180-181 
oC). Yield: 52.2 mg (0.136 mmol, 87%). 
1H NMR (500 MHz, C6D6) δ 7.48 (d, J = 8.5 Hz, 1H), 7.12 (d, J = 2.0 Hz, 1H), 6.85 (dd, J = 8.5, 
2.0 Hz, 1H), 4.16–4.06 (m, 1H), 3.82 (br.t, J = 11.7 Hz, 1H), 2.99–2.95 (m, 1H), 2.78–2.72 (m, 
1H), 2.48 (s, 3H), 2.27 (dd, J = 15.4, 4.4 Hz, 1H), 1.73 (br.s, 1H), 1.40 (s, 9H), 1.27 (br.s, 1H). 13C 
NMR (126 MHz, C6D6) δ 168.7, 156.6, 135.3, 134.8, 134.4 (+), 134.0, 130.7 (+), 127.4 (+), 80.1, 
45.3 (–), 43.8 (–), 36.0 (+), 35.6, 34.2 (+), 28.4 (+, 3C), 26.3 (–). FTIR (NaCl, cm-1): 2974, 2929, 
1700, 1656, 1474, 1428, 1380, 1366, 1277, 1253, 1174, 1145, 1107, 1079, 858, 829, 781. HRMS 
(TOF ES): found 407.0921, calculated for C18H22Cl2N2O3Na (M + Na) 407.0905 (3.9 ppm). 
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tert-Butyl 5-benzyl-6-oxo-7-phenyl-2,5-diazabicyclo[5.1.0]octane-2-
carboxylate (217aa). This compound was synthesized according to 
Typical Procedure from 1-phenylcycloprop-2-ene-1-carboxylic acid 
(169a) (200 mg, 1.25 mmol, 1.0 equiv.), and tert-butyl (2-(benzylamino)ethyl)carbamate (375 mg, 
1.5 mmol, 1.2 equiv.). After extraction and filtration through a silica plug crude tert-butyl (2-(N-
benzyl-1-phenylcycloprop-2-ene-1-carboxamido)ethyl)carbamate (216aa) was used at the 
cyclization step as is without additional purification. To this end, amide 216aa (60 mg, 0.153 mmol) 
was treated with powdered KOH (21.4 mg, 0.381 mmol). The reaction mixture was vigorously 
stirred at 35 °C for 8 h. The product was isolated by column chromatography eluting with a 
hexanes/EtOAc mixture (3:1) as a colorless solid (Rf 0.3, mp 103-105 
oC). Yield: 51.7 mg (0.132 
mmol, 86%). 1H NMR (500 MHz, C6D6) δ 7.19–7.14 (m, 3H), 7.14–7.06 (m, 5H), 7.08–7.00 (m, 
2H), 4.53 (br.s, 1H), 4.29 (br.s, 1H), 3.56 (br.s, 1H), 3.39 (td, J = 13.4, 4.0 Hz, 1H), 2.54–2.45 (m, 
2H), 2.41 (dd, J = 12.8, 3.9 Hz, 1H), 1.97 (t, J = 5.6 Hz, 1H), 1.52 (t, J = 6.9 Hz, 1H), 1.42 (s, 9H). 
13C NMR (126 MHz, C6D6) δ 169.9, 156.5, 139.4, 138.4, 129.0 (+, 2C), 128.9 (+, 2C), 128.4 (+, 
2C), 127.6 (+), 127.0 (+), 125.8 (+, 2C), 79.9, 49.6 (–), 44.5 (–), 43.4 (–), 37.4 (+), 36.4, 28.4 (+, 
3C), 26.5 (–). FTIR (NaCl, cm-1): 2975, 2928, 1701, 1652, 1496, 1470, 1425, 1394, 1366, 1346, 
1250, 1146, 1065, 1029, 987, 856, 811, 750, 698, 632, 606. HRMS (TOF ES): found 415.2008, 
calculated for C24H28N2O3Na (M + Na) 415.1998 (2.4 ppm). 
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tert-Butyl 5-benzyl-7-(2,4-dichlorophenyl)-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (217ca). This compound was 
synthesized according to Typical Procedure from 1-(2,4-
dichlorophenyl)cycloprop-2-ene-1-carboxylic acid (169c) (200 mg, 
0.87 mmol, 1.0 equiv.), and tert-butyl (2-(benzylamino)ethyl)carbamate (262 mg, 1.05 mmol, 1.2 
equiv.). After extraction and filtration through a silica plug crude tert-butyl (2-(N-benzyl-1-(2,4-
dichlorophenyl)cycloprop-2-ene-1-carboxamido)ethyl)carbamate (216ca) was used at the 
cyclization step as is without additional purification. To this end, amide 216ca (60 mg, 0.13 mmol) 
was treated with powdered KOH (18.2 mg, 0.324 mmol). The reaction mixture was vigorously 
stirred at 35 °C for 8 h. The product was isolated by column chromatography eluting with a 
hexanes/EtOAc mixture (3:1) as a colorless solid (Rf 0.33, mp 92-93 
oC). Yield: 50.9 mg (0.11 
mmol, 85%). 1H NMR (500 MHz, C6D6) δ 7.53 (d, J = 8.4 Hz, 1H), 7.12 (d, J = 2.3 Hz, 1H), 7.06–
6.97 (m, 5H), 6.86 (dd, J = 8.5, 2.3 Hz, 1H), 4.34 (br.s, 1H), 4.28 (br.s, 1H), 4.09 (td, J = 13.2, 3.7 
Hz, 1H), 3.61 (br.s, 1H), 2.99 (dd, J = 7.2, 4.4 Hz, 1H), 2.72–2.64 (m, 1H), 2.61–2.53 (m, 1H), 
1.84 (t, J = 5.4 Hz, 1H), 1.41 (s, 9H), 1.38–1.34 (m, 1H). 13C NMR (126 MHz, C6D6) δ 169.2, 
156.4, 138.0, 135.3, 134.8, 134.5 (+), 134.1, 130.8 (+), 128.9 (+, 2C), 128.2 (+, 2C), 127.7 (+), 
127.5 (+), 80.0, 50.4 (–), 44.5 (–), 43.2 (–), 36.3 (+), 35.7, 28.4 (+, 3C), 26.4 (–). FTIR (NaCl, cm-
1): 2973, 2927, 1701, 1653, 1585, 1473, 1419, 1392, 1366, 1346, 1253, 1168, 1145, 1107, 1078, 
1046, 992, 858, 820, 784, 734, 700. HRMS (TOF ES): found 483.1214, calculated for 
C24H26Cl2N2O3Na (M + Na) 483.1218 (0.8 ppm). 
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tert-Butyl 5-benzyl-7-(4-methoxyphenyl)-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (217ea). This compound 
was synthesized according to Typical Procedure from 1-(4-
methoxyphenyl)cycloprop-2-ene-1-carboxylic acid (169e) (200 mg, 
1.05 mmol, 1.0 equiv.), and tert-butyl (2-(benzylamino)ethyl)carbamate (316 mg, 1.26 mmol, 1.2 
equiv.). After extraction and filtration through a silica plug crude tert-butyl (2-(N-benzyl-1-(4-
methoxyphenyl)cycloprop-2-ene-1-carboxamido)ethyl)carbamate (216ea) was used at the 
cyclization step as is without additional purification. To this end, amide 216ea (60 mg, 0.142 mmol) 
was treated with powdered KOH (19.9 mg, 0.355 mmol). The reaction mixture was vigorously 
stirred at 35 °C for 8 h. The product was isolated by column chromatography eluting with a 
hexanes/EtOAc mixture (3:1) as a colorless solid (Rf 0.26, mp 103-105 
oC). Yield: 51.5 mg (0.122 
mmol, 86%). 1H NMR (500 MHz, C6D6) δ 7.15–7.07 (m, 6H), 7.07–7.02 (m, 1H), 6.77–6.73 (m, 
2H), 4.60 (br.s, 1H), 4.25 (br.s, 1H), 3.61 (br.s, 1H), 3.51 (td, J = 14.4, 2.2 Hz, 1H), 3.33 (s, 3H), 
2.58–2.41 (m, 3H), 1.96 (t, J = 5.4 Hz, 1H), 1.50 (t, J = 6.4 Hz, 1H), 1.43 (s, 9H). 13C NMR (126 
MHz, C6D6) δ 170.2, 159.3, 156.6, 138.5, 131.2, 128.9 (+, 2C), 128.3 (+, 2C), 127.6 (+), 127.2 (+, 
2C), 114.7 (+, 2C), 79.8, 55.0 (+), 49.5 (–), 44.6 (–), 43.4 (–), 36.8 (+), 35.9, 28.5 (+, 3C), 26.1 
(–). FTIR (NaCl, cm-1): 2974, 2928, 1700, 1651, 1515, 1496, 1428, 1393, 1366, 1346, 1250, 1179, 
1146, 1065, 1030, 829, 777, 731, 701. HRMS (TOF ES): found 445.2098, calculated for 
C25H30N2O4Na (M + Na) 445.2103 (1.1 ppm). 
 
tert-Butyl 5-benzyl-7-(3-chlorophenyl)-6-oxo-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (217fa). This compound 
was synthesized according to Typical Procedure from 1-(3-
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chlorophenyl)cycloprop-2-ene-1-carboxylic acid (169f) (200 mg, 1.03 mmol, 1.0 equiv.), and tert-
butyl (2-(benzylamino)ethyl)carbamate (309 mg, 1.23 mmol, 1.2 equiv.). After extraction and 
filtration through a silica plug crude tert-butyl (2-(N-benzyl-1-(3-chlorophenyl)cycloprop-2-ene-
1-carboxamido)ethyl)carbamate (216fa) was used at the cyclization step as is without additional 
purification. To this end, amide 216fa (60 mg, 0.141 mmol) was treated with powdered KOH (19.7 
mg, 0.351 mmol). The reaction mixture was vigorously stirred at 35 °C for 8 h. The product was 
isolated by column chromatography eluting with a hexanes/EtOAc mixture (1:1) as a colorless 
solid (Rf 0.4, mp 100-102 
oC). Yield: 52.9 mg (0.124 mmol, 88%). 1H NMR (500 MHz, C6D6) δ 
7.21 (s, 1H), 7.1–7.1 (m, 4H), 7.05 (t, J = 6.4 Hz, 1H), 7.02–6.98 (m, 2H), 6.81 (t, J = 7.9 Hz, 1H), 
4.50 (br.s, 1H), 4.19 (br.s, 1H), 3.51 (br.s, 1H), 3.22 (td, J = 13.3, 4.1 Hz, 1H), 2.44 (dd, J = 15.5, 
5.0 Hz, 1H), 2.35 (dd, J = 12.9, 4.0 Hz, 1H), 2.31 (dd, J = 7.2, 4.7 Hz, 1H), 1.92 (t, J = 5.7 Hz, 
1H), 1.41 (s, 9H), 1.39–1.29 (m, 1H). 13C NMR (126 MHz, C6D6) δ 169.2, 156.3, 141.7, 138.2, 
135.2, 130.2 (+), 128.9 (+, 2C), 128.4 (+, 2C), 127.7 (+), 127.2 (+), 125.8 (+), 124.3 (+), 80.0, 
49.6 (–), 44.3 (–), 43.4 (–), 37.4 (+), 36.1, 28.4 (+, 3C), 26.6 (–). FTIR (NaCl, cm-1): 2974, 2926, 
2855, 1699, 1651, 1593, 1510, 1478, 1392, 1366, 1344, 1248, 1223, 1148, 1065, 993, 852, 815, 
777, 736. HRMS (TOF ES): found 449.1618, calculated for C24H27ClN2O3Na (M + Na) 449.1608 
(1.0 ppm). 
 
tert-Butyl (1R*,7R*,8R*)-5-benzyl-6-oxo-7,8-diphenyl-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (217ha). This compound was 
synthesized according to Typical Procedure from 1,2-
diphenylcycloprop-2-ene-1-carboxylic acid (169h) (150 mg, 0.63 mmol, 1.0 equiv.), and tert-butyl 
(2-(benzylamino)ethyl)carbamate (191 mg, 0.76 mmol, 1.2 equiv.). After extraction and filtration 
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through a silica plug crude tert-butyl (2-(N-benzyl-1,2-diphenylcycloprop-2-ene-1-
carboxamido)ethyl)carbamate (216ha) was used at the cyclization step as is without additional 
purification. To this end, amide 216ha (50 mg, 0.107 mmol) was treated with powdered KOH (15 
mg, 0.267 mmol). The reaction mixture was vigorously stirred at 50 °C for 16 h. The product was 
isolated by column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless 
solid (Rf 0.43, mp 183-184 
oC). Yield: 45.6 mg (0.097 mmol, 91%). 1H NMR (500 MHz, C6D6) δ 
7.31 (d, J = 7.6 Hz, 2H), 7.20 (br. s, 2H), 7.10–6.98 (m, 5H), 6.96 (t, J = 7.6 Hz, 4H), 6.87 (t, J = 
7.3 Hz, 2H), 4.51 (br. s, 1H), 4.25 (br. s, 1H), 3.80–3.56 (m, 2H), 3.37 (d, J = 4.7 Hz, 1H), 3.22 (d, 
J = 4.7 Hz, 1H), 2.62 (d, J = 9.2 Hz, 1H), 2.49 (d, J = 10.6 Hz, 1H), 1.34 (s, 9H). 13C NMR (126 
MHz, C6D6) δ 170.3, 156.9, 138.2, 136.1, 134.7, 129.4 (+, 2C), 128.8 (+, 2C), 128.8 (+, 2C), 128.6 
(+, 2C), 128.4 (+, 2C), 128.0 (+, 2C), 127.6 (+), 127.4 (+), 126.6 (+), 80.2, 49.8 (–), 44.6 (–), 44.6, 
43.1 (–), 40.9 (+), 39.1 (+), 28.5 (+, 3C). FTIR (NaCl, cm-1): 2976, 2926, 2868, 1701, 1647, 1496, 
1469, 1423, 1363, 1252, 1170, 1142, 777, 735, 698. HRMS (TOF ES): found 491.2318, calculated 
for C30H32N2O3Na (M + Na) 491.2311 (1.4 ppm). 
 
tert-butyl (1R*,8R*,9R*)-6-benzyl-7-oxo-8,9-diphenyl-2,6-
diazabicyclo[6.1.0]nonane-2-carboxylate (217hh). This compound was 
synthesized according to Typical Procedure from 1,2-
diphenylcycloprop-2-ene-1-carboxylic acid (169h) (150 mg, 0.63 mmol, 1.0 equiv.), and tert-butyl 
(3-(benzylamino)propyl)carbamate (202 mg, 0.76 mmol, 1.2 equiv.). After extraction and filtration 
through a silica plug crude tert-butyl (3-(N-benzyl-1,2-diphenylcycloprop-2-ene-1-
carboxamido)propyl)carbamate (216hi) was used at the cyclization step as is without additional 
purification. To this end, amide 216hi (50 mg, 0.104 mmol) was treated with powdered KOH (14.5 
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mg, 0.258 mmol). The reaction mixture was vigorously stirred at 50 °C for 16 h. The product was 
isolated by column chromatography eluting with a hexanes/EtOAc mixture (2:1) as a colorless 
solid (Rf 0.4, mp 98-99 
oC). Yield: 43.9 mg (0.091 mmol, 88%). 1H NMR (500 MHz, CDCl3) δ 
7.42–7.17 (m, 15H), 5.39 (d, J = 15.0 Hz, 1H), 4.20 (d, J = 15.0 Hz, 1H), 4.22 (br. s, 1H), 4.09 
(dd, J = 15.3, 11.5 Hz, 1H), 4.05 (br. s, 1H), 3.78 (d, J = 6.5 Hz, 1H), 3.54 (ddd, J = 14.2, 9.7, 3.2 
Hz, 1H), 3.19 (ddd, J = 15.4, 5.3, 2.3 Hz, 1H), 2.08–1.97 (m, 1H), 1.89–1.78 (m, 1H), 1.60 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 171.1, 156.2, 137.5, 135.8, 135.2, 128.8 (+, 2C), 128.6 (+, 2C), 
128.4 (+, 4C), 127.9 (+, 4C), 127.4 (+), 127.2 (+), 126.3 (+), 80.9, 49.4 (–, 2C), 47.7 (+), 45.7 (–), 
45.4, 36.8 (+), 28.6 (+, 3C), 28.3 (–). FTIR (NaCl, cm-1): 2976, 2928, 1694, 1634, 1477, 1417, 
1365, 1294, 1258, 1155, 1078, 735, 698. HRMS (TOF ES): found 505.2472, calculated for 
C31H34N2O3Na (M + Na) 505.2467 (1.0 ppm). 
 
tert-butyl (1R*,7R*,8R*)-5-benzyl-7-(2,4-dichlorophenyl)-6-oxo-8-
phenyl-2,5-diazabicyclo[5.1.0]octane-2-carboxylate (217ia). This 
compound was synthesized according to Typical Procedure from 1-
(2,4-dichlorophenyl)-2-phenylcycloprop-2-ene-1-carboxylic acid 
(169i) (150 mg, 0.49 mmol, 1.0 equiv.), and tert-butyl (2-(benzylamino)ethyl)carbamate (148 mg, 
0.59 mmol, 1.2 equiv.). After extraction and filtration through a silica plug crude tert-butyl (2-(N-
benzyl-1-(2,4-dichlorophenyl)-2-phenylcycloprop-2-ene-1-carboxamido)ethyl)carbamate (216ia) 
was used at the cyclization step as is without additional purification. To this end, amide 216ia (50 
mg, 0.093 mmol) was treated with powdered KOH (13 mg, 0.232 mmol). The reaction mixture 
was vigorously stirred at 50 °C for 16 h. The product was isolated by column chromatography 
eluting with a hexanes/EtOAc mixture (4:1) as a colorless glass (Rf 0.33). Yield: 38.5 mg (0.072 
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mmol, 77%). 1H NMR (500 MHz, C6D6) δ 7.71 (d, J = 8.5 Hz, 1H), 7.03 (d, J = 9.7 Hz, 6H), 6.97–
6.89 (m, 4H), 6.89–6.79 (m, 1H), 6.71–6.55 (m, 1H), 4.48–4.27 (m, 3H), 3.93 (d, J = 4.8 Hz, 1H), 
3.78 (br. s, 1H), 3.20 (br. s, 1H), 2.85–2.80 (m, 1H), 2.64 (dd, J = 15.6, 5.3 Hz, 1H), 1.28 (s, 9H). 
13C NMR (126 MHz, C6D6) δ 169.8, 156.6, 137.8, 136.6 (+), 136.3, 134.6, 134.2, 130.6, 130.4 (+), 
128.9 (+, 2C), 128.6 (+, 2C), 128.2 (+, 2C), 128.2 (+, 2C), 127.7 (+), 127.6 (+), 126.8 (+), 80.2, 
50.5 (–), 44.3 (–), 44.3, 43.0 (–), 42.2 (+), 41.1 (+), 28.4 (+, 3C). FTIR (NaCl, cm-1): 2974, 2926, 
2864, 1701, 1649, 1473, 1386, 1365, 1250, 1142, 812, 736, 696. HRMS (TOF ES): found 559.1539, 
calculated for C30H30Cl2N2O3Na (M + Na) 559.1531 (1.4 ppm). 
 
tert-butyl (1R*,7R*,8R*)-7-(2,4-dichlorophenyl)-5-(4-
methoxybenzyl)-6-oxo-8-phenyl-2,5-
diazabicyclo[5.1.0]octane-2-carboxylate (217ib). This 
compound was synthesized according to Typical Procedure from 
1-(2,4-dichlorophenyl)-2-phenylcycloprop-2-ene-1-carboxylic acid (169i) (150 mg, 0.49 mmol, 
1.0 equiv.), and tert-butyl (2-((4-methoxybenzyl)amino)ethyl)carbamate (165 mg, 0.59 mmol, 1.2 
equiv.). After extraction and filtration through a silica plug crude tert-butyl (2-(1-(2,4-
dichlorophenyl)-N-(4-methoxybenzyl)-2-phenylcycloprop-2-ene-1-carboxamido)ethyl)carbamate 
(216ib) was used at the cyclization step as is without additional purification. To this end, amide 
216ib (50 mg, 0.088 mmol) was treated with powdered KOH (12.4 mg, 0.221 mmol). The reaction 
mixture was vigorously stirred at 50 °C for 16 h. The product was isolated by column 
chromatography eluting with a hexanes/EtOAc mixture (5:1) as a colorless glass (Rf 0.33). Yield: 
40.5 mg (0.071 mmol, 81%). 1H NMR (500 MHz, C6D6) δ 7.73 (d, J = 8.6 Hz, 1H), 7.02 (d, J = 
2.2 Hz, 1H), 7.00 (d, J = 8.3 Hz, 2H), 6.96–6.90 (m, 4H), 6.85 (ddd, J = 8.5, 5.7, 2.3 Hz, 1H), 6.68 
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(d, J = 8.6 Hz, 2H), 6.64 (dd, J = 8.6, 2.3 Hz, 1H), 4.36 (ddd, J = 15.4, 13.2, 4.4 Hz, 1H), 4.36 (br. 
s, 2H), 3.93 (d, J = 4.7 Hz, 1H), 3.79 (s, 1H), 3.27 (s, 3H), 3.21 (br. s, 1H), 2.85 (dd, J = 13.1, 4.2 
Hz, 1H), 2.70 (dd, J = 15.6, 5.2 Hz, 1H), 1.28 (s, 9H). 13C NMR (126 MHz, C6D6) δ 169.7, 159.8, 
156.6, 136.6 (+), 136.3, 134.6, 134.2, 130.7, 130.4 (+), 129.8, 129.6 (+, 2C), 128.4 (+, 2C), 128.2 
(+, 2C), 127.6 (+), 126.8 (+), 114.6 (+, 2C), 80.2, 54.8 (+), 50.0 (–), 44.4 (–), 44.4, 42.8 (–), 42.2 
(+), 41.1 (+), 28.4 (+, 3C). FTIR (NaCl, cm-1): 2974, 2928, 1701, 1647, 1512, 1474, 1364, 1248, 
2242, 1035, 810, 769, 736, 696. HRMS (TOF ES): found 589.1639, calculated for 
C31H32Cl2N2O4Na (M + Na) 589.1637 (0.3 ppm). 
 
tert-butyl (1R*,8R*,9R*)-8-(2,4-dichlorophenyl)-6-(4-
methoxybenzyl)-7-oxo-9-phenyl-2,6-
diazabicyclo[6.1.0]nonane-2-carboxylate (217ii). This 
compound was synthesized according to Typical Procedure 
from 1-(2,4-dichlorophenyl)-2-phenylcycloprop-2-ene-1-carboxylic acid (169i) (150 mg, 0.49 
mmol, 1.0 equiv.), and tert-butyl (3-((4-methoxybenzyl)amino)propyl)carbamate (173 mg, 0.59 
mmol, 1.2 equiv.). After extraction and filtration through a silica plug crude tert-butyl (3-(1-(2,4-
dichlorophenyl)-N-(4-methoxybenzyl)-2-phenylcycloprop-2-ene-1-
carboxamido)propyl)carbamate (216ii) was used at the cyclization step as is without additional 
purification. To this end, amide 216ii (50 mg, 0.086 mmol) was treated with powdered KOH (12.1 
mg, 0.216 mmol). The reaction mixture was vigorously stirred at 50 °C for 16 h. The product was 
isolated by column chromatography eluting with a hexanes/EtOAc mixture (5:1) as a colorless 
glass (Rf 0.25). Yield: 37.9 mg (0.065 mmol, 76%). 
1H NMR (500 MHz, C6D6) δ 7.46 (d, J = 8.4 
Hz, 1H), 7.11 (d, J = 7.7 Hz, 2H), 7.04 (d, J = 1.7 Hz, 1H), 7.00–6.93 (m, 4H), 6.88 (t, J = 7.3 Hz, 
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1H), 6.64 (d, J = 8.5 Hz, 2H), 6.65–6.63 (m, 1H), 5.02 (d, J = 14.6 Hz, 1H), 4.61 (br. s, 1H), 4.21 
(t, J = 13.3 Hz, 2H), 3.91 (br. s, 1H), 3.83 (d, J = 14.6 Hz, 1H), 3.47 (br. s, 1H), 3.35 (br. s, 1H), 
3.24 (s, 3H), 2.77 (dt, J = 15.2, 3.1 Hz, 1H), 1.70–1.27 (m, 2H), 1.44 (s, 9H). 13C NMR (126 MHz, 
C6D6) δ 170.1, 159.7, 155.6, 136.3, 135.4 (+), 134.0, 132.6, 130.6 (+), 130.2, 129.6 (+, 2C), 128.4 
(+, 2C), 128.4 (+, 2C), 127.2 (+), 126.9 (+), 114.4 (+, 2C), 80.3, 54.8 (+), 49.5 (–), 49.1 (+), 45.0, 
44.8 (–, 2C), 37.2 (+), 28.5 (–), 28.5 (+, 3C). FTIR (NaCl, cm-1): 2974, 2928, 1695, 1636, 1512, 
1471, 1413, 1365, 1246, 1153, 1105, 1033, 158, 808, 767, 696. HRMS (TOF ES): found 603.1793, 
calculated for C32H34Cl2N2O4Na (M + Na) 603.1793 (0.0 ppm). 
tert-Butyl (1S,4S,7S)-5-benzyl-7-(4-fluorophenyl)-4-isopropyl-6-
oxo-2,5-diazabicyclo[5.1.0]octane-2-carboxylate (217bk). This 
compound was synthesized according to Typical Procedure from 1-(4-
fluorophenyl)cycloprop-2-ene-1-carboxylic acid (217b) (100 mg, 0.56 
mmol, 1.0 equiv.), and tert-butyl (S)-(2-(benzylamino)-3-methylbutyl)carbamate (197 mg, 0.67 
mmol, 1.2 equiv.). After extraction and filtration through a silica plug crude tert-butyl (S)-(2-(N-
benzyl-1-(4-fluorophenyl)cycloprop-2-ene-1-carboxamido)-3-methylbutyl)carbamate (216bk) 
was used at the cyclization step as is without additional purification. To this end, amide 216bk (50 
mg, 0.11 mmol) was treated with powdered KOH (15.5 mg, 0.276 mmol). The reaction mixture 
was vigorously stirred at 50 °C for 16 h. The product was isolated by column chromatography 
eluting with a hexanes/EtOAc mixture (5:1) as a colorless solid (Rf 0.33, mp 155-157 °C). Yield: 
44.6 mg (0.099 mmol, 89%). [α]D20 +97.8 (c = 0.9, CHCl3). 1H NMR (400 MHz, CDCl3) δ 
7.32–7.21 (m, 5H), 7.14–7.06 (m, 2H), 7.05–6.97 (m, 2H), 5.44 (br. d, J = 15.1 Hz, 1H), 3.99 (br. 
d, J = 15.2 Hz, 1H), 3.54 (ddd, J = 12.6, 10.3, 3.9 Hz, 1H), 3.01 (br. s, 1H), 2.86 (dd, J = 12.6, 3.9 
Hz, 1H), 2.60 (dd, J = 7.1, 4.6 Hz, 1H), 2.20–2.05 (m, 1H), 1.91 (dd, J = 7.0, 4.6 Hz, 1H), 1.79 (t, 
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J = 7.1 Hz, 1H), 1.69 (s, 1H), 1.42 (s, 9H), 0.88 (dd, J = 10.1, 6.4 Hz, 6H). 13C NMR (151 MHz, 
CDCl3) δ 172.1, 161.8 (d, J = 245.8 Hz), 156.4, 138.4, 134.0 (d, J = 3.1 Hz), 128.7 (+, 2C), 127.9 
(+), 127.4 (+, 2C), 126.2 (d, J = 8.1 Hz, +, 2C), 115.7 (d, J = 21.5 Hz, +, 2C), 80.5, 61.1 (+), 46.9 
(–), 44.3 (–), 39.0 (+), 35.2, 28.3 (+, 3C), 27.4 (–), 21.9 (+, 2C), 19.9 (+). 19F NMR (376 MHz, 
CDCl3) δ –115.7. FTIR (NaCl, cm-1): 2973, 2929, 1701, 1649, 1513, 1368, 1147, 832, 730. 
HRMS (TOF ES): found 475.2375, calculated for C27H33FN2O3Na (M + Na) 475.2373 (0.4 
ppm). The relative and absolute configuration of compound 217bk was unambiguously confirmed 
by single-crystal X-ray crystallography (CCDC #1854746).  
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Appendix 
 
A1. Evaluation of biological activitie of azabicyclo[5.1.0]octanones 
 
The preliminary biological studies were performed by the group of Prof. Frolova (New Mexico 
Institute of Mining and Technology, Socorro, New Mexico) in the framework of a collaborative 
project.3 
MTT assay for mycobacterium abscessus (ATCC 19977). Approximately 5.5 · 105 mycobacteria 
per mL or a dilution of 1:500 from an overnight growth were plated at a final volume of 400 
μL/well in 48-well plates. Compounds were initially screened at a concentration of 100 μM on M. 
abscessus. Compounds with antimycobacterial activity at 100 μM were screened for further 
activity by adding the selected compounds to cells at a concentration of 50 μM and 2-fold serially 
diluting. The plates were incubated in a shaking incubator for 48 h at 37 °C. Following the 
incubation, 40 μL or 10% w/v of MTT reagent (5 mg/mL) was added to each of the wells. The 
plates were incubated for 2 h at 37 °C. An amount of 650 μL of solubilization solution was added 
to each of the wells, and the plate was incubated at 37 °C for an additional 12 h. An amount of 100 
μL from each well was transferred into a clear 96-well microtiter plate, and A595 was read in a 
Thermomax Molecular Device plate reader. Wells containing Middlebrook 7H9 medium and 
nontreated cells served as negative controls, and a well containing 10 μM phenyl arsine oxide 
treated cells (PAO) served as a positive kill control. The experiments were performed in triplicate. 
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Figure 16. Cytotoxicity of 201aa towards mycobacterium abscessus 
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* >50% reduction in viability was observed at 3 µM treatment for compound 201ab, but 
the absence of data at lower concentrations prevented determination of an accurate IC50 
value. 
Additionally, only very slight reductions in viability were observed upon treatment with 
higher concentrations of the compound 
 
Figure 17 Cytotoxicity of 201ab towards mycobacterium abscessus 
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Figure 18 Cytotoxicity of 201ad towards mycobacterium abscessus 
 
 
Figure 19 Cytotoxicity of 201ba towards mycobacterium abscessus 
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* >50% reduction in viability was observed at 3 µM treatment for compound 201cb, but 
the absence of data at lower concentrations prevented determination of an accurate IC50 
value. 
Additionally, further reductions in viability were not observed upon treatment with higher 
concentrations of the compound 
 
Figure 20 Cytotoxicity of 201cb towards mycobacterium abscessus 
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* >50% reduction in viability was observed at 3 µM treatment for compound 201bb, the 
absence of data at lower concentrations prevented determination of an accurate IC50 value. 
Additionally, further reductions in viability were not observed upon treatment with higher 
concentrations of the compound 
 
Figure 21 Cytotoxicity of 201bb towards mycobacterium abscessus 
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Figure 22 Cytotoxicity of 207a towards mycobacterium abscessus 
 
 
Figure 23 Cytotoxicity of ent-207a towards mycobacterium abscessus 
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Figure 24 Cytotoxicity of 207d towards mycobacterium abscessus 
 
 
Figure 25 Cytotoxicity of 210a towards mycobacterium abscessus 
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MTT assay for HeLa (ATCC CCL-2). All compounds were dissolved in DMSO at a 
concentration of either 100 or 50 mM prior to cell treatment. The cells were treated at 
concentrations ranging from 0.004  to 100 μM and incubated for 48 h in 200 μL of media. An 
amount of 20 μL of MTT reagent in serum-free medium (5 mg/mL) was added to each well and 
incubated further for 2 h. Media was removed, and the resulting formazan crystals were solubilized 
in 100 μL of DMSO. A490 was measured using a Thermomax Molecular Device plate reader. The 
experiments were performed in quadruplicate and repeated at least twice for each compound per 
cell line. Cells treated with 0.1% DMSO were used as a vehicle control, and phenyl arsine oxide 
(PAO) was used as a positive killing control. 
 
 
Figure 26 Cytotoxicity of 201aa towards HeLa cells 
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Figure 27 Cytotoxicity of 201ab towards HeLa cells 
 
 
Figure 28 Cytotoxicity of 201ad towards HeLa cells 
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Figure 29 Cytotoxicity of 201ba towards HeLa cells 
 
 
Figure 30 Cytotoxicity of 201cb towards HeLa cells 
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Figure 31 Cytotoxicity of 201bb towards HeLa cells 
 
 
Figure 32 Cytotoxicity of 207a towards HeLa cells 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
Untreated PAO 0.4 0.8 1.6 3.1 6.3 12.5 25 50 100
A
b
s
o
rb
a
n
c
e
 a
t 
5
9
5
 n
m
Treatment (µM of compound)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Untreated PAO 0.4 0.8 1.6 3.1 6.3 12.5 25 50 100
A
b
s
o
rb
a
n
c
e
 a
t 
5
9
5
 n
m
Treatment (µM of compound)
220 
 
 
Figure 33 Cytotoxicity of ent-207a towards HeLa cells 
 
 
Figure 34 Cytotoxicity of 207d towards HeLa cells 
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Figure 35 Cytotoxicity of 210a towards HeLa cells 
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A2. Evaluation of biological activitie of 2,5-diazabicyclo[5.1.0]octan-6-ones and 2,6-
diazabicyclo[6.1.0]nonan-7-ones 
 
The preliminary biological studies were performed by the group of Prof. Frolova (New Mexico 
Institute of Mining and Technology, Socorro, New Mexico) in the framework of a collaborative 
project.4 
To evaluate antiproliferative properties of the synthesized compounds, the cells were 
trypsinized and seeded 4 · 103 cells per well into 96-well microtiter plates. The cells were grown 
for 24 h before treatment. MTT assay for HeLa: All compounds were dissolved in DMSO at a 
concentration of either 100 or 50 mM prior to cell treatment. The cells were treated at 
concentrations ranging from 0.004 to 100 μM and incubated for 48 h in 200 μL of media. Twenty 
microliters of MTT reagent in serum-free medium (5 mg/mL) was added to each well and 
incubated further for 2 h. Media was removed, and the resulting formazan crystals were 
resolubilized in 100 μL of DMSO. A490 was measured using a Thermomax Molecular Device 
plate reader. The experiments were performed in quadruplicate and repeated at least twice for each 
compound per cell line. Cells treated with 0.1% DMSO were used as a negative control, and phenyl 
arsine oxide (PAO) was used as a positive killing control. 
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Figure 36 Cytotoxicity of 217ac towards HeLa cells 
 
 
Figure 37 Cytotoxicity of 217ad towards HeLa cells 
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Figure 38 Cytotoxicity of 217ag towards HeLa cells 
 
 
Figure 39 Cytotoxicity of 217ah towards HeLa cells 
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Figure 40 Cytotoxicity of 217be towards HeLa cells 
 
 
Figure 41 Cytotoxicity of 217ch towards HeLa cells 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Untreated PAO 0.39 0.78 1.56 3.125 6.25 12.5 25 50 100
A
b
s
o
rb
a
n
c
e
 a
t 
5
9
5
 n
m
Treatment (µM of compound)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
Untreated PAO 0.39 0.78 1.56 3.125 6.25 12.5 25 50 100
A
b
s
o
rb
a
n
c
e
 a
t 
5
9
5
 n
m
Treatment (µM of compound)
226 
 
 
Figure 42 Cytotoxicity of 217gc towards HeLa cells 
 
 
Figure 43 Cytotoxicity of 217gj towards HeLa cells 
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Figure 44 Cytotoxicity of 217ha towards HeLa cells 
 
 
Figure 45 Cytotoxicity of 217hh towards HeLa cells  
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